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HIV persists during long-term, effective antiretroviral therapy within reservoir 
cells. While CD4-positive lymphocytes are accepted as bona fide reservoirs, the 
contribution of other HIV-susceptible cell types to viral persistence remains 
unknown. ART therapy is a lifelong commitment for those with HIV, as treatment 
interruption induces swift rebound of peripheral viremia and progression toward 
AIDS. This demonstrates that persistent HIV reservoir cells are not eliminated by the 
virus or cleared by the immune system. However, while the memory T-cell HIV 
reservoir was discovered twenty years ago, strategies to specifically target these 
cells for destruction remain elusive. Furthermore, we know far less about HIV-
susceptible cells within tissues than those in the blood, including subsets of myeloid 
cells such as tissue macrophages. Indeed, challenges in the study and isolation of 
tissue macrophages and the sheer number of organ-specific myeloid subsets has 
complicated unified efforts to learn whether these cells harbor HIV during 
treatment.  
 Here I present a series of experimental platforms for the study of HIV tissue 
reservoirs, with a focus on pulmonary alveolar macrophages of the human lung.  To 
learn whether these cells are HIV-infected in vivo, I describe a flow-cytometry assay 
using fluorescence RNA in situ hybridization (FISH) that reveals individual HIV-
infected primary cells in a cell suspension. These assays are amenable to multiplex 
 HIV antigen staining and sorting of HIV-expressing cells for RNAseq analyses. Using 
this FISH:FLOW tool I demonstrate a universal caveat in the industry standard cell 
line 8E5, used routinely as a calibration standard for clinical measurements of the 
HIV reservoir. Secondly, I engineered several reporter cell platforms for the 
outgrowth of HIV from tissue reservoirs, and use these tools to develop novel 
paradigms in the study of HIV replication and cellular transmission in myeloid cells. 
Finally, I deploy some of these cell lines in a combined HIV outgrowth pipeline to 
capture and characterize Clade C HIV in the blood and lungs of adults in Blantyre, 
Malawi. Together, these contributions will accelerate our progress toward therapies 
that specifically target HIV reservoir cells in the tissues, the key obstacle to an HIV 
cure.  
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pref·ace 
ˈprefəs/ 
noun 
1. an introduction to a book, typically stating its 
subject, scope, or aims. 
PREFACE 
 
How do you preface a dissertation?  
 
This dissertation is a story about one young scientist’s quest for the truth about 
the human immunodeficiency virus. The experiments I describe below were 
centered on the hypothesis that, contrary to an overwhelming body of evidence, 
HIV persists during antiretroviral therapy in a diversity of cell types in addition to CD-
4 positive lymphocytes.  
 
The aim of this document is to summarize several years of work. But like so 
many projects in scientific research, this dissertation will pose more future questions 
than those of the present it definitively answers.  
 
The scope of the work below spans reporter cells and macrophage biology, 
and the technical challenges encountered while studying HIV in these cells. My 
work has revealed (to me) how little we know about a powerful category of 
immune cells, often summarily affronted by the term “myeloid reservoirs” by 
members of the field.  I describe what seemed to me a logical and first principles 
approach to the study of HIV replication in several cell types, and found myself 
reading literature published around the earliest days of HIV discovery, when minds 
 xxi 
in the field were not overburdened with details and conclusions were less censored 
during peer review.  
 
Long before I had sufficient data to present, I attended a Keystone HIV 
persistence meeting in Boston to eavesdrop. I found a group of ~160 scientists, 
mostly clinicians, engaging in healthy debate about substantial issues in the field. 
Like most clinicians, these people were focused on numbers, survival curves, and 
patient outcomes. As a graduate student in basic research, I admit I was 
unprepared for how it feels to stand somewhere between the bench and the 
patients, debating the outcomes that turn into standards of care. Many in the HIV 
cure field – and I do mean many – are the same physicians who first saw the young 
men emerging from the woodwork in California and New York city beginning in April 
1980. They describe the sinking feeling of personally meeting the exponentially-
increasing number of patients with classic AIDS-relating wasting symptoms, without 
knowledge of the agent or any form of treatment.  It wasn’t until 1987 – seven years 
– that the first HIV treatment, AZT, was approved. By that time, there were 50,000 
reported AIDS diagnoses in the United States and hundreds of thousands more 
infected. The researchers in session at that Boston meeting diagnosed and ‘treated’ 
many of these first patients, but they had all trained in an era where communicable 
disease was largely controlled by antibiotics, and periodic influenza outbreaks were 
something to be feared but its symptoms were predictable and its etiology known. 
For the first time in a generation, modern clinical medicine faced an unknown 
enemy with absolutely no arsenal. Hearing these individuals speak to one another 
 xxii 
was inspiring. While HIV has always been a field packed with controversy, these 
investigators had all faced the epidemic together and there was a reverence to 
their debate that still bore the scars of not knowing any answers when asked by a 
dying patient.  
 
 In a way, these stories concern us all, because this is how the clinics will look 
when our antibiotics no longer work. And while the HIV pandemic in some areas of 
the globe is “under control”, the virus is driving the emergence of multidrug-resistant 
tuberculosis in places like sub-Saharan Africa and Asia, for reasons that are 
socioeconomic, biological and difficult to study. On days when you forget why 
you’re in research or feel like tossing this or that experiment, it helps to remember 
that what you are doing actually matters. Working on any project in the basic 
sciences, we need to remember that somewhere, somebody’s child is sick or dying 
because as a field – as a team – we have not yet reached them. Entering the field 
of HIV persistence, hearing the co-morbidities, the millions infected, the reasons 
patients can’t or won’t stay on their medications, the unbelievable efforts made to 
exhaust every avenue, you are humbled, driven, and quietly optimistic that you too 
can contribute. 
 
 A PhD dissertation is a bit like a teenage romance, isn’t it? It consumes your 
thoughts, you can’t sleep, you often stop eating. During your PhD you feel at once 
despondent, excited, furious, and sublime. It’s an unreasonable and time-costly 
commitment toward something much greater than yourself, made in the prime of 
 xxiii 
your life. You enter as a juvenile and leave as an adult, but don’t have much 
opportunity to look back and see whether in the process you’ve grown. And finally, 
we make decisions so much differently at the outset compared to the end. But if 
over the course of my studies I didn’t stumble on a cure for HIV, or even finally put 
to rest the “simple” question of HIV persistence in alveolar macrophages, I can look 
back and say with confidence that I had a hand in something that may change 
how we think. With this dissertation, I may actually help reach those people.  
 
All over the world, there are scientists who give up much of what is available 
to them in life to find the answers and define the truths that will one day bring relief 
to the sick. Despite my toughest moments in science, to have played even a small 
role in this effort is the opportunity of a lifetime, and for that I will always be grateful. 
 1 
Structure of this dissertation 
one  The first chapter is an introduction to the biology of HIV, the prototype lentivirus. 
two The second chapter details work to identify HIV infection at the level of single 
cells.  
The section in chapter 2 on Quantitative HIV biology with FISH:FLOW 
population analyses is published as a corresponding author paper:  
Wilburn KM, Mwandumba HC, Jambo KC, Boliar, Solouki, Russell DG, 
Gludish DW. Heterogeneous loss of HIV transcription and proviral 
DNA from 8E5/LAV lymphoblastic leukemia cells revealed by RNA 
FISH:FLOW analyses. Retrovirology. 2016 Aug 11;13(1):55 
three The third chapter describes the development of multiple reporter cell lines 
and associated assays to rigorously study cellular transmission of different strains of 
HIV.  
The data in chapter 3 form the foundations of two manuscripts: (1) 
on the construction and application of TZM-gfp cells and (2) on the 
development of novel viral outgrowth tools MoltGGR and SupGGR. 
SupGGR cells are now being validated in a clinical setting by our 
collaborator Dr. Andrew Lever, University of Cambridge, prior to 
submission for publication. 
 
four The fourth chapter applies knowledge from Chapters 2 and 3 toward capture, 
quantification, and characterization of primary HIV isolates in a clinical pipeline.  
The data described in Chapter 4 are being validated and 
 2 
expanded through enrollment of additional patients into the 
patient cohort in Malawi. These findings will be submitted for 
publication within the coming year.  
 
five The fifth and final chapter addresses the many questions raised by my research, 
and what I view as the future trajectory for these lines of inquiry.  
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CHAPTER ONE 
 
Introduction to HIV replication biology and what it means for cells in the deep 
tissues 
 
 
In this chapter I introduce the basics of HIV replication, the cell types it infects, 
and where these cells live. I describe the human airway as a compartment that 
may harbor HIV-infected reservoir cells, and present the alveolar macrophage as a 
compelling reservoir candidate. This chapter also discusses the current means to 
measure the HIV reservoir in human patients, including the strengths and relative 
weaknesses of these assays. The available literature and gaps in our knowledge 
frame the questions posed in the remainder of this dissertation and beyond.  
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Lifecycle of Human Immunodeficiency Virus 
 
 HIV is a positive sense, enveloped RNA retrovirus of the Lentiviridae genus1,2, 
and the only lentivirus known to infect humans (HIV-1 and HIV-2).  Mature virions are 
largely homogeneous, approximately 120nm in diameter, with a conical fullerene 
shell capsid that encloses two linear copies of the single-stranded RNA genome 3; 
these two copies need not be identical in sequence, and may recombine prior to 
integration to drive genetic diversity 4. As a retrovirus, HIV is defined by its RNA-
dependent DNA polymerase “reverse transcriptase”, a fascinating enzyme that 
reverses the central dogma of biology 5. David Baltimore, and Howard Temin 
received the Nobel prize for their 1970 discovery of the enzyme and with it, founded 
the field of retrovirology 6,7.  
HIV entry, reverse transcription and integration 
 
Like all enveloped viruses, HIV gains entry to the cell by specific interaction 
of its envelope/spike protein with receptors on the cell, CD4 8 and CCR59-13 (Fig. 1, 
reference14) CD4, a co-receptor of the CD3/T-cell receptor complex, is involved in 
interactions with antigen presenting cells during T-cell activation15. CCR5 is a 
chemokine receptor driving chemotaxis and activation of various immune cell 
subsets, including macrophages, osteoclasts and lymphocytes15, though the 
receptor is expressed at much reduced levels in lymphoid cells16. Receptor binding 
is followed by an endocytosis-mediated pathway, where a membrane hemifusion 
event in early endosomes delays viral capsid ejection into the cytosol, a process 
that may or may not be pH dependent17.  
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Figure 1. The HIV lifecycle. Access to the cell (1) is gained by binding of the 
envelope protein (gp120) to the cellular receptor CD4 and co-receptor CCR5, and 
conformational change, causing viral fusion. (2) the capsid is released into the 
cytoplasm, and is uncoated, releasing the viral genome and enzymes reverse 
transcriptase and integrase. (3) Proviral DNA is reverse transcribed and associates 
with the integrase/pre-integration complex for (4) transport into the nucleus and 
integration into the genome. Transcription factors drive HIV expression, and HIV-1 
Tat amplifies this transcription (5). (6) Virions are assembled as structural proteins 
encapsidated the RNA genome. The virus is then released, causing maturation of 
the new capsid and resulting with infectious virus (7).  SOURCE: NIAID 
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Release of the capsid into the cell is followed by uncoating of the RNA 
genome (Fig. 1,#2), and reverse transcription18 (Fig.1, #3). Viral enzymes reverse 
transcriptase and integrase are packaged into virions and are functional upon 
release into the cytoplasm18. Importantly, cellular dNTP pools determine the rate of 
reverse transcription, and are modulated by the host restriction factor SAMHD119-23; 
in non-replicating cells like macrophages, excess dNTPs are eliminated to interfere 
with viral polymerase activity.  Production of proviral DNA from the RNA genomic 
template is completed in the cytosol, with the RNAseH activity of reverse 
transcriptase degrading the RNA template strand18.  
 
Proviral DNA then associates with the integrase enzyme and viral protein vpr 
(also packaged in the virion) into a pre-integration complex24-26, a structure 
responsible for import of the provirus through the nuclear pore and integration of 
the DNA onto the host chromosome (Fig. 1, #4). Integration occurs at random, but 
is reported to bias toward euchromatin regions of the genome that are also close 
or tethered to the nuclear envelope27.  
 
Integration and transcription of the HIV provirus (Fig.1, #5) are dependent on 
the LTRs (long terminal repeat) found on both ends of the genomic RNA and 
integrated proviral DNA28. Sequence homology in both LTRs is required for proper 
topology of the provirus during integration29, without which integration may fail or 
result in circularized LTRs30.  
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Regulation of HIV transcription 
 
Once integrated, the earliest HIV transcription events proceed in the 
absence of any viral proteins, relying solely on host transcriptional activators NF-
kb/SP-1 or NFAT28. Baseline transcription in newly-infected cells drives inefficient 
production of HIV transcripts that are multiply spliced by the host machinery. The 
HIV genome encodes nine genes and several splicing variations that produce 
transcripts of three main sizes: ~1.8, 4.0, and 9.0 kb28. Four splice donor and seven 
acceptor sites govern the output from the primary transcript pool. The earliest 
translation product of HIV is the transcriptional co-activator Tat, and derives from 
the early multiply-spliced RNA class. Tat is a transcription factor unlike most, as it 
binds a sequence on the nascent RNA transcript and not the genomic DNA31, 
significantly increasing elongation by recruitment of pTEF-b and associated 
factors28,31.  
 
Upon robust Tat-dependent transcription, other multiply-spliced, early genes 
are translated, notably Rev. As another RNA-binding protein, Rev binds with high 
affinity to the Rev response element (RRE), a region of RNA secondary structure 
within the HIV env ORF28. Rev binding to the HIV RNA results in additional Rev 
monomers oligomerizing, a process that increases the REV:RRE affinity by 500-fold32. 
These events drive rapid export of the message from the nucleus, dependent on 
the interaction of Rev with Crm1/ exportin-1 through the nuclear pore complex33, 
delivering singly spliced and unspliced transcripts into the cytosol for translation. 
Importantly, the structural proteins of the gag-pol polyprotein and the env spike 
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protein are only translated during these later stages of transcription, dependent on 
Rev accumulation, and are characterized as ‘late’ genes of the HIV lifecycle28.  
 
 Multiple higher order RNA structures on the HIV transcript govern its trafficking 
and encapsidation, most notably in the proximal region of the gag RNA34,35. 
Interestingly, the gag protein product binds its own coding transcript during the 
loading of genomic HIV RNA onto the nucleocapsid structure36, an interesting 
wager by the virus on the importance of gag37. These features drive the strict 
sequence conservation of the gag region, both at the protein level and primary 
sequence level required for RNA secondary structure and protein binding.  
  
Early establishment of HIV infection 
 
Chronic HIV-infection in humans is characterized by a period of 
asymptomatic viral dissemination38. During this time, the virus spreads and adapts 
to a multitude of cellular reservoirs, including memory CD4-positive T-cell subsets, 
the definitive ‘latent reservoir’ for HIV in vivo39-42. The asymptomatic chronic phase 
is characterized by only a slow decline of CD4 cells in the mucosa and blood, 
coupled with persistent immune activation and gradually increasing viremia 43. 
During this phase, humoral immunity suppresses any explosive replication, such as 
that observed during the acute phase of infection before seroconversion (the 
emergence of HIV antibodies in the blood). For patients on fully suppressive 
antiretroviral therapy (ART), new infections or reactivation of latent provirus will 
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produce virions that are then rendered non-infectious by drugs in the blood, or in 
the deep tissues where drug penetration reaches therapeutic concentrations 44.  
 
The foundation of current ART regimens is the rapid arrest and death of HIV-
infected T-cells, a process naturally mediated by the HIV protein Vpr 45, combined 
with the drug-based inactivation of any virions that are produced. Thus, after an 
initial period of viral decay following ART initiation 46 the number of HIV virions or HIV-
infected/transcribing cells found in the bloodstream is vanishingly small. However, 
identification of these cells is a key challenge, since monitoring ‘blips’ or flare-ups 
of HIV infection during ART regimens is critical for the quantification of the size and 
temporal decay of the HIV reservoir with prolonged drug treatment 39.  
 
Biphasic decay during ART reveals the HIV reservoir 
 
Measurement of bloodborne HIV decay kinetics from patients newly started 
on ART therapy reveals a biphasic curve 46 similar to that in Figure 2. The two slopes 
of decay have been suggested to implicate two principal cell populations with 
different half-lives that continue to produce HIV after ART initiation, declining until 
HIV falls below the theoretical assay detection limit 41,43.  The interpretation of these 
results has been problematic for two reasons. First, with continued improvement of 
assay methodology, additional HIV replication activity below the theoretical 
detection limit has been proposed, suggesting HIV production is being ‘missed’ in 
standard assays47,48. Secondly, the shedding of HIV virions into the bloodstream 
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during ART must occur by rare cells in the blood or in tissues with ready access to 
the bloodstream. Thus, while our ability to detect bloodborne HIV has improved 
dramatically since the initial interpretation of the biphasic decay curves, an 
unmitigated obstacle remains: we still have no reliable means to relate the 
measured HIV burden in blood with the true HIV burden within tissue. More so, there 
is no data on the extent to which HIV-infected cells in tissues contribute directly to 
plasma viremia, if at all. In the same way that cerebrospinal fluid proteins or 
pulmonary surfactant proteins are not found in the bloodstream, tissue HIV virions 
are compartmentalized and do not cross endothelial boundaries passively49,50. 
During ART, HIV found in the blood is therefore a symptom of underlying tissue HIV 
infection; upon ART interruption or failure, these tissue reservoirs seed new infections 
in CD4 lymphocytes and other target cells that can actively enter the bloodstream 
to produce viremia39.  Hence, the identification of HIV-infected cells during ART 
treatment remains a key paradigm in the search for curative HIV therapy. Ongoing 
work with humanized mice will likely soon provide some clarification of these issues 
51, but these mouse models do not recapitulate the full spectrum of human HIV 
infection or persistence. 
 
Myeloid reservoirs of HIV 
 
Of considerable interest is whether these reservoirs can form in macrophages 
in addition to the well-described memory T-cell reservoir. Such a possibility is 
strengthened by the observation that HIV replicates and adapts within 
macrophages in late stage AIDS in humans when T-cell numbers dwindle 52, in T-cell 
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poor environments like the brain53, and in humanized mice lacking CD4 T cells 
altogether 54,55. In these scenarios macrophage-tropic virus strains emerge, 
indicative of underlying macrophage replication and adaptation over time. 
Macrophage-tropic viruses are able to infect cells with low expression of CD4 
protein and high CCR5 expression, as found on a variety of myeloid cells in vivo and 
monocyte-derived macrophages and dendritic cells in vitro 53, but are also able to 
infect T-cells with high levels of CD4 and much lower CCR5 expression56. The reverse 
is not true, however: viruses highly adapted to infect T-lymphocytes (T-cell tropic) 
require very high levels of CD4 expression and are thought to infect macrophages 
with many fold lower efficiency57. Importantly, the key group of viruses called 
transmitted/founder (T/F) HIV are uniformly T-cell tropic using CCR5 as the co-
receptor and high concentrations of CD457, and appear to have reduced entry 
and replication in human monocyte-derived macrophages (HMDM)58. These T/F 
viruses are identified within individual patients by careful population analyses59. In 
short, the sequence of the furthest common ancestor virus can be deduced from 
a pool of diverse strains found in a single patient by clustering related populations 
of viral genotypes. This ancestral genotype represents the closest estimate of the 
virus that infected the patient, and thus its properties including cell tropism, 
mechanism of transmission, and replication in various cell types are of intense 
interest. However, the likelihood that T/F viruses reside in tissue macrophages in vivo 
has been questioned, an argument supported by several key findings: (1) poor T/F 
virus replication over time in HMDM cultures in vitro58, (2) inefficient entry of T/F 
envelope (env) proteins into cultured HMDM60, (3) lack of available data showing 
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robust macrophage infection in human patients 61, and (4)  the predominance of 
T-cell CCR5-tropic HIV at all stages of HIV infection in acute, chronic, or ART-treated 
HIV patients62,63.  
 
Taken together these observations seem to argue against a role for 
macrophages in harboring T/F HIV in vivo. However, they overlook key features of 
HIV biology in macrophages, and may underestimate the true ability of these 
complex cells to harbor T/F virus in vivo during persistence and transmission. First, 
these studies were performed on primary HMDM cultures, an arguably weak model 
for human tissue-resident macrophages. The classical monocyte-macrophage 
lineage was thought for many years to be the source of tissue-resident 
macrophages; over time, tissue macrophages were thought to be turned over and 
replaced by incoming blood monocytes that differentiate locally to macrophage 
cells64,65. Recently, however this paradigm has been revised. A series of critical and 
rigorous experiments demonstrated that tissue resident macrophages such as 
Kupffer cells (liver), microglia (brain) and alveolar macrophages (lung) derive from 
an embryonic yolk sac-fetal liver lineage that swarms the tissues in the days 
surrounding parturition66-68. Moreover, these studies showed the self-renewal of 
tissue macrophages by proliferation during normal homeostasis; thus, resident 
macrophages may persist for many years, even the life of the organism. Contrast 
this with HMDM, which differentiate from blood monocytes but are terminally 
differentiated and do not proliferate in vitro or in vivo69. Furthermore, HMDM are 
inflammatory effector cells, subject to polarization along the classical M1 and 
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alternative M2 activation pathways in the initiation and resolution of inflammation69. 
Conversely for example, alveolar macrophages (AMs) are largely anti-inflammatory 
cells, sentinels of the airway that discern true incoming pathogens from the 
continuous barrage of innocuous airborne stimuli that flood the airway with each 
breath70,71. In mammals, there is perhaps no greater evolutionary pressure than that 
of a maintained airway, and the function of AMs is to prevent non-specific 
inflammation in this compartment. Hence, AMs and HMDMs are highly divergent, 
yet HMDM are the exclusive human macrophage population used to model in vivo 
myeloid infection. On the basis of cell proliferation alone, a process disrupted by 
HIV, the HMDM model cannot represent proliferative tissue macrophage lineages. 
On a backdrop of the challenges to harvest macrophages from solid human tissues, 
and the scant information about optimal culture conditions ex vivo, the shortage of 
robust data on HIV in tissue macrophages is not surprising. However, their relevance 
to persistence and cellular transmission remains highly provocative, and recent 
findings of tissue macrophage embryonic origins has opened new opportunities to 
study these cells in the context of HIV infection.  
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CHAPTER TWO 
 
Molecular identification of cellular HIV infection: Tools for functional genomics of 
HIV-infected cells in vivo 
 
In this chapter, I describe the development of a fluorescent in situ hybridization 
assay to identify individual HIV-infected cells by flow cytometry. I discuss several 
ways the assay was refined to adapt it for improved sensitivity and specificity, and 
using the FISH:FLOW tool I present important caveats for the use of a standard HIV 
reagent.   
 
The section in chapter 2 on Quantitative HIV biology with FISH:FLOW 
population analyses is published as a corresponding author paper:  
Wilburn KM, Mwandumba HC, Jambo KC, Boliar, Solouki, Russell DG, 
Gludish DW. Heterogeneous loss of HIV transcription and proviral 
DNA from 8E5/LAV lymphoblastic leukemia cells revealed by RNA 
FISH:FLOW analyses. Retrovirology. 2016 Aug 11;13(1):55 
 
 
 
The experiments described in this chapter were performed in co-operation with two 
rotation students in the laboratory, Kaley Wilburn (FISH protocol optimization with 
zwittergent and probe titrations, and 8E5 subcloning and FISH:FLOW 
characterization) and Sabrina Solouki (8E5 p24/FISH co-labeling).  
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INTRODUCTION 
Cell-level identification of HIV in vivo 
 
Identification of HIV-infected cells in vivo using current technology is 
challenging72. While the p24 antigen assay (measure of HIV gag production by flow 
cytometry or ELISA) is an industry standard approach for research purposes, 
background staining and the small yield of HIV-positive cells in even large volumes 
of patient blood makes this approach prone to artifacts; the theoretical detection 
limit of these assays is 0.1%72, which in many cases far exceeds the proposed HIV-
infected fraction in the blood during ART (0.5-10 cells per million)72,73. Molecular 
identification of HIV by protein antigen staining alone is highly problematic, and 
must be considered a very minimal estimate of the true cell-associated HIV burden. 
Furthermore, recent movements in the field suggest that targeting HIV in tissues – 
not just in the blood – will be a necessary step to clear HIV reservoirs that persist 
during ART39. A streamlined approach to identify HIV-positive cells from patient 
tissue material is needed to understand where to find HIV reservoir cells, to quantify 
their decay in the face of current ART regimens, and to learn how to target them 
for destruction with future therapies.  
 
To this end, we pursued a novel molecular assay to detect HIV-positive cells 
in a bulk population. Using a fluorescent in situ hybridization approach (FISH), 
individually fluor-conjugated, single stranded DNA oligonucleotide probes are 
hybridized to cell-associated HIV-1 RNA in a cell suspension (Fig. 2). After washing, 
cells are analyzed by flow cytometry (FLOW) or by fluorescence-associated cell 
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sorting (FACS) to detect HIV-1 probes, even in rare cells. Importantly, many short 
(~25bp) probes cover a long section of the target HIV RNA, enabling more 
tolerance of mismatches in the genetic sequence than would be accommodated 
during antibody staining. We present a workflow for identification of prospective 
probe targets, and highlight the flexibility of the FISH:FLOW platform in multiple cell 
systems.  
FISH:FLOW optimization: toward RNAseq on sorted cells 
 
Our laboratory previously developed the HIV FISH:FLOW assay using 
probesets targeting HIV-1 gag74 (Fig. 2). The discovery of HIV-positive cells among 
AMs in human BAL was a first, important step towards characterizing this tissue 
compartment as an anatomical HIV reservoir. However, several key points 
remained unresolved. For example, does the RNA signal observed correlate to 
productive HIV infection? The FISH:FLOW method cannot distinguish full length HIV 
from highly deficient proviral insertions that are now thought to predominate in 
vivo75,76. Similarly, does the HIV RNA observed give rise to replication competent 
virions that could initiate infection in new host cells? To qualify as reservoirs, HIV-
positive AMs must shed new infectious virus capable of initiating rebound infection 
after ART treatment is interrupted.  
 
 Definitive answers to these questions require at least one of two lines of 
evidence. Either the complete sequence from individual infected cells must be 
determined and the full-length virus synthesized for testing replication competence, 
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Figure 2. Schematic of FISH:FLOW pipeline. A 
series of short (~25nt) single stranded (ss)DNA 
probes each with a fluorescent label are 
hybridized to RNA within PFA-fixed and ethanol- 
permeabilized cells in suspension. 
Approximately 1000bp of contiguous HIV mRNA 
is detected with a given probeset. After 
washing the cells are passed through a flow 
cytometer to quantify increased HIV signal in 
the infected subset (red cells). Using a 
fluorescence activated cell sorter (FACS), the 
HIV probe-positive and -negative cell 
populations can be purified for transcriptional 
profiling and functional genomics.  
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 or the primary AMs must be cultured with susceptible cells to establish supernatants 
with replicating virus. Ultimately the demonstration of infectivity must include some 
measure of virus outgrowth in vitro or in vivo48,77-80. In complimentary approaches, 
we pursued both the sequence-based and outgrowth-based platforms to 
characterize the potential HIV reservoir within AMs of the human lung. 
RESULTS 
Adaptation of the FISH:FLOW platform for purification of HIV-infected cells 
The primary objective of these early experiments was to identify the viral 
genetic sequence within HIV-infected AMs isolated from Malawian adults by BAL. 
By staining BAL cells with FISH probes and physically sorting the positive cells by 
FACS, enrichment of viral RNA in the cell population would enable PCR- or RNAseq-
based derivation of viral sequences. A key strength of the RNAseq pipeline is the 
potential to discern multiple sequence variants, and thereby examine the 
heterogeneity of the virus in the airway compartment during various phases of HIV 
infection. In theory, one could determine the types of mutations/variants 
accumulating in specific cell populations (AM vs. lymphocyte) in the airway in the 
presence or absence of ART therapy, or during acute or chronic infection. These 
are highly compelling opportunities, given the paucity of robust clinical data on 
cellular reservoirs and viral persistence among Clade C patient cohorts in Africa.  
 
Based on our lab’s prior success using FISH:FLOW staining in human AMs74, I 
planned a pilot experiment to demonstrate proof of principle in human-derived 
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in this experiment given their ease of access from all patients attending the HIV 
clinic at the Queen Elizabeth Hospital in Blantyre, Malawi. Bulk PBMC were stained 
with HIV gag FISH probes and prospective HIV-positive cells were FACS-purified on 
a BioRad S3e instrument (Patient No.272, Fig.3A). RNEasy FFPE-isolated RNA was 
prepared for RNAseq and the sequence analysis performed as described in 
Methods.  
 
 Alignment of the RNA reads to the HIV genome illustrated what is perhaps 
not surprising in retrospect. The greatest abundance of HIV reads aligned with the 
LTR sequences: areas of the genome present on every transcript off the provirus 
(Fig. 3). Conversely, the V3 ectodomain loop region of env had the lowest 
coverage, suggesting the genetic divergence of the input virus in this region 
precluded correct alignment with the NL4-3 reference genome. Confidence in the 
transcription data is increased by the observation that the aligned reads begin just 
PBMCs
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RNAseq
Figure 3. HIV transcriptomics of HIV-infected PBMC by FISH:FACS purification. A Bulk 
PBMC from patient No.272 were stained with HIV gag FISH probes and purified on a 
BioRad S3e instrument. Isolated RNA was sequenced on the MySeq instrument as 
described in Methods and B reads were aligned to the NL4-3 reference genome using 
Geneious 8. The area in the gag ORF targeted by FISH probes is highlighted in yellow. 
The V3 loop is highlighted in pink, and represents an area of high sequence variability 
where the reads returned failed to align with the reference genome. 
 20 
downstream of the annotated transcription start site in the distal 5’ LTR TAR region, 
suggesting a transcription product, and not contaminating plasmid or genomic 
DNA, is the source of the aligned reads.  
 
While the fluorescence shift of gag-positive cells in the PBMC cell population 
was discernable, somewhat limited separation was observed between positive 
signal and background staining (Fig. 3A). I hypothesized that multi-color staining or 
improved probe design might also improve gating for future sorts, especially from 
primary human tissues where transcription of HIV might be lower than in peripheral 
lymphocytes. Human AMs in particular are variably auto-fluorescent, thus robust 
detection reagents will aid identification of the HIV-positive and -negative cell 
fractions in BAL samples.  
Development of improved FISH probes (NEF) 
Informed by the coverage distribution of RNAseq reads above (Fig. 3B), I 
reasoned that FISH probes targeting the LTR or nef regions might yield improved 
assay performance. To test this, additional probesets were designed against the 
5’LTR region, the 3’LTR (including some nef ORF) and the nef-exclusive region (Fig. 
3). These sequences are present in every transcription product of the inserted 
proviral genome and thus may represent more optimal detection targets.  The 
probes were tested in JC-53 HeLa cells (stably express HIV co-receptors CXCR4, 
CCR5, and  CD4)81 infected 48 hours prior with VSV/G-pseudotyped HIV-GFP (Fig. 
4A). Relative to mock-infected cells (Fig. 4B-G), comparison was made between 
gag probe staining and each of the new probes (Fig. 4H-M). Interestingly, versus the 
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gag probeset (Fig. 4I, orange) a more dramatic shift was observed using the probes 
to nef (Fig. 4JK, purple) and 3’LTR (Fig. 4L, magenta), while the 5’LTR (Fig. 4M, blue) 
probe generated an intermediate shift. The separation of these populations is better 
Figure 4. HIV1 nef FISH:FLOW probe 
validation. JC-53 cells were infected 
with VSV-HIV-GFP (A) for 48 hours. Cells 
were trypsinized, fixed and processed 
for FISH:FLOW. Background staining in 
each channel from mock-infected cells 
(B-G) is used to set gates. Multi-color 
overlay of infected cells shows the 
relationship of internal GFP reporter to 
gag and nef probes (H-J), and of all FISH 
probes to gag staining (K-M). N-R 
Histogram for positive (bright) and 
negative gates (darker shades) with 
mock-infected signal in grey. S 
Interquartile bar plots with median 
fluorescence intensity of the positive 
(bright) and negative gates (darker 
shades), with the mock-infected signal 
for each channel (hatched). The 
calculated signal to noise ratio (S/N) for 
each channel is given.  
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appreciated in the fluorescence histograms, Fig. 4N-4R.  Importantly, these probes 
yielded improved signal to noise ratios over gag FISH staining (gag S:N 6.8x, Fig. 4S 
orange). Indeed, the signal to noise ratio of 13.6-fold for the nef probe (Fig. 4S 
purple) was a twofold increase over the ratio of gag probe, and even gave greater 
signal separation than internal GFP reporter carried by the virus (8.0-fold S:N, Fig. 4S, 
green). For each channel, the median fluorescence intensity (MdFI) for the positive 
and negative gates in infected and FISH-stained cells (colored bars in Fig. 4S) were 
compared with the MdFI of uninfected cells stained in the same experiment 
(hatched bars, “mock”, Fig. 4S). Uninfected (FISH-negative) bystander cells and the 
bulk cells from uninfected wells exhibited similar staining distributions, suggesting 
cells from infected wells that stain positive for FISH probes harbor true HIV 
transcription, even in a mixed population of high HIV penetrance.  
 
  A key observation was made that for nef and 3’LTR probe staining, almost 
no gag signal was observed in the nef-negative (0.05%, Fig. 4K gag+/nef-) or 3’LTR-
negative gate (0.77%, Fig. 4L gag+/3’LTR-). This finding is consistent with the well-
described staged transcription of HIV and the ‘late’ character of gag gene 
transcription28; no gag transcription is expected in any cell without early transcripts 
such as nef first expressed. Together, the data demonstrate (1) that additional FISH 
probes to these high-abundance transcript regions might improve the separation 
of HIV probe-positive cells in clinical samples, and importantly that (2) FISH:FLOW 
provides a means to dissect the lifecycle of HIV in vivo, discriminating early from late 
gene transcription at the level of individual cells. This is of particular interest given 
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the shortage of methods to conveniently quantify the reactivation of latent HIV 
during ‘shock and kill’ approaches to target the HIV reservoir in human clinical 
trials39; the effects of such strategies on the size of the viral reservoir remain difficult 
to quantify.  
 
Importantly during the course of this work, similar RNA FISH-based 
approaches to reservoir quantitation were published72,73, reflecting heightened 
interest in cell-level readouts during HIV reservoir analyses. The authors focused on 
a mixed protein/RNA FISH staining platform both tied to the gag/pol ORF, and thus 
lack resolution to distinguish early (new) from late (established) infections. In 
relevant tissue reservoirs like the human airway, it is of great interest to learn whether 
established infection in AMs persist during ART, or whether evidence of new 
infection can be found. The FISH:FLOW method with physical purification is ideally 
suited to enrich HIV-infected cells from a bulk lavage population, simultaneously 
learn whether any of these infections are likely to be recently-infected cells, and to 
characterize the transcriptional profile of the infected host cells. This last point is 
critical to specifically target HIV-infected cells in the tissues. A recent report made 
a similar advance for peripheral blood reservoirs, and identified CD32a as a specific 
surface marker of T-lymphocytes harboring latent HIV proviruses82.  
Establishment of the FISH:FLOW assay for Simian Immunodeficiency Virus (SIV) 
 
Controlled in vivo studies of the HIV latent reservoir are confined to model 
systems like macaque monkeys with SIV or SHIV hybrid viruses. Any broad adoption 
of the FISH:FLOW platform requires portability to the related but not identical SIV 
 24 
model system. To establish the utility of the FISH assay in this arena, new gag and 
nef probes were manufactured to target SIVmac239, a common reference virus 
used during SIV studies in vivo83. VERO cells (from African green monkey kidney) 
were infected for 48 hours with viral supernatants containing SIVmac239, then 
trypsinized, PFA-fixed and stained with SIV FISH probes as described above for HIV 
in vitro infections.  
 
Figure 5. SIVmac239 nef FISH:FLOW probe validation. 
VERO cells were infected with SIVmac239 for 48 hours. Cells 
were trypsinized, fixed and processed for FISH:FLOW. 
Background staining for each probe in mock-infected cells 
(A,C,E) was used to set gates. Infected cells (B,D,F) stain 
positive for FISH probes to nef (B) and 5’LTR (D), but not with 
an irrelevant probe (scramb, F). 
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FISH:FLOW analyses revealed that cultured VERO cells generated clean SIV 
nef-positive signal compared to uninfected control cells and, importantly, to cells 
stained with an irrelevant/scrambled, fluor-labeled probe (Fig. 5). However, the shift 
in SIV nef fluorescence was less robust than that observed during parallel 
experiments staining in vitro infected JC-53 cells with the HIV nef probe (Fig. 6). While 
VERO cells may be less ideal hosts for SIV transcription, the results suggested 
additional optimization might improve the dynamic range of the assay. After taking 
stock of the FISH:FLOW assay strengths and weaknesses, considerable investment 
was made to address some systematic issues, and to improve the specificity and 
sensitivity of the FISH:FLOW assay, summarized below.  
 
 
TABLE 1.   Optimization of the RNA FISH:FLOW assay 
Technical issue Remedial action/troubleshooting Data 
Weak shift with gag probe New probe design: nef Fig. 4 
Cell loss during liquid transfer Detergent/ Denhardt's Solution Not shown 
Uncertain probe target RNAseA treatment post-fixation Fig. 6 
Low RNA quality post-fixation OneStep fixative, RNAse inhibitor Not shown 
Low signal:noise ratio Blocking reagent optimization Fig. 7 
Single criterion (RNA) detection Multiplex with antigen staining Fig. 11 
 
Determination of FISH:FLOW probe target specificity 
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 It is important to determine whether the signal observed during FISH:FLOW 
analyses corresponds to HIV RNA, and not genomic DNA or other non-specific 
binding. To address this, JC-53 cells were infected with a titration series of HIV-GFP 
(Fig. 6), and monitored for GFP expression. At 36 hours post-infection, the cells were 
trypsinized, fixed in PFA and treated with RNAse A (or 2X SSC vehicle control) prior 
to processing for FISH:FLOW analyses with gag probes (Fig. 6). Thirty-six hours after 
inoculation with the highest dose (1mL) of virus supernatant, approximately 9% of 
analyzed cells were positive for GFP expression compared to mock-infected 
controls, with less than half of those (3.8% total) also staining gag-positive by FISH. 
This result highlights the nature of the GFP reporter in the HIV-GFP construct, where 
the IRES-GFP cassette is regulated with the nef ORF (Fig. 4A), an early Rev-
Figure 6. FISH probes detect mRNA in HIV-infected 
JC53 cells. A-D Titration of HIV-GFP inoculum dosage 
yields increasing fractions of GFP-positive JC-53 cells. 
Gates were set using uninfected cells (A). Replicate 
cultures of the highest HIV dosage (1,000uL, D) were 
treated with 100µg/mL RNAseA for 20 minutes at 37°C in 
2X SSC buffer prior to washing and processing for RNA 
FISH:FLOW. To analyze shifts with and without RNAse 
treatment, the elliptical gates in D and E are plotted in F. 
The median fluorescence intensity (black line, F), 
interquartile range (colored bars), and the 1-99 
percentile error bars demonstrating signal range are 
shown.   
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independent gene, while gag is a late gene requiring production of Rev. Thus, the 
GFP-positive but gag-negative cells represent a population of recently-infected 
cells in the early phase of viral transcription – this is an expected finding at this early 
timepoint post-infection (36 hours).   
 
Importantly, treatment of the cells with RNAseA prior to FISH hybridization 
revealed two key insights. First, loss of total cellular RNA completely ablated the gag 
FISH signal (note the GFP fluorescence signal was spared), showing the species 
detected by HIV FISH is in fact RNA. And secondly, a nearly fourfold decrease in 
FISH probe signal intensity was observed in the HIV-negative cell population upon 
treatment with RNAseA (Fig. 6, 3.9x MFI decrease), suggesting that cellular RNA in 
general serves as a site for non-specific probe binding. While the FISH protocol 
includes E.coli T-RNA as a blocking reagent in the hybridization buffer, the 
observation that non-specific signal was ablated upon digestion of cellular RNA 
suggested that a strategy to block the binding of fluorescent probes to cellular 
mRNA would enhance the specificity of the assay.  
  
Optimization of FISH:FLOW hybridization conditions 
 
I devised a modified blocking strategy to (1) compete with non-specific  
binding of ssDNA probes and (2) provide more stringent interactions of probe 
with target. The first aspect was approached with a scrambled, unlabeled ssDNA 
oligonucleotide, more akin to the actual target FISH probes used for staining than 
the highly ordered tRNA reagent used in the existing FISH protocol. The second  
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parameter of stringency was addressed by titrating a detergent, Zwittergent 3-12, 
into the hybridization reactions. Hybridization reactions were carried out using 
various concentrations of zwittergent and equal concentrations of either E.coli tRNA 
(“H-buffer”) or the new dsDNA oligo blocking reagent (“X-buffer”), and the 
hybridization carried out as previously. The performance of the blocking reagent 
was established in SIV-infected VERO cells, given the relatively weaker signal-to-
noise ratio in this system.  
 
The SIV nef-positive signal obtained using X-buffer hybridizations was 
modestly lower (~15%) compared to the standard H-buffer sample (geometric 
mean calculations, Fig. 7B). However, a much larger decrease of more than 50% 
was observed in the SIV-negative gate, indicating the oligo blocking reagent 
improved the separation of the negative and positive cell populations in the FISH 
assay. This was quantified as the mean signal to noise ratio, dividing the geometric 
means of the positive and negative gates (Fig. 7, ratios indicated above each 
group).  
 
Interestingly, signal improvements were also gained using Zwittergent 
addition, but the effect observed was inversely correlated with zwittergent dosage. 
While zwittergent addition routinely provided improved signal to noise metrics 
compared to no detergent added, the most dilute preparations of zwittergent 
yielded the best signal separation (Fig. 7AB). Using standard hybridization conditions 
(H-buffer, no zwittergent), the signal to noise ratio for the SIV probes was 4.3-fold, 
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while the best condition tested was oligo/X-buffer hybridization (9.3-fold) with the 
lowest concentration of Zwittergent tested in this experiment (0.00125 mg/mL). 
These results were repeated in several experiments with similar results, revealing that 
Zwittergent performance was optimal with low concentrations of FISH probe in 
oligo-containing X-buffer (unpublished data).  
 
The inverse dose response of Zwittergent could be due to several factors, 
including potential autofluorescence of the detergent, or its induction of 
autofluorescence among fixed cells or nucleic acids within FISH-stained cells at 
higher detergent concentrations. In this scenario, any effects of lowering 
background probe binding would be counteracted by higher autofluorescence. 
However, acquired signal in the unstained FTIC channel was not affected at any 
zwittergent concentration, arguing the improved hybridization signal to noise ratio 
in the presence of zwittergent was related to the probe:target or probe:non-
specific target interaction, and not to fluorescence of the zwittergent reagent itself. 
Future experiments should test this using titrations of a labeled, scrambled/irrelevant 
probe, and confirm the effects in primary cultured macrophages prior to its use in 
human clinical samples. However, the reproducible effect of zwittergent in these 
reactions suggests this additive is a useful tool to gate FISH-positive cells during flow 
cytometry.  
 
Quantitative HIV biology with FISH:FLOW population analyses 
 
It is well established that HIV establishes a latent reservoir in memory CD4+ T-
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cell subsets39,40, rare cells that exit the cell cycle following activation and HIV 
infection. In the absence of activation-associated genes such as NF-kB, HIV 
transcription is ceased and the provirus enters ‘latency’. The infected cell circulates 
until a time when the cell encounters specific antigen, or is otherwise activated into 
proliferation. This latent reservoir is the roadblock to an HIV cure, since latent virus is 
not immunogenic, produces no cytopathic effects, and is not cleared by the 
immune system39.  ‘Shock and kill’ is a recently proposed strategy to achieve 
functional HIV cure, and involves screening for chemical compounds or other 
biomodulators that can drive HIV proviral transcription in latent cells84. This strategy 
aims to avoid wholesale activation of all memory cells, a scenario leading to 
hyperactivation and a likely fatal cytokine storm. While some progress has been 
made toward this goal, it became clear early on that we lacked a robust assay to 
measure the HIV transcription at the cellular level to learn whether prospective 
treatments were having the desired effects in vivo. Whole sessions at several recent 
high-profile HIV meetings were dedicated to such assays. A suitable approach 
would also directly quantify the inducible reservoir, and thereby help illuminate the 
scale of the challenge faced in pursuit of an HIV cure. Currently, the field has several 
means to measure the inducible HIV reservoir, and they all seem to give different 
answers and make different assumptions about the underlying cell biology77,79,80,85. 
Until very recently, cell-level readouts were not available for such studies. 
 
The FISH:FLOW assay would seem an ideal tool for quantitation of HIV-
transcribing cell populations. While the assay requires the provirus to be actively 
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transcribing (it is an RNA assay), and is therefore not useful in measuring the latent, 
resting HIV reservoir, I reasoned that any approach to shock cells out of latency 
could be easily quantified with FISH staining.  In an effort to establish the quantitative 
sensitivity of the assay using a cell platform in common use among HIV researchers, 
I turned to the 8E5 cell line86.  
8E5 lymphoblastic leukemia cells 
The 8E5 subclone was isolated from HIV(LAV)-positive A3.01 lymphoblastic 
leukemia cells that survived HIV infection in vitro86, and was the first such reagent 
described in the literature. Early analyses revealed that all 8E5 cells harbored a 
single HIV-1/LAV provirus, shedding intact but defective HIV virions86. A single amino 
acid substitution in the reverse transcriptase (RT) coding region of the gag-pol 
polyprotein renders the virions non-infectious87, effectively holding static the 100% 
HIV penetrance among 8E5 cells in culture. It was not established why this particular 
cell clone was refractory to the cytopathic effects of the virus, but a lesion in the 
cell cycle arrest machinery required by the HIV gene vpr seems a likely candidate. 
As a result of their properties, these cells have been employed worldwide for the 
standardization of patient sample PCRs in the clinic88, and are ideally suited as tools 
for validating single cell approaches to study the latent HIV reservoir. Using serial 
dilutions of 8E5 cells with known proportions of uninfected lymphoblasts, a standard 
curve can be generated using cell associated RNA or DNA – the same input 
material that can follow an identical sample pipeline as the patient-derived 
material being tested by PCR or other approaches.  
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Unexpected low penetrance of HIV mRNA expression in 8E5 cultures 
 
To test the limits of the FISH:FLOW assay, I generated a dilution series of 
8E5/CEM cell standards and analyzed them by FISH:FLOW. Surprisingly, I found the 
starting 8E5 population was heterogeneous with only 4.5% positive for HIV nef (Fig. 
8A) and 2.9% for gag transcripts detected by RNA FISH (Figure 8B). However, almost 
all gag-positive cells also stained nef-positive as expected (Fig. 8C). Dilutions of 8E5 
cells with uninfected CEM cells yielded a linear standard plot (Fig. 8D), as might also 
be expected from PCR analysis of comparable dilution series. However, the 
absolute number of viral genomes inferred by this method would underestimate the 
true values obtained using standards that assumed 100% of 8E5 cells in the starting 
population were HIV-infected.  
 
Figure 8. 8E5 cells exhibit partial HIV mRNA penetrance but yield linear standard 
curves in dilution series. A,B 8E5 cells stained with HIV nef FISH probe (Quasar670, A) or 
HIV gag570 probe (B), revealing low penetrance of HIV transcription in the 8E5 
population. C Multiplex FISH stain, showing that all gag-positive cells are also HIV nef-
positive. D Sub-penetrant 8E5 cells were mixed in known proportions with uninfected 
CEM cells to generate a standard curve. Populations were stained by FISH and 
quantified for HIV penetrance by flow cytometry (not shown). The measured % nef-
positive population was plotted against the expected % nef-positive fraction, 
according to a fully penetrant 8E5 population. A linear titration curve is obtained 
despite the actual penetrance of 8E5 of less than 5% in this population, revealing the 
inherent weakness of the 8E5 calibration standard for HIV genome quantification.  
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Maintenance of HIV expression in a cloned subpopulation of 8E5 cells 
  
 HIV transcription may not proceed in all 8E5 cells at all points in the cell cycle, 
a scenario that could explain a subpopulation of HIV RNA-negative cells in 8E5 
cultures. However, given the observed low fraction of positive cells, I reasoned that 
proviral loss or durable silencing89,90 would more likely account for a majority of cells 
negative for HIV nef or gag mRNA. To assess the maintenance of the HIV proviral 
genome in 8E5 cells 200 subclones were generated by limiting dilution, and 
expanded for analyses by FISH:FLOW (Fig. 9).  Subclones were first combined into 
pools of 20, and screened for HIV positivity. Surprisingly, only one subclone pool 
(Pool J) showed signal for HIV nef at a frequency suggesting that only a single clone 
in the pool was positive (Figure 9B).  When subclones were analyzed individually it 
was found that most clones were entirely negative for nef RNA (representative 
clone J3, Figure 9B). By contrast, clone J20 was homogeneously positive for HIV nef 
Figure 9. HIV FISH analyses of 8E5 subclones yields a single HIV-positive clone, 
J20.The sub-penetrant 8E5 population was subcloned by limiting dilutions in multiwell 
plates. Individual clones were picked and pooled into groups of 20 subclones to screen 
for HIV-positive pools. Pool J (A) was the only pool staining positive for nef. Analyses of 
individual “J” subclones (B,C) reveals nineteen subclones are HIV negative 
(representative clone J3, B), and a single subclone “J20” (C) is fully penetrant for HIV 
nef transcription.  
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RNA by FISH:FLOW analyses (Figure 9C). FISH:FLOW analysis with HIV gag RNA probes 
yielded similar results (data not shown).  Interestingly, the lower than expected 
frequency of HIV-transcribing clones (1/200 vs. ~4.5/100 expected) suggests that 
cells containing active HIV proviral genomes are at a survival or clonogenic 
disadvantage compared to those that have silenced or lost the provirus.  
 
 Absence of HIV transcription could result from proviral silencing or loss of 
proviral genomic DNA. Either scenario could be the product of negative selective 
pressure experienced by HIV-infected lymphoblasts in long-term culture. 
Transcriptionally silent or HIV-negative subclones within the 8E5 population would 
have a growth advantage, and would rapidly outcompete the HIV-expressing 
population. To address this experimentally I compared relative frequencies of 
Figure 10. 8E5 subclones exhibit proviral silencing and DNA loss. A HIV gag DNA PCR 
identifies pool J subclones harboring provirus. B Corresponding gag qRT-PCR products 
reveals only clone J20 expresses gag mRNA. C Amplification of cellular RNA samples 
with no RT added. D Corresponding nef FISH plots reveal that HIV nef FISH:FLOW predicts 
gag PCR outcome.  
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proviral DNA (Qiagen QIamp) and HIV gag mRNA (Trizol) by qPCR and qRT-PCR 
(BioRad iTAQ). Two independent regions of gag were amplified and normalized to 
GAPDH genomic DNA or cDNA from the same sample (Figure 10AB, GAPDH data 
not shown). Intriguingly, some subclones lacking HIV nef transcripts still harbored 
gag proviral DNA, while in other subclones the HIV provirus was undetectable. 
Possible genomic DNA contamination was ruled out using controls lacking reverse 
transcriptase (no RT, Figure 10C). The segregation of positive and negative clones is 
clearly visible in the corresponding FISH contour plots for each subclone (Figure 
10D). This is the first molecular evidence that RNA FISH:FLOW analyses accurately 
predict the HIV status of individual infected cells. Together the data indicate that 
both proviral genome silencing and genome deletion are occurring in 8E5 cells 
maintained in culture.  Interestingly, the LAV provirus in 8E5 is integrated at 
Figure 11. 8E5 cells commercially available 
demonstrate HIV heterogeneity and loss of 
penetrance over time. A Fresh 8E5 cells obtained 
from the AIDS Reagent Program were cultured for 5 
days prior to analysis by FISH:FLOW with nef and gag 
probes. High dilution subculture for 10 passages (B) 
leads to loss of HIV transcription and gag protein 
production. 
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chromosome 13q14-q2191, a site containing common fragile sites that would render 
this clone susceptible to proviral loss by genomic instability.  
 
A fresh aliquot of 8E5 cells was obtained from the HIV AIDS Reagent Program 
to determine whether population heterogeneity might be a consistent feature of 
these cells. These 8E5 cells were tested by nef and gag RNA FISH within 5 days of 
their establishment in culture.  The nef-positive gate constituted the main population 
of cells (72%, Figure 11A). Importantly, no cells stained positive for gag RNA without 
also expressing nef RNA in this multiplex assay as would be expected based on the 
staged transcription of HIV28. This representation highlights the ability of FISH:FLOW 
to discern among different stages of HIV infection (gag heterogeneity in the nef+ 
population).  Subsequent passaging of the newly obtained cells at a 1:10 ratio led, 
by passage 10, to the reduction of nef and gag RNA-positive cells below 50% (not 
shown). Aggressive subculture by splitting the cells very low (bottleneck founder 
effect) accelerated the loss of nef transcription, where only 15% of 8E5 cells fresh 
from a public repository transcribed HIV nef by passage 10 (Figure 11B); importantly 
almost all of the nef-positive cells also stained p24-positive (Beckman anti-p24 
KC57). These data demonstrate that FISH:FLOW is a surrogate assay for standard 
measures of HIV production and that the HIV transcriptional loss documented in 8E5 
subclones is a reproducible characteristic of this cell line. I believe this observation 
reflects the strong selection of founder subclones that achieve spontaneous loss of 
HIV proviral DNA or silencing of transcription.  
 
 38 
Model for loss of HIV penetrance in continuous 8E5 cultures 
 
Together these data support a model where 8E5 cells acquire a selective 
advantage in continuous cell culture if they extinguish HIV expression, either by 
transcriptional silencing or by proviral genome loss. We suspect that stressing the 
cells during culture through delayed passage is likely to exacerbate this behavior, 
hastening a bottleneck of HIV-positive cells in the population. The loss of HIV from 
8E5 cultures is of practical significance considering the widespread utilization of 
these cells for quantitation of HIV genome abundance in patient samples. My 
findings appear consistent with cautions raised in a recent analysis, which found 
variable numbers of proviral insertions within common latently-infected cell lines 
previously assumed to be homogeneous92. Furthermore, my specific findings on 8E5 
cells were confirmed by a subsequent report using digital PCR93. My conclusions 
highlight the robust data these cell lines yield and underscore their intrinsic value to 
the field, but also support recent initiatives to validate common reagents in pursuit 
of reproducibility.  The data show the FISH:FLOW method is a convenient means to 
rigorously validate the penetrance of HIV in the 8E5 starting population in any 
laboratory with access to a flow cytometer; without such validation, we suggest 
that quantification of HIV genomes using 8E5 cells should be restricted to relative 
comparisons only.  
DISCUSSION 
Worldwide, investigators studying persistence and therapeutic reactivation 
of latent HIV reservoirs are heavily invested in PCR readouts of genome quantitation. 
The FISH:FLOW method we have developed is one example of the very few tools 
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that allow quantification of HIV infection at the level of the individual cell; 
importantly this resolution is lost in PCR studies of cell-associated DNA or RNA from 
bulk populations. We feel strongly that a critical mass of laboratories investing in cell-
level tools has not yet been reached, and the simple results presented here using a 
common cell line highlight the value of such studies as a complement to PCR 
approaches. Importantly, combining FISH:FLOW with antibody surface phenotyping 
meets the evermore urgent need to characterize specific cell subsets that harbor 
HIV in vivo. Multiple probe colors can assay different HIV transcripts in a single cell, 
allowing one to discern between early and late stage transcription, and increases 
the confidence that positive signal corresponds to intact provirus. The ability to then 
FACS-purify infected cells from human patient samples and study their 
transcriptional profile adds functional genomics to the growing list of possibilities.  
We feel these are opportunities not to be missed in context of the current 
challenges facing the field of HIV persistence and eradication.  
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CHAPTER THREE 
 
Tractable viral outgrowth platforms to study host and viral adaptations during HIV1 
cellular transmission  
In Chapter 3, I describe viral outgrowth reporter cell lines to 
follow HIV replication in real time. This chapter has two sections:  
Chapter 3A details construction and validation of TZM-gfp 
cells These experiments will be combined with some ongoing 
validation work on a sister cell line, TZM-GGR, and will be submitted 
for publication in the spring of 2018.  
Chapter 3B is a combination of two short stories detailing the 
construction of lymphoid reporter cell lines for HIV infection. Clinical 
validation of the SupGGR cell platform is underway, with anticipated 
submission for publication in the summer of 2018. Dependent on the 
results of those experiments in a patient setting (HIV reservoir 
determination), the MoltGGR cell line will either be included in the 
same submission (novel lymphoid cellular tools as robust QVOA 
platforms), or will be submitted separately as a short report. Some 
additional work using outgrowth and titer of transmitted/founder 
viruses will be performed in both MoltGGR and SupGGR in the spring 
of 2018 to complete these manuscripts for submission.  
The experiments described in this chapter are my own work, with important 
contributions from Shannon Caldwell, an electron microscopist in our laboratory. 
Shannon and I worked closely together to develop the correlative EM techniques 
described for targeted identification of HIV-infected foci.   
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CHAPTER 3A: TZM-gfp cells inform studies of HIV replication in vitro 
INTRODUCTION 
 
 Emergence of HIV reservoirs 
 
The past 3 decades of HIV research have yielded critical data that has saved 
countless lives, prevented millions of new infections, and brought the HIV pandemic 
under control in most developed nations. However, the speed of HIV research 
forced the virus ‘underground’ in human patients on ART, such that we eliminated 
bloodborne HIV before we understood anything about HIV replication in reservoir 
cells of the underlying tissues. These tissue reservoirs have now become the cells to 
beat, but we have little data on where to find them or how they harbor HIV long-
term39.  
 
The tissue reservoirs established during acute HIV infection persist, and may 
evolve during the years and decades of ART therapy in a single patient44. These 
reservoir cells have become formidable adversaries in our fight to establish 
functional cures – that is, long term drug-free HIV remission. While it is recognized 
that a sterilizing cure – complete eradication of HIV from the body – is highly 
unlikely94, targeted reduction of HIV burden in reservoir tissues will form the 
cornerstone of all efforts to reach a functional cure. However, we still lack the 
understanding of many such reservoir cells and similarly lack the specialized tools to 
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study HIV replication in these diverse cell populations. While memory T-cells form the 
bona fide latent reservoir (HIV provirus-positive cells that extinguish HIV transcription 
during the resting phase of cellular immunity), the ‘expressed reservoir’ such as that 
in myeloid subsets may remain transcriptionally active39. The pressures and 
mechanisms of transmission in these different cell types must obviously be different, 
and it is likely that HIV evolves means to excel in these distinct scenarios. The key 
difference that separates lymphoid from myeloid cells as potential reservoirs derives 
from the mechanism of latency establishment in lymphocytes.  
 
Comparing characteristics of distinct cellular HIV reservoirs 
 
Proliferating, activated lymphocytes become infected with HIV and 
generate new virions. The lifespan of an infected T-cell is estimated at ~48 hours46. 
Rare T-cells (including some HIV-positive) exit the cell cycle to form the memory 
lymphocyte subset, a process initiated by as yet unknown signals that results in 
shutting down NF-kB expression and consequent silencing of the HIV-1 LTR 
promoter28. Thus, in T-cells, HIV-1 expression requires host NF-kB expression, found 
only during activated proliferation of T-cells. Productive infection in lymphocytes is 
therefore a race against the clock, with the objective to generate offspring virions 
and infected daughter cells prior to G2 arrest and cell death induced by HIV-1 vpr45. 
The emergence of ART treatment has all but eliminated HIV viremia in treated 
patients: productively HIV-infected T-cells are depleted by attrition, while drugs 
prevent new infections by inactivating newly produced virions. Thus, the efficacy of 
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ART regimens depends on natural mechanisms by which HIV-infected cells die or 
are cleared by the immune system. 
 
By contrast, myeloid cells such as macrophages are largely quiescent and 
lack the cell cycle machinery targeted by HIV vpr during infection25,45; these cells 
are not cleared by cytopathic effects of the virus, survive for months in culture95, 
and would thus be spared in vivo by conventional attrition-dependent ART therapy. 
Infected macrophages also retain the capacity to transcribe HIV constitutively, and 
in the context of their longevity are hypothesized to form part of the expressed HIV 
reservoir during ART39. These characteristics make macrophages seemingly ideal 
candidates as reservoir cells in vivo, but the data supporting this hypothesis is 
fragmented and hotly contested. However, a growing number of investigators are 
becoming interested in the role of macrophages during HIV persistence and 
pathogenesis in vivo96,97, especially in anatomic regions of relative immune privilege 
such as the brain98.  
 
Viral outgrowth assays as an estimate of in vivo HIV heterogeneity 
 
In general, the studies to date of HIV outgrowth from blood-derived samples 
likely represent the ‘low hanging fruit,’ and rely on sampling pools of virus with a 
higher likelihood of replicating during proliferation-dependent in vitro culture assays 
such as the gold-standard QVOA (quantitative viral outgrowth assay)78,99. But other 
viral strains exist, including those comparatively unfit for replication ex vivo99,100. For 
example, the presence of HIV transcripts in AMs of the human airway was 
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suggested by our lab’s early data74, and has been repeatedly observed in 
vivo74,95,96,101-112, but these findings were not immediately supported by 
straightforward outgrowth studies using standard cell lines at the point of care in 
Blantyre, Malawi. Such challenges in studying the outgrowth of more diverse HIV 
strains and reservoir cell types are reinforced by very recent data showing that 
humanized mouse models will detect and replicate certain HIV strains where 
industry standard culture assays fail48,77,79. Together the data suggest there is HIV 
present in vivo we are not equipped to capture by current outgrowth assays: either 
the infected cells or the virus itself may govern the fitness of these reservoirs to 
replicate in culture99. Given the non-renewable source of our patient material (BAL) 
and the need to iteratively optimize our outgrowth conditions to follow their 
progress in real time, my entry to the human subjects HIV persistence project in the 
laboratory of David G. Russell began as a study in reporter cell biology: can we see 
HIV infection and encourage its progress? You can’t study virus replication if your 
assay says there isn’t any.   
 
Here I report the generation of multiple novel cell lines to follow the 
replication of HIV ex vivo using co-cultured primary macrophages as a source of 
virus. My overarching objective was to establish an outgrowth platform for use in 
studying BAL-derived HIV in AMs. In many cases I model anticipated scenarios, but 
recognize that some facets of human alveolar macrophage biology are not 
faithfully recapitulated by human monocyte-derived macrophages (HMDM). I 
apply these tools to established paradigms and open several lines of inquiry based 
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on the emergence of novel phenotypes. 
RESULTS 
Fluorescence readout for standardized HIV infectivity assays: TZM-gfp 
 
JC53 cells are HeLa cell derivatives overexpressing the three major HIV co-
receptors, CD4, CCR5 and CXCR481. Subsequent work in the lab of John Kappes 
produced JC53-bl cells (later renamed TZM-bl), which added E.coli beta-
galactosidase (b-gal) and firefly luciferase reporter genes to quantify inoculum 
infectivity113. The TZM-bl cell line has become a household reagent in HIV basic 
research, and has recently found expanded utility in the clinic as a sensitive viral 
outgrowth assay platform114.  
 
We previously pursued outgrowth of HIV from human BAL (BAL) in TZM-bl, 
CEM, and THP-1 cells, but found the experiments challenging to repeat and 
optimize, since these studies were performed in a clinical setting in Blantyre, Malawi, 
and used non-renewable human samples as input. The endpoint-nature of the 
qPCR, luciferase or b-gal assay (in TZM-bl) meant that outgrowth could not be 
followed in real time. Importantly, it remained unclear whether HIV in the human 
airway would exhibit macrophage- or lymphocyte-tropic character, or even 
whether human AMs would readily transfer infectious HIV to TZM-bl cells under these 
culture conditions. I reasoned that a visual readout in addition to quantitative 
reporters would enable the refinement of culture conditions to maximize the 
efficiency of HIV capture and longitudinal analyses even from limited input material. 
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To this end, I re-visited the sample pipeline in Malawi where outgrowth 
cultures could be followed by fluorescence microscopy and flow cytometry, of 
which the latter is a notable strength among our research collaborators there74. 
Using parental JC53 cells (a kind gift of Dr. David Kabat, Oregon Health Sciences 
University) I engineered TZM-gfp cells using an HIV Tat- and Rev-responsive reporter 
virus pNL-GFP-RRE(SA)115 (Fig. 12). The vector is a relatively recent and valuable 
addition to a large set of available transcriptional reporters of HIV output. However, 
transcription from the HIV-1 LTR can be leaky, generating background reporter 
transcripts in the absence of HIV infection. Notably, most current cellular reagents 
in widespread use (including TZM-bl, CEM-GFP and others) are exclusively LTR-
driven, and thus subject to this background activation116. The pNL-GFP-RRE(SA) 
Figure 12. Lentiviral constructs dependent on HIV Tat and Rev expression for reporter 
signal. Top Fluorescence-only reporter expresses hrGFP downstream of the IRES. 
Bottom Bicistronic reporter expresses gaussia luciferase (GLuc) and hrGFP from a 
single messenger RNA. In the absence of HIV infection leaky transcription from the 
reporter proviral LTR produces messenger RNA. In these uninfected cells lacking Rev 
protein, cellular splicing machinery excises leaky reporter transcripts between the 
splicing donor (D) and acceptor (A) sequences. Conversely, productive infection 
with HIV generates Tat and Rev protein, which drive robust reporter transcription 
(Tat, green) and rapid nuclear export of RNA through the action of Rev (purple) 
binding the Rev response element (RRE, orange) on the nascent message. These 
exported transcripts are then translated and the reporter signal produced.  
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vector was developed to include HIV-1 transcriptional splice sites flanking the 
reporter gene hrGFP, meaning both HIV-1 Tat and Rev proteins are required for 
fluorescence detection. In the absence of true HIV infection and Rev protein 
production, the hrGFP reporter gene is excised from the nascent transcript in the 
nucleus prior to export and ribosomal translation. In HIV-infected reporter cells the 
virus produces Tat, a transcriptional activator that drives transcription and 
accumulation of Rev protein (Fig. 12); Rev then binds the reporter proviral transcript 
and actively exports it, a splicing machinery “short circuit” that delivers full-length 
reporter gene message for translation and expression. The structure and fidelity of 
the pNL-GFP-RRE(SA) vector makes it an ideal choice for ex vivo HIV reporter assays.  
Construction of TZM-gfp 
 
Parental JC53 cells (a HeLa clone expressing CD4, CCR5, and CXCR4) were 
transduced with VSV/G-pseudotyped pNL-GFP-RRE(SA) reporter virions to derive a 
population of TZM-gfp cells in culture. Cells were then seeded at clonal density (0.5-
0.7 cells per well in 96-well format), and cultured for further analyses. Wells with single 
foci were scored under low magnification by inverted phase contrast microscopy, 
and after 14 days were reseeded into replica 96-well plates. Validation of reporter 
activity was performed by infection for 4 days with HIV-1 ADA virus (a gift of Dr. Mario 
Stevenson, Miami CFAR), which is a CCR5- and macrophage-tropic HXB2 chimeric 
molecular clone isolated from the blood of an HIV-positive patient117,118. TZM-gfp 
clones were screened for strength of reporter output by fluorescence microscopy 
(Fig. 13). At this 4 day timepoint, widespread cytopathic effects were observed in 
most cultures (Fig. 13), including formation of multinucleate syncytia and many 
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detached free-floating cells. The two clones shown in Figure 13 (2G and 2H) were 
chosen for further analyses.  
TZM-gfp cells report HIV infection of primary human macrophages  
 
To establish the utility of TZM-gfp in reporting HIV infection from primary 
human macrophages, trypsin-harvested TZM-gfp reporter cells were added onto 
established monolayers of HMDM infected 14 days prior with VSV/G-ADA. Forty-
eight hours after co-culture, cells were harvested and GFP-positivity was quantified 
by flow cytometry (BioRad S3e). At this timepoint, a threefold enrichment was 
observed in HIV (GFP) penetrance in clone 2H vs. 2G (29.8% vs. 10.3%), while the 
geometric mean signal to noise ratio was also greater in clone 2H (9.8-fold vs. 6.7-
fold, respectively) (Fig. 14). On the basis of these results, clone 2H was designated  
Figure 13. TZM-gfp clones are susceptible to HIV-1 infection and produce no 
background signal.  A-D and F-G TZM-gfp clone 2G and E,J TZM-gfp clone 2H. A,F 
representative uninfected clone (2G) showing no background fluorescence signal 
in the absence of HIV infection. Infection with HIV induces strong reporter signal, 
multi-nucleate syncytia (arrow, C,H), and widespread cytopathic effects (note 
membrane blebbing, arrowhead, D,I). Infection in clone 2H occurs faster, much of 
the culture is detached or dead by 4 days post-infection (E,J).  
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Figure 14. TZM-gfp cell clones 
report HIV transfer from infected 
HMDM at 48hours post-infection. 
A,B Uninfected TZM-gfp clones 2H 
and 2G reveal an absence of 
background signal or cytopathic 
effects. C-F Clone 2H exhibits 
higher HIV susceptibility on day 2 
with greater induction and lower 
background, quantified in G.  
 50 
‘TZM-gfp’ and used in all future analyses.  
 
If TZM-gfp cells were to be used to report infectious HIV from human clinical 
samples in Malawi, the specificity of the signal was important – especially if infected 
cells are rare in human BAL. One would want to be sure a positive signal was real, 
and establish zero background in the absence of a true HIV infection. To address 
this, I co-cultured TZM-gfp cells and HMDM infected 7 days prior with various 
laboratory strains of HIV (Fig. 15). Widespread cytopathic effects in HMDM were 
observed 7 days post-infection with high titer VSV/G pseudotyped HIV-1 ADA stocks 
(MOI 20, 150 ng/mL p24, Fig. 15E-F), and to a much lesser extent with an inoculum 
of tenfold lower MOI (MOI 2, 12 ng/mL Fig. 15C-D). Interestingly this phenotype was 
not dependent on replication competent virus, since VSV/G-pseudotyped R9-Denv 
also caused cytopathic effects at high titer in HMDM (MOI 20, Fig. 15G-H); VSV-R9-
Denv virions perform cell entry, integrate and transcribe, but lack an encoded 
envelope and thus do not package new virions in HMDM cells. Importantly, 
compared to robust development of GFP reporter signal in ADA-infected 
HMDM::TZM-gfp co-cultures, similar wells with R9-Denv infection 
 
developed no GFP fluorescence (Fig. 15G,H). However, the VSV/G-R9-Denv virus 
can drive robust reporter expression if used for direct VSV/G-mediated infection of 
TZM-gfp (Fig. 15H, inset panel), showing the lack of signal in Fig. 15H is due to failed 
virus transfer from HMDM to TZM-gfp in the absence of an encoded envelope. These 
data highlight the strict regulation of the GFP reporter construct, and show that  
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Figure 15. TZM-gfp reporter signal requires replicating HIV 
infection. HMDM were either mock-infected (A-B) or 
established for 5 days with two doses of VSV/G-ADA (C-F) or 
VSV/G-R9∆env stock (G,H). TZM-gfp cells were then added for 
72 hours prior to confocal imaging. C-F Replicating infection 
(ADA) induces dose-dependent cytopathic effects (red 
arrows, C,E) and GFP fluorescence in reporter TZM-gfp (D,F). 
Healthy macrophages are marked with white arrows. G,H 
VSV/G-R9∆env pseudovirus is capable of entry and 
integration in HMDM but not forward replication (env 
deficient) in TZM-gfp and cannot drive development of GFP 
reporter signal (H) in cell to cell transfer. The VSV-R9 
pseudovirus stock is single round infectious, however, as is 
causes macrophage cytopathic effects (G) and drives GFP 
reporter signal after direct VSV/G-mediated infection of TZM-
gfp (inset H). HIV-uninfected cells that are transfected with 
tat+rev plasmid DNA express GFP reporter (inset B). 
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soluble Tat and/or Rev protein in the medium shed from cells harboring defective 
virus are insufficient to drive non-specific reporter expression in co-cultured TZM-gfp 
cells. By contrast, I show that Tat and Rev protein are sufficient to drive reporter GFP 
expression (Figure 15H, inset) by transfection of tat/rev plasmid DNA in HIV-
uninfected TZM-gfp cells.  
 
TZM-gfp assay refinement for durable reporter signal 
 
While TZM-gfp cells added to cultured primary HMDM developed robust GFP 
reporter signal (Fig. 15), cytopathic effects and overall poor adhesion to the culture 
surface precluded longer-term culture for HIV harvest. Considering the dominant 
adherence properties of HMDM in culture, I hypothesized that incoming TZM-gfp 
cells in macrophage co-culture could not compete efficiently for the culture 
surface. To improve outgrowth conditions, I reversed the seeding strategy to overlay 
HIV-infected HMDM on top of an established TZM-gfp monolayer (Fig. 16). Different 
dilutions of TZM-gfp (5 x 103 – 1 x 105 cells/cm2) were seeded in 35-mm imaging dishes 
(ibidi) in the morning and allowed to adhere. Four hours later, HMDMs infected 7 
days prior with HIV-1 ADA in teflon screwtop jars (Savillex) were harvested by gentle 
pipetting, counted, and 100 cells were added to each 35mm TZM-gfp culture. 
 
This reversed assay yielded a wealth of information about the infection 
behavior of macrophages and the performance of TZM-gfp cells in co-culture. First, 
it appeared that infection of TZM-gfp was primarily a local phenomenon, as the 
 53 
vast majority of infection at 48h and 72h was focal (Figure 16B-E). Multinucleate 
syncytia formed by 48h, and continued to increase in size throughout the assay; by 
120h there was evidence that cell-free virus had initiated infection independently 
of HMDM, triggering formation of multifocal syncytia that in many cases began to 
coalesce (Fig. 16F-K). This suggested that at the outset of the assay, virus was being 
efficiently transferred from HMDM to TZM-gfp by cell-to-cell transfer, with cell free 
virus infection proceeding with much slower kinetics. Indeed, associated with many 
primary syncytia at 48 hours was a single adhered HMDM (white arrows in Fig. 16B-
E), presumably the offending HIV-infected cell of each focus. However, the GFP 
that filled the cytoplasm of cells within and surrounding the growing syncytium did 
not mix with the cytoplasm of the macrophage, indicating that HIV-infected HMDM 
initiate syncytium formation, but do not themselves form heterotypic fusions with 
TZM-gfp cells. The susceptibility of various types of cell membranes to HIV-mediated 
fusion has not been rigorously investigated, but this co-culture system seems ideally 
suited to such studies in the future. Given the importance of maximizing reporter cell 
sensitivity to capture trace HIV during reservoir studies in blood and tissue, the 
parameter of cell fusion and its relationship to HIV outgrowth seem fertile ground for 
follow up studies.  
 
TZM-gfp infection is cell-density dependent  
 
Interestingly, it was also clear that infection of TZM-gfp (as judged by reporter 
activity) was dependent on their seeding density. At lower seeding densities (50,000 
and 100,000 cells per dish), robust GFP signal developed at multiple foci across the  
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Figure 16. Focal infection of TZM-gfp by HMDM via cell-to-
cell transfer is inhibited at high cell density. A Experimental 
setup showing infection of HMDM in Teflon jars for 
convenient harvest 4-14 days post-infection. Harvested 
HMDM are inoculated onto monolayers of TZM-gfp cells 
seeded at four densities (B-E), showing inhibition at high 
densities (I,M and also H,L). Number of seeded TZM-gfp cells 
is indicated in each panel.   
 55 
culture surface by 48 hours (Fig. 16); much less infection was observed at higher 
density (500,000 cells per dish). In these experiments, an equal dose of 100 HMDMs 
was added to all wells with TZM-gfp dilutions. This suggested high density might 
inhibit the susceptibility of TZM-gfp to HIV-1 infection by cell-to-cell transfer from 
macrophages.  
 
The impact of TZM-gfp cell density in permissiveness for HIV infection might 
be related to several factors, including the available surface area of target cell 
membrane, density inhibition of cell cycle, localization or quantity of HIV co-
receptors or biophysical properties of membranes in tight proximity versus 
adequately spaced target cells. However, physical interaction of HIV-infected 
macrophages with target T-lymphocytes during virological synapse is a key 
requirement for cell-to-cell infection119. Thus, an alternative possibility is that 
overdense TZM-gfp cultures might be defective as targets for cell-to-cell infection, 
but unchanged in terms of susceptibility to canonical cell-free virus infection. To 
address this, I tested whether cell seeding density was a factor during cell-free HIV 
infection of TZM-gfp cells. Serial twofold dilutions of TZM-gfp cells were seeded in 2µL 
drops arrayed on optical bottom 35mm culture dishes (ibidi) and allowed to adhere 
overnight (1.1 x 106 – 5.0 x 101 cells/cm2, or 20,480 cells – 1 cell per 2µL drop). The 
following morning, arrayed foci were overlaid with wild type HIV-1 ADA viral 
supernatant such that all drop cultures in a single dish were exposed to equal 
concentrations of the viral inoculum. At 72h post-infection cultures were analyzed 
by fluorescence microscopy. With increasing cell density, a dose-dependent 
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decrease was observed in infection outcome at the center of each cell focus (Fig. 
17). These results matched those obtained with density inhibition of HIV infection in 
HMDM:TZM-gfp co-cultures (Fig. 16), suggesting the inhibition was related to viral 
entry or post-entry and independent of HMDM:TZM-gfp physical interaction. 
Interestingly, cells at the perimeter of each focus that were exposed to empty 
Figure 17. TZM-gfp cells are refractory to HIV infection at high cell density, and report 
HIV infection even at clonal density. A Serial dilutions of TZM-gfp were plated in 2uL 
drops on a 5 x 5 array in ibidi 35mm plates, and cells allowed to adhere overnight. Drop 
cultures were then overlaid with HIV-1 ADA supernatant such that all foci shared the 
same concentration of virus. Forty-eight hours post-infection, foci were examined for 
HIV infection. Brightfield images are shown for the highest (B) and lowers (P) dose of 
TZM-gfp cells. Signal in O represents HIV infection even when very few cells are plated. 
The number of cells plated per droplet are indicated in each panel.  
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culture surface on their apical edge became HIV-infected, independent of the 
central density of the focus (not shown), confirming that space constraints affected 
HIV-1 entry dynamics or the underlying transcriptional profile of spaced vs. packed 
TZM-gfp cells.  
 
It was observed during earlier HMDM:TZM-gfp co-cultures that optimal 
infection outcomes were achieved at same day TZM-gfp seeding densities of 5 x 
103 – 2 x 104 cells/cm2 with absolute inhibition at 1 x 105 cells/cm2 (Fig. 16). In drop 
culture assays of cell-free virus infection, the optimal range of seeding densities 
ranged from single cell density (~250 cells/cm2) up to ~7.2 x 103, with absolute 
inhibition above 6 x 104 cells/cm2 (Fig. 17D). Thus, despite significant technical 
differences, the effective density ranges of TZM-gfp HIV susceptibility returned by 
the two assays were comparable. Consistent with these findings, during the course 
of my studies, a report quantifying the optimal seeding density of the related TZM-
bl cell line120 suggested a linear range up to 3.1 x 104 cells/cm2, with a precipitous 
loss of monolayer infection above 6.2 x 104 cells/cm2. These results support my 
current findings and suggest an optimal seeding density between 5,000 and 20,000 
cells/cm2, with a preference toward lower densities if low numbers of incoming 
virions or HIV-infected co-culture cells are interrogated. This is highlighted by my 
later observations that cultures with very low numbers of HIV-positive foci will report 
HIV infection, but a large spreading infection throughout the well is precluded by 
the continued proliferation and eventual inhibition of uninfected reporter cells over 
several days of co-culture. Thus, a ‘wait and see’ approach for low-input inocula 
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may be a flawed strategy in the recovery of trace HIV from patient material, and 
upon positive foci identification, supernatants should be harvested early and used 
to inoculate fresh target cells at optimal densities.  
 
This guidance overlooks the fact that HIV genetic variation may produce 
viruses with increased fitness for cell-free virus infection compared to other variants 
that rely on a higher efficiency transmission such as cell-to-cell infection121. A 
strategy to harvest viral supernatants from low-outcome primary co-cultures to 
passage onto lower density receiver cells might bias toward strains of high cell-free 
infection fitness, and may miss bona-fide HIV strains that replicate poorly in the 
absence of cell-to-cell transfer. Importantly, the well-established paradigm of cell-
to-cell transfer from HIV-infected macrophages suggests that these cells may 
harbor strains with reduced pressure on cell-free infection kinetics, especially in 
macrophage-rich (and lymphocyte-poor) anatomical reservoirs such as the testes, 
lung, CNS and others. Studies to investigate human macrophages as potential HIV 
reservoirs should consider this potential handicap during assay design, and develop 
outgrowth strategies that emphasize cell-to-cell infection or risk underestimating the 
real HIV burden in tissue macrophages in vivo.   
 
Analyses of single infection events with TZM-gfp 
 
The TZM-gfp cell reagent is a scalable, versatile platform for the detection 
and outgrowth of HIV. However, the JC-53 parental cell line was developed prior to 
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our more advanced knowledge of the diverse HIV target cells in vivo or the key 
strains of HIV that predominate during chronic infection and person-to-person 
transmission of the virus, the so-called transmitted/founder (T/F) viruses58. The TZM 
platform is widely-employed and trusted for its reproducibility, but less is known 
about HIV genotypes that may be missed or underperform during outgrowth in TZM-
related cell lines. In the context of low-input inocula such as might be obtained from 
human tissue macrophages, variable HIV fitness might prevent robust outgrowth if 
culture conditions are a poor surrogate for the in vivo environment to which the HIV 
strain in question is adapted. For this reason, it is said that all culture systems for 
quantitative viral outgrowth assays (QVOAs) can only serve as minimal estimates of 
the HIV reservoir or of the input inoculum122. However, since essentially no 
background GFP expression is observed in the absence of a true HIV infection, any 
reporter signal should be considered a potential HIV infection. This is true even if the 
virus produced is of insufficient fitness to replicate robustly in culture. In such a 
scenario, a valuable tool would be able to demonstrate virus production from rare 
infected cells despite the potentially poor replication capacity of the virus itself. I 
sought the means to capture HIV by cell-to-cell transfer, identify rare infected cells 
by reporter gene activity, and demonstrate the virus exists even if ex vivo culture 
conditions do not support robust replication. 
 
Correlative electron microscopy of HIV-positive foci in TZM-gfp 
 
To learn whether rare GFP-positive foci could be evaluated for productive 
HIV infection, I turned to correlative electron microscopy to image cells from such  
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Figure 18. GFP-guided correlative electron microscopy identifies HIV virions in 
and around HMDM-associated foci. A-E Cultured TZM-gfp were co-cultured 
with 100 HIV-infected HMDM. Two days after plating, cultures were examined 
for reporter activity and regions chosen for embedding. Strips of coverslip 
were cut and embedded on top of a resin-filled Beem capsule, polymerized, 
then snapped off under liquid nitrogen. Sections were cut and EM analyses 
performed to view budding virions H-I. Previous analyses revealed the 
presence of VCCs within macrophage monoculture (J), but these structures 
were not observed in co-culture with TZM-gfp (H-I) 
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foci in HMDM:TZM-gfp co-cultures. HMDM were harvested from teflon jars as 
described above and 100 cells were seeded onto TZM-gfp monolayers on 
Thermanox coverslips (Nunc) cultured in 6-well dishes. A schematic of this 
experiment is shown in Fig. 18. At 72 hours after co-culture, GFP-positive foci were 
located by fluorescence microscopy; their location is readily marked with a 
hypodermic needle. Correlative microscopy coverslips with a pre-etched grid are 
also suitable for landmarking HIV-positive foci. Coverslips were fixed in 
glutaraldehyde and cut with scissors into 3-4mm strips, thinner than the width of a 
small Beem capsule. After EM staining and equilibrating in resin, each coverslip strip 
was inverted onto the rim of a filled Beem capsule such that liquid resin contacted 
the coverslip surface and extruded above the coverslip on either side between the 
capsule rim and the coverslip edge (Fig. 18). Polymerization of the resin was 
followed by snapping the plastic coverslip off the resin under liquid nitrogen, leaving 
embedded cells in the resin; this technique was developed in close collaboration 
with Shannon Caldwell in the Russell laboratory, to whom I am deeply grateful. 
Blocks were trimmed and sectioned from the apical side down, giving only a 
handful of sections per block, with potentially high yield data. Indeed, samples 
prepared and imaged in this way revealed HIV infection in TZM cells of identified 
loci (Fig. 18H,I), including assembly and budding of new HIV from the surface of TZM-
gfp cells (Fig. 18I).  
 
HIV within infected HMDM assembles and buds into intracellular virus-
containing compartments (VCCs) continuous with the extracellular space and 
bounded by plasma membrane invaginations; the virus accumulates to large 
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numbers, visible as sacs of mature and maturing virions by transmission electron 
microscopy123-126. We have previously observed such VCCs in HMDM cultures 
infected with high-titer macrophage-tropic HIV supernatant (Fig. 18J). By contrast 
however, when co-cultured with TZM-gfp cells we found very few intracellular HIV 
virions within HMDM (not shown), despite the large numbers of extracellular and 
budding virions observed on and around TZM-gfp cells infected by HMDM. These 
results suggest that macrophage-resident VCC may be evacuated upon 
establishment of heterotypic cell contact, an interesting possibility that should be 
tested in future experiments. This scenario is consistent with existing observations 
showing that VCCs in macrophages align toward the point of T-cell contact in vitro 
and open during the synapse, ejecting a large number of accumulated HIV virions 
onto the lymphocyte surface at a time when it is most likely to become activated 
by antigen presentation119,127-130. This process requires actin cytoskeletal 
reorganization131, and in macrophages can also be induced by exogenous ATP 
added to culture medium in the absence of any co-cultured cells132. Future work 
should investigate the efficiency of virion release from macrophages upon co-
culture with various types of HIV-susceptible cells, and whether this process is at all 
influenced by viral genotype (see Chapter 5). For example, it is well established that 
HIV env directs the entry tropism of HIV for diverse target cell types, but less is known 
of how HIV adapts for efficient egress from specific cell types.  There is evidence to 
suggest that viral fitness and adaptation in culture depends both on viral genotype 
but on host cell pressures as well99. For example, subcellular trafficking of env and 
matrix depends on sequences within gp41133, mutations of which compromise 
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budding and accumulation of HIV into VCCs. Such lesions would impose a greater 
fitness cost on the virus in cells such as macrophages, where VCC-dependent cell-
to-cell transfer predominates. Conversely, certain strains of virus may adapt toward 
cell-to-cell or synaptic transfer where the effective MOI on target cells is much 
higher thus reducing pressure on virion infectivity. The abundance of such viruses in 
vivo is unclear, but it is attractive to speculate that strains adapted to synaptic 
transfer would rely on this decreased burden for efficient replication, and hence 
may not be captured during in vitro outgrowth assays that rely on cell-free virus 
infection122. In vivo, such strains would still seed rebound viremia, but adaption for 
rapid outgrowth in different host cell types would take time, prolonging the period 
between ART interruption and emergence of rebound viremia.  Indeed, these 
insights may offer a long-sought explanation for the lengthy period of drug-free 
remission in some of the more famous cases of HIV ART interruption. For example, 
the two “Boston patients”, who lived for 12 and 32 weeks, respectively without ARV 
treatment or viral rebound, are unexplained exceptions to the relatively rapid (2-6 
weeks) rebound in most patients following ART discontinuation. Indeed, 
investigators studying the rebound viremia of the Boston patients suggested that 
underlying macrophage infection may explain the duration of drug-free remission 
and the timing of eventual rebound in these patients134.  
 
DISCUSSION 
 
The TZM-gfp platform was developed to provide the means to follow rare or 
low-frequency infection events during primary HIV outgrowth from potential 
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reservoir tissues. Intrinsic to this paradigm is the need to iteratively optimize the assay 
format for the HIV source being studied. A primary challenge here is the limiting 
nature of the human patient material, in our case BAL cells. The deployment of TZM-
gfp to the point of care in Blantyre, Malawi (described below in Chapter 4) is a 
critical first step toward a robust assay for HIV infection in AMs of the human lung. 
My subsequent work with multiple cell lines, including adherent (HeLa- or HEK293-
derived) and lymphoblastic cells (Molt4- and SupT1-derived) has revealed 
important features and caveats of each system. The predominant theme that 
emerged is the particular suitability of the TZM cell platform for macrophage co-
culture assays. One reasonable hypothesis is that the solid-phase format of the 
assay (adherent macrophages and adherent reporter cells) maximizes the physical 
contact between the cells for efficient cell-to-cell transfer. I found that the seeding 
order (HMDM or TZM first) and the cell density in these co-culture assays determined 
the outcome and durability of the reporter signal, highlighting that the adherence 
properties of TZM-gfp cells are key considerations of the assay’s performance.  
 
Importantly, I show that TZM-gfp exhibit extremely low background signal 
with strong induction upon HIV infection. Both HIV Tat and Rev are required for this 
function, as these and other factors secreted from HIV ∆env-infected TZM-gfp cells 
are unable to drive reporter expression in uninfected bystander cells.  This is an 
improvement over the standard TZM-bl cell line113, which harbors the HIV LTR only 
and does not require Rev function.  
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The strict regulation of the GFP reporter in TZM-gfp cells makes identification 
of rare infection events possible. I applied this feature to develop a correlative 
electron microscopy workflow that would enable fluorescent location of rare HIV-
infected foci in TZM-gfp:HMDM co-cultures, followed by targeted embedding and 
ultrastructural imaging of HIV virions in situ. This protocol allows investigators to derive 
proof of infectious HIV that may not meet the high burden of in vitro replication 
fitness shared among established viral outgrowth platforms. The contribution of such 
viral strains to HIV persistence remains unknown, but is a key paradigm as the field 
continues to categorize HIV genotypes associated with specific facets of 
transmission, persistence, or rebound. TZM-gfp and reporter cells like it are designed 
to capture these events, providing an opportunity to study viral reservoirs that might 
otherwise go undetected48,77,79.  
 
Future efforts with TZM-gfp cells in Blantyre, Malawi should focus on the 
quantification of potential HIV reservoir cells in the human airway. Proof-of-concept 
experiments are planned for the near future to infect cultured naïve human AMs 
with HIV ex vivo and test their performance in a TZM-gfp QVOA. Importantly, very 
recent work using TZM-bl cells114 reported improved sensitivity in quantifying the HIV 
reservoir compared to standard QVOA assays. In support of these findings, the rapid 
kinetics and focal nature of HMDM-derived outgrowth in TZM-gfp cells shown here 
confirm the potential for this platform in clonal serial-dilution HIV outgrowth assays 
using primary human macrophages as input. 
 
 
 66 
CHAPTER 3B:  
Accessible quantitation of HIV reservoirs using improved cell lines with reporter 
activity 
INTRODUCTION 
 
Recent progress has been made toward streamlining quantitative viral 
outgrowth assays (QVOA)78,114,135, which estimate the size of the HIV reservoir in the 
context of antiretroviral therapy (ART) or latency reversing agents (LRAs). The QVOA 
and other quantitative measures are key paradigms in developing strategies to 
reduce the HIV reservoir and thereby accelerate the path toward curative HIV 
therapy39. While several recently described assays exist to measure the size or 
changes in the HIV reservoir48,85,122,136-138, the gold standard remains the QVOA. 
However, the standard QVOA protocol relies on human donor lymphoblasts and is 
therefore beset by donor variability, cost and scalability issues, while also relying on 
secondary readout such as p24 ELISA or qRT-PCR78,135.  
 
Recently, two separate reports describe improved cell line reagents to serve 
as surrogates for uninfected human lymphoblasts in QVOA pipelines78,135. These cell 
lines - SupT1/CCR5 (SupR5) and Molt4R5 (Molt4R5) – appear to offer enhanced 
stability and outgrowth properties compared to primary human lymphoblasts, are 
more convenient, and do not suffer the donor variability that can be observed in 
the classical QVOA platform. Despite these features, both reagents offer no direct 
quantitative readout of HIV replication, and still rely on nucleic acid amplification 
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or viral gag (p24) determination. Guided by the success of the TZM-gfp cell platform 
and the published, quantitative nature of the Tat/Rev responsive pNL-RRE(SA) 
vector series115,116, I sought improvements to the SupR5 and Molt4R5 reagents that 
would enable reporter-based quantitation of HIV replication in QVOA-type assays.  
 
RESULTS 
Design concept of GGR-reporter lymphoid outgrowth platforms 
To facilitate HIV reporter activity, I chose the reporter construct pNL-GGR-
RRE(SA) (Fig. 12, hereinafter referred to as the ‘GGR’ construct) from the well-
characterized Affinofile-GGR cell line, derived from HEK-293 cells57. The GGR 
construct expresses a secreted luciferase protein from the copepod Gaussia 
princeps, and the humanized recombinant green fluorescent protein from Renilla 
reniformis in a bicistronic IRES cassette. Importantly, gaussia luciferase (GLuc) is up 
to 1,000 times more sensitive than renilla or firefly luciferases, and is naturally 
secreted into the culture medium, enabling periodic sampling while sparing the 
reporter cells in culture139,140. Like other vectors of the pNL-RRE series, the reporter 
genes of the GGR construct are flanked by HIV splicing sites, meaning that any 
background transcripts downstream of the HIV-1 LTR in this provirus are spliced out 
in the absence of Rev protein.  
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SupR5 and M4R5 cells were each transduced with the GGR lentiviral vector 
(Fig. 12) and a panel of clones were generated by serial dilution. Individual clones 
were replica plated and selected for robust reporter gene expression (Fig. 19) after 
infection with HIV-nef-IRES-mCherry/BaL env (HIV-Cherry). Flow cytometric analyses 
at early timepoints (48 and 72 hours post-infection) demonstrated that many cells 
expressed mCherry while a subset of those were also GFP-positive, suggesting early 
infection (mCherry-positive only) could be distinguished from cells at later stages of 
infection (double positive). Importantly, in both cases very few cells expressed GFP 
in the absence of HIV-Cherry expression (Fig. 19) showing strong coordination of the 
GFP reporter gene with the virus driving its expression in these reporter cells.  
Figure 19. SupGGR and MoltGGR cells report HIV infection at early timepoints post-
inoculation. A SupGGR cells were infected with VSV/G HIV-mCherry stocks for 48 
hours prior to analysis by flow cytometry for GFP reporter signal and HIV-mCherry 
signal. B Similar analyses performed in MoltGGR cells infected for 72 hours with the 
same virus.  
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Comparative HIV susceptibility in MoltGGR and SupGGR 
 
To compare the sensitivity of these two cell lines with the standard TZM-bl cell 
platform, a titration series of cell-free virus stock (wild type HIV-mCherry) was used 
to infect each cell line (standing infection without DEAE-Dextran or spinoculation). 
Seventy-two hours post-infection, HIV-positive wells were scored for each dilution 
and the TCID50 calculated for this stock in each cell line tested141.  I found the 
TCID50 of the HIV-Cherry stock was comparable in SupGGR and MoltGGR cells (6.4 
x 103 vs 5.0 x 103, respectively, Fig. 20), versus that in TZM-bl cells of 9.0 x 103. Infections 
of lymphoid cells are usually carried out using spinoculation and in the presence of 
a polycation (DEAE-dextran or polybrene) to enhance virus binding, which would 
Figure 20. Titration of HIV-mCherry(BaL) in MoltGGR, 
SupGGR and TZM-bl cells. Fivefold dilutions of viral stock 
were added to cultures without additives or 
spinoculation to directly compare infectivity. Titer was 
calculated as TCID50 according to the Reed-Muench 
method). 
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significantly increase the performance of these cells in this titration assay. However, 
here these procedures were omitted to compare all cell lines tested using as 
unbiased approach as possible. Nevertheless, more rigorous testing of HIV 
susceptibility for these platforms with various strains of virus is presented below.  
 
The Molt4-CCR5 cell line was reported by Dr. Bob Siliciano78 as a surrogate 
for human peripheral blood lymphocytes in their quantitative viral outgrowth assays, 
and is now used exclusively in their laboratory for human patient assays. To validate 
the new MoltGGR cell reagent for use with human HIV isolates, I performed a stock 
titration experiment using 27ZP, a Clade C HIV strain I isolated from the peripheral 
blood of an HIV-positive human subject in Blantyre, Malawi. In a first experiment, I 
sought to demonstrate the quantitative nature of the fluorescent GFP readout. 
Fivefold serial dilutions of strain 27ZP were inoculated in replicate wells (96-well 
format) of cultured MoltGGR cells, and the cultures were incubated for 8 days. Wells 
were harvested by simple pipetting and analyzed for GFP fluorescence on a BioRad 
S3e instrument. GFP-positive cells were gated and the fraction positive was plotted 
as a function of dilution (Fig. 21). A log plot of the dilution series reveals a highly 
correlated (R2 = 0.9995) linear region, suggesting the GFP readout provides robust 
quantitation of HIV infection.  
 
The MoltGGR platform was designed to provide convenient means to 
capture HIV from co-cultured human tissue cells (notably macrophages) by viral 
outgrowth. Ideally a portion of the suspension MoltGGR cells could be readily 
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sampled to monitor outgrowth by flow cytometry, without sacrificing the co-
cultured primary human cells in the same well.  The strong linear correlation returned 
by the limiting dilution series with low numbers of sampled MoltGGR cells (96-well 
format) is an important proof of concept using a primary human HIV isolate (27ZP).  
 
To expand the characterization of MoltGGR cells, the gaussia luciferase 
(Gluc) assay was tested with a dilution series of the same 27ZP viral stock. Serial 
dilutions were inoculated in MoltGGR cells (96-well format) and incubated for 8 
days without medium changes. Supernatant was harvested from the top of each 
well at three and eight days post-infection for GLuc assay, without disturbing the 
cultured cells beneath. A particular feature of the GGR platform is the capacity for 
longitudinal sampling, which enables high-throughput screening for virus-positive 
wells prior to harvest for downstream analyses. This feature enables the early 
identification of outgrowth for subsequent molecular confirmation by env cloning 
or single genome amplification (SGA); importantly, a key focus is the generation of 
early isolates that have not undergone cell culture adaptation or accumulated 
mutations. The sensitive Gluc readout enables such analyses, and can provide 
rapid, high throughput detection in minutes using this accessible assay. Figure 21C 
shows the results of GLuc reporter activity at two timepoints post-infection. The linear 
region of the titration plot reveals that higher concentrations of viral inoculum yield 
detectable results by day 3, but that some wells harboring HIV are not detectable 
until day 8 (compare dark vs. light blue curves of Fig. 21C). No additional wells 
became GLuc-positive after day 8, suggesting this cell-free virus titration assay was  
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Figure 21. Quantitative detection of primary Clade C isolate 27ZP in MoltGGR cells. 
A Fivefold dilution series of cell free viral stock in MoltGGR cells cultured for 8 days 
post-infection. The GFP-positive fraction for each dilution is indicated in black (as a 
percentage), with the corresponding dilution indicated in green text. Before flow 
cytometry, cells were harvested from 96-well culture format with simple pipetting. B 
Plot of log percent GFP-positive fraction from A versus log5 viral dilution showing high 
correlation in the linear region of the curve. C A similar experiment using serial 
tenfold dilutions of 27ZP in MoltGGR cells. Supernatants were sampled in triplicate 
on day 3 and day 8 to quantify GLuc activity without disturbing the cultured cells. 
Titration curve shows saturation at three highest doses on day 8, with absence of 
signal at the lowest dose.  
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maximally sensitive by this point. However, further work is necessary to robustly 
discern the time to reliable detection using a daily GLuc timecourse of many single 
virion-inoculated wells of MoltGGR cells.   
 
Single cell inoculum quantitative viral outgrowth assay in MoltGGR cells 
 
The performance of the MoltGGR system as a viral outgrowth platform 
depends on a single HIV-infected cell initiating replication in an individual well. To 
model this scenario, I generated input cells by infecting TZM-gfp cells with human 
Clade C PBMC isolate 27ZP for 5 days. Cells were trypsinized and the proportion of 
GFP-positive cells was established by flow cytometry (~10.2%, Fig. 22A). Unsorted 
cells from the infected population were then diluted to a frequency of 0.75 cells per 
50uL, such that about 75% of the wells on the plate were expected to receive a 
single cell, with about 10% of these being GFP-positive. Wells pre-seeded with 5x103 
MoltGGR cells were then inoculated with 50µL of cell suspension. For a 96-well plate 
plated at 75% density with a GFP penetrance of 10% one would expect 7-8 wells 
positive for HIV outgrowth (96 wells x 0.75 x 0.10 = 7.2). Under these conditions eight 
wells were detected by GLuc assay at 3 days post co-culture, using the Tukey 1.5x 
interquartile range (IQR) to establish significantly induced wells as ‘outliers’ (Fig. 
23B). For this population, there was a very small IQR, confirming most wells (~90%) 
were uniformly negative for GLuc activity. This small IQR spread revealed a range 
of induction (2- to 36-fold induction above background, mean 14-fold) among the 
GLuc-positive wells on day three. This induction range at early timepoints (3 days) is 
likely driven by differences in HIV lifecycle within single TZM-gfp cells plated, where 
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input cells harboring late stage HIV infection express the GFP reporter and produce 
virions immediately upon co-culture. By contrast, very early infections prior to 
integration would exhibit a delay before production of new virus and by GFP 
estimate of HIV status would score false negative at the time of seeding, causing 
an underestimate of the true HIV-infected population by flow cytometry. The GGR 
induction range increased (4- to 130-fold above background, mean 37-fold) by day 
seven (Fig. 22B), with the emergence of additional GLuc- positive wells (total to 
13/96 = 13.5% positive vs. 10.2% GFP scored on day of seeding). As with the cell-free 
titration experiment detailed above (Fig. 21C), it will be important to establish the 
timepoint at which the MoltGGR QVOA assay is maximally sensitive by daily 
longitudinal sampling using a wider panel of viruses (see Future Directions).  
 
Analyzing GGR reporter induction on day 3, I compared outgrowth from 
single TZM-gfp cells infected with either 27ZP or HIV-1 BaL. Interestingly, among the 
wells scoring positive for BaL infection, GLuc induction on day 3 was lower by 
twofold on average than in positive wells harboring a single 27ZP-infected cell (Fig. 
22B). This finding suggests genetic variation among different HIV strains may drive 
fitness for cell-to-cell transfer in this outgrowth assay, which may be a strong 
platform to identify and characterize the sequences responsible. The high 
efficiency of cell-to-cell transfer means that reporter signal at early timepoints 
derives predominately from this mode of infection during co-culture outgrowth 
assays. This is an important future application of the assay, since essentially nothing 
is known about cell transmission fitness at the level of the viral genotype.  
 75 
  
Figure 22. Single HIV infected cells seed a robust quantitative viral outgrowth assay 
in MoltGGR cells. A TZM-gfp cells were infected with the indicated virus stocks and GFP-
positive cells were quantified as an estimate of true HIV penetrance.  The bulk TZM-
gfp population was then seeded at single cell density to quantify HIV outgrowth by MoltGGR 
QVOA. Input GFP penetrance is indicated in green, the resulting percentage GLuc-positive 
fraction for each timepoint indicated in the grey box below. B Tukey statistical analyses 
reveals outliers (> 1.5 IQR) that harbor GLuc activity. GLuc signal for the whole seeded 
population is plotted for each virus and timepoint (solid color bars), with GLuc-positive 
outliers marked above (colored dots). appearing above each box. Boxes represent the 
interquartile range (25-75 percentile), with median drawn as a straight line. Whiskers 
delineate the 1.5x IQR, and the geometric mean is indicated by the round '+' symbol. All 
wells scoring positive were then re-plotted to show their distribution (hatched 
bars). The distribution of positives at early timepoints reveals that single HIV-infected BaL cells 
transfer HIV and induce reporter signal twofold less efficiently than 27ZP cells, a key metric 
that highlights an interesting application of this assay to study cell-to-cell transmission of 
different viral genotypes.  
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Experiments are now underway to interrogate a panel of 
transmitted/founder (T/F) HIV clones for cell-to-cell transfer fitness using variations 
on this MoltGGR QVOA theme, and to determine the time to maximum sensitivity 
described above. The power of this type of assay combines quantitative population 
studies (how many cells are infected?) with qualitative features such as propensity 
for cell-to-cell transmission and drug/neutralizing antibody susceptibility.  
 
Since the readout in this assay derives from HIV outgrowth seeded by a single 
cell, much resolution can be gained by assigning specific viral mutations to 
observed outgrowth phenotypes. For example, primary HIV isolates may replicate 
poorly in vitro, and may suffer extinction or adapt to culture conditions over time142. 
The sensitive single cell platform described here identifies viral clones early during 
their replication ex-vivo (low genetic diversity), and can be used to compare the 
outgrowth kinetics of these early isolates with progeny, culture-adapted virus. The 
existing longitudinal data pertaining to sequence variation that drives performance 
in cell culture, suggests that HIV adaptation is dependent on the cell host an 
though. However, this is an important question since all labs employing QVOA-type 
assays admit these platforms are at best a minimal estimate of the virus burden in 
vivo: many strains will fall below detection thresholds of standard outgrowth assays 
and be lost in subsequent analyses.   
 
Refinement of the SupGGR platform 
 
From the original heterogeneous SupGGR population, clones were seeded  
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Figure 23. Characterization of SupGGR clone HIV susceptibility and reporter 
induction. A-C Confocal images of the indicated SupGGR clones infected with 
VSV HIV-mCherry. Clone F1 is more susceptible to HIV infection assessed by 
fluorescence microscopy (B), flow cytometry (E)and by florescence signal to 
noise quantitative analyses H,K,M. In M, positive and negative gates were 
analyzed for median and interquartile range fluorescence intensities, with the 
range of signal reflected by the whiskers in plot M. Clone F1 was chosen for 
further analyses based on high GFP induction, lowest and least spread 
background (GFP-negative gate, grey bar in M). Signal to noise ratios for each 
clone are indicated in red text.  
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and expanded for characterization. A panel of 55 clones was interrogated for 
reporter induction upon HIV infection, and three of the strongest inducers were 
chosen for more thorough analyses, clones H3, C6, and F1. These clones were 
spinoculated for 2 hours with stocks of VSV- HIV-mCherry, and cultured for six days 
post-infection. Cells were then imaged by confocal microscopy and in parallel 
analyzed by flow cytometry for reporter induction.  
 
Imaging analyses revealed that a high fraction of SupGGR F1 cells became 
infected with HIV-mCherry, with predominantly co-localized GFP signal (Fig. 23). This 
data was confirmed by quantitative flow cytometric analyses, showing an 
increased penetrance of HIV infection by 48 hours (53.6% GFP penetrance, vs 38.6% 
and 30.4% for clones C6 and F1, respectively, Fig. 23A-I). As a caveat, VSV/G 
pseudotyped HIV-mCherry was used in this experiment to quantify reporter 
activation absent varied efficiency of HIV entry among the clones tested. However, 
SupGGR cells were later extensively tested with wild-type HIV stocks to confirm their 
utility in outgrowth assays. Clone F1 also exhibited the lowest background 
fluorescence (compare grey bars in Fig. 23M) with the least amount of spread 
around the median background. This property becomes important for assays of co-
culture, where reporter cell background complicates gating strategies to separate 
primary cells from reporter cells. Clone F1 and H3 had higher signal to noise ratios 
than clone C6 (red text in Fig. 23M), despite the highest median fluorescence in the 
GFP-positive gate of clone C6. With these data, clone F1 was designated ‘SupGGR’ 
and advanced for further analyses. 
 79 
Validation of SupGGR cell performance using relevant HIV strains 
 
The MoltGGR platform performed very well in my hands for the outgrowth of 
both lab-adapted HIV and primary virus isolated from Malawian adults (27ZP). 
However, recent reports describing the SupT1/CCR5 as an alternative outgrowth 
platform pursued these cells after variable success with MoltGGR cells in primary 
outgrowth  assays135, a concern echoed by others in the field [D. Richman, UC San 
Diego, personal communication]. Building on these findings, I sought to expand the 
utility of the SupGGR cell line by characterizing the outgrowth of highly relevant, 
early isolates of HIV such as those encountered during reservoir quantification 
studies using patient-centered QVOA assays.  
 
High content sequencing technology has made possible the sequence 
determination of many HIV strains within a single patient, the hierarchical clustering 
of which can illuminate the sequence of viruses that most likely initiated HIV 
infection in that patient. Such ancestral strains are the strongest candidates for the 
viruses that are actually transmitted from person to person, and defining their 
biology for large groups of patients can help us learn potential targets for 
prevention of transmission. These have been coined transmitted/founder viruses 
(T/F)58, and have also been subsequently shown to comprise much of the early 
rebounding HIV burden upon therapy interruption143,144. Given the very limited 
knowledge we have of T/F virus biology, there remain many key unanswered 
questions about these special HIV strains, particularly their adaptations to different 
cell types and the subtleties of their transmission between cells. Studying these 
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strains using a tractable, biologically rich platform such as that described here will 
yield extremely valuable insight into potential future targets.   
 
An expanded outgrowth toolkit: SupGFP and TZM-GGR 
 
I generated two additional reagents, SupGFP and TZM-GGR reporter cells, 
using an identical workflow as that described above for SupGGR and TZM-gfp cells. 
SupGFP (clone 8C) cells harbor the pNL-GFP-RRE(SA) reporter vector and do not 
express gaussia luciferase or any enzymatic reporter. Conversely, TZM-GGR cells 
(clone 4H12) harbor the GGR construct expressing both gaussia luciferase and GFP.  
I do not describe the generation of these cells here in detail here, but validate their 
use below with primary human outgrowth supernatants (SupGGR, Figure 24) and 
primary macrophages (TZM-ggr, Figure 27).  
 
Transmitted/founder virus infection of SupGGR cells 
 
A key feature of any outgrowth platform is the ability to replicate the virus 
that matters for transmission, persistence, and rebound. The recent discovery of T/F 
HIV strains has illuminated these genotypes as the HIV that matters in this context, 
and thus any viable QVOA platform must capture and replicate these strains. To 
test this in SupGGR, I infected these cultures with a panel of full-length, wild type T/F 
infectious molecular clones, representing both Clade C (Africa predominant) and 
Clade B (North America predominant). SupGGR cells were spinoculated for 2 hours 
in the presence of DEAE-Dextran and plated for culture for 48 hours, followed by 
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fluorescence imaging and flow cytometry.   
 
All strains of HIV tested in this experiment infected SupGGR cells with varying 
efficiency, as judged by reporter induction compared to mock-infected cells (Fig. 
25). Input virus was not normalized using p24, so these varying efficiencies may 
represent differences in viral entry or simply differences in infectious titer of each 
stock. Interestingly, GFP-positive SupGGR cells exhibited distinct phenotypes among 
the viruses studied. Several, but not all, viruses induced formation of multinucleate 
syncytia, a finding described previously for the SupT1/CCR5 parental cell line after 
infection with several human isolates as well as lab strains LAI, BaL, and MCV135. 
Notably, THRO.C, a Clade B T/F clone infected 84% of SupGGR cells after 48 hours, 
but despite this high penetrance, no significant formation of syncytia was observed. 
By contrast, ZM249M and CH067.c (Clade C T/F clones) infected many fewer cells 
overall (12.6% and 7.7%, respectively), but the overwhelming majority of GFP-
positive cells in these cultures were aggregated and/or fused with irregular 
morphology (Fig. 24). A separate Clade C clone, CH162.c infected a much higher 
fraction of SupGGR cells and also formed small syncytia, though these exhibited a 
prevailing round phenotype with very few irregularities. While these are descriptive 
and preliminary findings, they illustrate that viral genotype drives a wide diversity of 
phenotypes that may impact the entry and exit (budding) of HIV among different 
cell types. Reporter cells such as MoltGGR and SupGGR provide the means to 
identify and characterize such phenotypes using viral outgrowth platforms already 
employed for HIV reservoir studies in human patients.  
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Figure 24. Efficient infection of SupGGR cells (clone F1) with a panel of 
transmitted/founder HIV strains. Control viruses (left column) were compared with 
infectious molecular clones of T/F viruses from Clade C (middle column) and Clade B 
(right column) 48 hours after infection of SupGGR cells. For each virus, representative 
confocal images are shown with GFP contour plots generated by flow cytometry. 
Irregular morphology is visible among syncytia and aggregates in Clade C clones 
ZM249M and CH067.c, with a notable absence of syncytium formation in Clade B clone 
THRO.c despite the high HIV penetrance in this culture at 48 hours.  
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Titration of HIV primary transmitted/founder clones in lymphoid (SupT1) vs. myeloid 
cells (HMDM) 
 
It is well established that T/F clones exhibit poor replication in monolayers of 
HMDM (monocyte-derived macrophages) in vitro when compared to the 
expansion of these same clones in PBMCs58. In addition, molecular and functional 
data show the viral envelope of T/F clones is universally CCR5/T-tropic, arguing 
these strains do not adapt to macrophage infection in vivo143,145. These data have 
been interpreted to strongly suggest that T/F HIV strains are not likely to be found in 
myeloid cells in vivo, and by extension that macrophages are unlikely to play key 
roles in the main features of T/F biology: patient to patient transmission and 
rebound/persistence. One particular study compared p24/gag viral output in the 
supernatant of CD4 T-cells and HMDM cultures over a period of 10 days, and found 
that T/F virus production in HMDM was up to two orders of magnitude lower than 
control lab-adapted macrophage-tropic strains, and 1-3 logs lower than T/F 
replication in lymphocytes58.   However, I reasoned that such kinetic analyses omit 
consideration of the proliferative (lymphocyte) versus static (macrophage) 
character of each cell type, which would have a logarithmic effect on the results. 
As a simple example, assuming a conservative 24 hour doubling time, 5,000 
lymphoid cells seeded on day one of a ten-day assay would yield 5.1x106 cells (3 
orders of magnitude) on day ten, not including any HIV-induced death. By 
comparison, 5,000 HMDM cells seeded on day one would remain 5,000 cells or 
fewer by day ten. A more effective measure of T/F HIV biology would address the 
fitness of these strains at the single cell level. Furthermore, a central tenet of HIV 
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persistence is the presence of durable HIV infected cells that can seed new 
infection in new target cells upon interruption of ART. Any estimation of this capacity 
in macrophages or other cells needs to consider the question of whether a given 
cell type infected with a T/F HIV strain can productively infect target lymphoid cells 
and thus give rise to rebound viremia.  
 
I devised an assay to address these questions by comparing the infectious 
titer of selected HIV clones in HMDM vs SupT1/CCR5 cells. Both of these cell choices 
are suboptimal surrogates for the cells HIV most readily encounters in vivo, but they 
are commonly used reagents to model in vivo myeloid and lymphoid HIV infection, 
respectively. This experiment was designed to establish the absolute titer of a given 
virus stock in different cell types, calculated as the TCID50141. This absolute titer can 
then be compared among different cell platforms.  
 
It is well known that the infectivity of HIV in different target cells can be 
influenced by culture additives, tissue culture and inoculation format, and one can 
tailor the infection to maximize entry of HIV for a given target cell type. Such 
techniques can make it difficult to compare directly the efficiency of HIV entry 
across cell platforms. Often used in macrophages, SIV virus-like particles carrying 
VPX protein increase reverse transcription in myeloid cells20, a rate limiting step 
owing to the host restriction factor SAMHD1 that degrades cellular pools of dNTPs in 
these post-mitotic cells to reduce viral replication21,22,146. Antagonizing SAMHD1 
leads to dramatic increases in the kinetics and penetrance of HIV infection in 
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cultured HMDM and other myeloid cultures ex vivo21,147. Similarly, cell-free virus 
infection of lymphoid cells is inefficient in culture148, and can be augmented by an 
order of magnitude or greater combining target cells with polycationic reagents 
such as DEAE-dextran or polybrene, and centrifuging the target cells with HIV in a 
process called spinoculation. However, none of these features are available in vivo, 
and a basic comparison of infectious titer drives at the minimal requirements, not 
maximized infection, of the target cell types. I reasoned that an even playing field 
without culture or inocula additives was an equitable approach to titer comparison. 
 
To establish the TCID50 of several HIV stocks in cultured SupT1/CCR5 and 
HMDM cells, serial tenfold dilutions of virus were prepared and added to these 
cultures in round bottom 96-well dishes. Three 96-well plates were prepared per 
virus: (1) SupT1/CCR5 @ 2500 per well, (2) HMDM @ 2500 per well, (3) medium only, 
with 50µL of diluted viral stock added to 8 replicate wells per dilution. Cultures were 
incubated for five days to allow infections to establish (or for inoculum virus to decay 
in medium-only wells). On day five, 104 reporter SupGGR cells were added to each 
well to read out replication competent HIV in each well. Using the number of 
positive wells for each dilution (Fig. 25B), the Reed-Muench method was used to 
calculate TCID50 in each well type. Background-subtracted TCID50 titers were 
plotted for each virus in Fig. 25C). 
 
 
 
 86 
  
Fi
gu
re
 2
5.
 A
 sc
al
ab
le
 a
bs
ol
ut
e 
tit
er
 a
ss
ay
 m
ea
su
re
s v
ira
l f
itn
es
s i
n 
m
ul
tip
le
 c
el
l p
op
ul
at
io
ns
. A
 S
ch
em
at
ic
 o
f a
ss
ay
 se
tu
p
. 
Th
e 
in
fe
ct
io
us
 ti
te
r o
f a
 g
iv
en
 v
ira
l s
to
ck
 is
 e
st
a
bl
ish
ed
 in
 m
ul
tip
le
 c
el
l t
yp
es
 in
 a
 si
ng
le
 e
xp
er
im
en
t. 
A
fte
r t
he
 fi
rs
t r
ou
nd
 (t
a
rg
et
) 
in
fe
ct
io
n 
is 
es
ta
bl
ish
ed
 fo
r 4
 d
ay
s,
 a
 c
on
sis
te
nt
 b
ol
us
 o
f r
ep
or
te
r c
el
ls 
(h
er
e 
Su
p
G
G
R)
 a
re
 a
d
d
ed
 to
 e
ve
ry
 w
el
l, 
a
nd
 re
po
rte
r 
ge
ne
 a
ct
iv
ity
 u
se
d 
to
 s
co
re
 w
el
ls 
po
sit
iv
e 
or
 n
eg
at
iv
e 
fo
r H
IV
 o
ut
gr
ow
th
. B
 P
lo
ts
 o
f 
pe
rc
en
t 
w
el
ls 
po
sit
iv
e 
vs
. v
ira
l d
ilu
tio
n.
 
Th
es
e 
va
lu
es
 a
re
 u
se
d 
to
 c
al
cu
la
te
 th
e 
TC
ID
50
 fo
r e
ac
h 
ta
rg
et
 c
el
l p
op
ul
at
io
n,
 a
nd
 in
 w
el
ls 
re
ce
iv
in
g 
no
 fi
rs
t-r
ou
nd
 ta
rg
et
 
ce
lls
 (m
ed
iu
m
 o
nl
y)
. “
M
ed
iu
m
 o
nl
y”
 b
ac
kg
ro
un
d
 su
bt
ra
ct
io
n 
th
en
 p
ro
vi
d
es
 th
e 
co
m
p
ar
iso
n 
TC
ID
50
 in
 p
a
ne
l C
, s
ho
w
in
g
 th
at
 
vi
ru
s 2
7Z
P 
is 
eq
ua
lly
 in
fe
ct
io
us
 in
 ly
m
p
ho
id
 a
nd
 m
ye
lo
id
 c
el
ls,
 w
hi
le
 T/
F 
cl
on
e 
TH
RO
.c
 is
 h
ig
hl
y 
in
fe
ct
io
us
 in
 b
ot
h 
m
ac
ro
ph
a
ge
s 
a
nd
 S
up
G
G
R 
ce
lls
 b
ut
 si
gn
ifi
ca
nt
ly
 m
or
e 
ef
fic
ie
nt
 in
 ly
m
ph
oi
d 
in
fe
ct
io
n.
 
 87 
Control viruses JR-CSF and JR-FL were isolated from the cerebrospinal fluid 
and frontal lobe, respectively, of an AIDS patient at autopsy, and have become 
valuable reagents for the study of HIV receptor biology. JR-CSF is a T-cell tropic 
(CCR5) strain that is considered either very weakly or non-macrophage-tropic149, 
while JR-FL is a CCR5-dependent highly macrophage-tropic strain. Interestingly, 
serial dilutions of these viruses in both SupT1 and HMDM cultures confirmed these 
existing data, showing a strong preference of JR-CSF for SupT1/CCR5 infection 
(TCID50 = 5.9x105/mL) versus HMDM infection (TCID50 = 1.7x103/mL), a difference of 
almost 2.5 logs (Fig. 25C). Conversely, JR-FL was more infectious in macrophages 
(TCID50 = 2.6x104/mL) than in SupT1/CCR5 cells (TCID50 = 4.8x103/mL). These data 
validate the assay as an approach to study cellular tropism using full-length 
infectious molecular clones of HIV.  
 
The human Clade C strain 27ZP was isolated in our lab from PBMC outgrowth 
of a chronic HIV patient not on ART therapy. This stock is not a cloned reagent but 
a viral swarm propagated in Molt4R5 cells over 21 days. It has been reported that 
isolates of Clade C – the subtype of HIV predominant in Africa – use CCR5 as a co-
receptor much more efficiently than other HIV subtypes, especially when CD4 levels 
are low57, such as on macrophages. The authors found that Clade C envelopes 
were nearly equally dependent on CD4 and CCR5, while other subtypes were 
much more strongly dependent on CD4 concentrations on target cells. Here I show 
that titration of viral stocks of 27ZP – a Clade C virus derived from peripheral blood 
– revealed approximately equal infectious titer in SupT1/CCR5 (TCID50 = 4.5x104/mL) 
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and HMDM cells (TCID50 = 3.5x104/mL, Fig. 25C), a finding consistent with previous 
data but demonstrated using full length infectious HIV.  
 
Finally, I confirmed that the Clade B T/F viral clone THRO.c is more highly 
infectious in lymphoid SupT1/CCR5 cells (TCID50 = 1.2x107/mL) than in HMDM 
(7.4x105) as previously reporter (Fig. 25C)58. However, this 16-fold difference in 
infectious titer does not preclude macrophages as viable targets for T/F infection, 
since the stock was still highly infectious in HMDM cultures (note that the TCID50 of 
THRO.c in HMDM was approximately the same as the TCID50 of the T-cell tropic JR-
CSF stock in SupT1/CCR5 infection). While preliminary, the data generated here 
using the absolute titer assay demonstrates a small sample of the many questions 
that become possible to address with accessible reporter readouts. Future 
experiments are planned to examine a wider panel of T/F clones for absolute titer 
in HMDM versus SupT1/CCR5, primary CD4 T-cells and TZM-based cell platforms.  
 
These findings demonstrate that the absolute titer assay uncovers 
meaningful variations in HIV tropism using infectious clones of HIV. Importantly, while 
existing assays provide ‘cleaner’ systems using cloned envelope genes to 
pseudotype replication-incompetent reporter viruses (a single-round infection 
assay), these systems can only consider envelope as a determinant of replication 
fitness in various target cell types, and also bias the results toward HIV strains that 
excel at cell-free virus transmission. The new model presented here permits flexibility 
for choices of target cells and outgrowth platforms, including the option to 
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inoculate multiple different cell formats using the first-round supernatants.      
Applications of improved outgrowth platforms to study HIV infection of 
macrophages 
My findings above that T/F clone THRO.c is highly infectious in both 
macrophages and lymphoblastic cells highlight an important paradigm that has 
not been adequately addressed in the literature. A bona fide HIV reservoir cell must: 
(1) be susceptible to HIV infection with relevant strains, (2) survive the infection for 
long periods during ART therapy, and (3) seed rebound infection upon interruption 
of ART drugs. So, do macrophage cells qualify as reservoirs? First, while it is clear that 
T-tropic HIV replication in pure macrophage cultures might be significantly 
disadvantaged compared to T-cells58, macrophages do not exist in monoculture in 
vivo. Indeed, the kinetics of viral replication in a single cell type are irrelevant to the 
reservoir capacity of the cells in question. I show above that HMDM are highly 
susceptible to infection with T/F clone THRO.c, despite lower apparent infectivity 
than in parallel lymphoid cultures. Secondly, I and others have shown that HMDM 
infected with HIV persist for long periods in culture, while mice harboring human 
myeloid (but no lymphoid) cells can support viral replication, viremia, and 
demonstrate persistence of HIV during ART therapy54,55,95. And finally, using HMDM 
models in vitro, it is well established that macrophages not only seed infection in 
naïve target cells, they do so with a highly efficient mechanism that appears highly 
targeted and evolved119,123,125,127,130. However, while macrophages surpass all the 
basic requirements for a reservoir cell, robust data remains scarce pertaining to HIV 
persistence within macrophages in vivo.   
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For this reason, the HIV macrophage question has been debated for the last 
30 years, even as our understanding of the monocyte-macrophage lineage has 
matured66-68. Recent reports from multiple groups have shown that tissue 
macrophages such as lung AMs are not derived from adult bone marrow 
macrophages as was long assumed, but are seeded by human fetal liver cells 
during embryonic development and around parturition, and can persist through 
the life of the organism without substantial contribution from circulating monocytes. 
Implicit in this observation is that tissue macrophages like AMs are self-renewing, 
capable of proliferation in response to mitogenic stimuli in their environment71. For 
AMs in particular, it has been shown in mice and humans that GM-CSF is a necessary 
factor for the maturation of AMs in the lung66,68,103, while GM-CSF signaling is required 
for the proliferation of AMs in situ and ex vivo150-156.  
 
These findings have enormous ramifications for the study of HIV persistence. 
IT has been known since the early days of HIV research that primary macrophages 
(HMDM) infected with HIV ex vivo remain viable for weeks, continually producing 
virus with a reported peak between 40-60 days95; compare this with an average 
half-life of 48 hours for HIV-infected lymphoblasts. While it would be difficult to 
quantitatively compare the sum total virion production in a single infected 
macrophage vs. a single infected lymphocyte over their respective lifetime, only 
infected T-lymphocytes are known to have a finite half-life once productively HIV-
infected46. The added possibility that HIV infected macrophages might also 
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proliferate in vivo raises the possibility of clonal expansion of virus without exposure 
to ART drugs or immune pressure, a concept now being intensely explored even in 
lymphocyte subsets157,158. Finally, the biology of HIV infection in macrophages 
appears highly evolved to maximize the efficiency of cell-to-cell spread during 
virological synapse, a process that has been quantified, and imaged in real time119. 
Macrophages may form a self-renewing, long-lived, and consistent source of 
infectious virus that is not cleared by the immune system or by HIV cytopathic 
effects. However, despite their seemingly ideal candidacy as long-lived HIV 
reservoir cells, it remains unresolved whether or to what extent they contribute to 
viral rebound, persistence, or the HIV latent reservoir.  
 
These are key paradigms to study, but the generally poor access to tissue 
macrophages from live HIV-infected patients, and the perceived challenges of 
studying this diverse and complex set of immune cells ex vivo, have together 
impeded widespread entry of investigators into this arena. Furthermore, the HMDM 
platform may not be a relevant model for tissue-resident macrophages. HMDM are 
a terminally differentiated, reactionary cell population with no proliferative 
capacity ex vivo, while tissue macrophages like AMs are self-renewing and 
generally exhibit an anti-inflammatory phenotype. This is a fertile area of research, 
but a systematic approach in pursuit of a better model of tissue macrophage HIV 
infection has not yet been reported.  Here, I explore the potential of fetal liver 
progenitors as a model of tissue-resident macrophages during HIV infection.  
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Comparison of monocyte-derived and fetal-liver macrophage HIV infection 
 
HMDM are generated by slow differentiation from adult blood bone marrow-
derived monocytes in medium containing 10% human pooled AB serum. During a 
one week differentiation period, the rounded blood monocytes gradually adhere, 
transiently assume a spindle shape, then eventually a canonical “fried egg” 
morphology (Fig. 26B). Proliferation of HMDM cultures during this timeframe is 
absent. By contrast, fetal liver CD34+ progenitors are cultured for 2-3 weeks in the 
same human serum-containing medium, but with added recombinant human GM-
CSF at 100ng/mL. Their morphology is blastic for the first 1.5-2 weeks, after which the 
formation of aggregates and progressively adherent foci is observed, during a 
period of intense proliferation. Eventually, this cell division plateaus and after 3-4 
passages in vitro, the cultures become static.  Interestingly, mouse fetal liver cells 
cultured under similar conditions are reported to proliferate indefinitely without 
transformation151, a scenario I was unable to reproduce with the human cultures. At 
3 weeks of culture human fetal liver-derived macrophages (HuFLM) were post-
mitotic, morphologically indistinguishable from HMDM (Fig. 26AB), and were 
advanced for further analyses.  
 
I first tested the susceptibility of HuFLM to HIV infection under the same 
conditions as infection in HMDM. Equal numbers of HMDM and HuFLM were seeded 
for HIV infection and could not be distinguished by morphology upon adherence 
(Fig. 26AB). However, these outward phenotypic similarities concealed a significant 
functional difference related to HIV susceptibility. Six days following infection with a 
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macrophage tropic (BaL) enveloped GFP reporter virus (HIV-GFP, Fig. 4), HuFLM 
exhibited a threefold increase in HIV-GFP penetrance compared to an equal 
number of HMDM (~16.6% HuFLM vs ~5.4% HMDM, Fig. 26CD). This effect was 
reproducible, observed in three separate experiments performed on different days. 
These data indicate that HuFLM cells are more permissive hosts for HIV infection in 
vitro. While factors influencing this outcome are unknown, it is possible that dNTP 
levels in HuFLM remain higher than in HMDM owing to their more recent history of 
cell proliferation during in vitro differentiation. However, the effect was likely not 
directly due to proliferating HuFLM at the time of infection, as no differences in 
PCNA (proliferating cell nuclear antigen) staining were observed between HMDM 
and HuFLM. Future analyses should investigate the hypothesis that low SAMHD1 
expression and the consequent higher residual dNTP levels s in HuFLM cells might 
contribute to their increased efficiency of HIV infection in culture.  
 
Importantly, cultured HuFLM represent the same lineage that seeds the 
diversity of tissue-resident macrophages66-68, and may serve as a more accurate 
model of their biology than do HMDM. The increased susceptibility of these 
embryonic-lineage cells to HIV infection is an interesting, reproducible preliminary 
finding that indicates a divergent host/pathogen interface in HMDM versus HuFLM. 
However, much more work is needed to redefine in HuFLM some of the paradigms 
established so firmly in the literature using HMDM, notably pertaining to T/F virus 
replication and HIV persistence; these features of myeloid HIV infection may be 
underestimated in HMDMs. 
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Potential of fetal liver macrophages as HIV reservoirs 
 
 The increased infection of HuFLM with HIV compared to parallel cultures of 
Figure 26. Human fetal liver-derived macrophages (HuFLM) are more susceptible 
hosts for HIV infection than HMDM. A-B Cultured HuFLM and HMDM are 
morphologically equivalent at the time of HIV infection with HIV-GFP (BaL env). C-
D On day six, HuFLM (C) show a threefold higher penetrance of HIV infection than 
HMDM (D), an effect that did not correlate with any changes in expression of cell 
cycle antigen PCNA.   
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HMDM raised the possibility that HuFLM and their in vivo tissue macrophage progeny 
might be likely targets for HIV infection in vivo. However, the relevance of these cells 
as HIV reservoirs would be impacted by their ability to then productively infect 
target cells during rebound in vivo or co-culture in vitro. To address this, I designed 
a limiting dilution viral outgrowth assay using lymphoid SupT1/CCR5 cells, and 
myeloid HMDM and HuFLM infected with VSV/G-pseudotyped HIV-mCherry. The 
objective was to quantify efficiency of HIV transfer from each cell type to different 
outgrowth platforms (Affinofile-GGR cells, and the TZM family of cell reagents).   
 
Based on the previously observed robust infection of HuFLM cells with HIV, I 
hypothesized that these cells might be similarly enhanced in their ability to harbor 
and transmit the virus to new cells. To normalize for infection efficiency, HIV-mCherry 
positive cells (SupT1/CCR5, HMDM or HuFLM) were harvested from culture and FACS 
purified on a BioRad S3e instrument. The sort was straightforward and demonstrates 
a clear proof of concept for flow- and FACS-mediated experiments with live primary 
human macrophages. The plots of sorted cells are shown in Fig. 27 B-D, again 
showing a much higher (~4-fold) higher HIV penetrance in HuFLM versus HMDM. 
Interestingly, this experiment suggested the difference in susceptibility is not due to 
HIV env-dependent entry, since VSV/G-pseudotyped HIV-mCherry was used for the 
initial infection. Sorted mCherry-positive cells were gently centrifuged and 
resuspended at a concentration of 3-5 cells per 50µL of medium. To initiate co-
culture, a total of 50µL (3-5 cells) was then aliquoted into multiple replicate wells 
containing monolayers of target reporter cells and the cells incubated overnight.  
 96 
 
Two days later, wells were inspected for the presence of viable HIV-mCherry-
infected macrophages and the development of reporter signal by confocal 
microscopy. In all wells seeded with macrophages (HMDM or HuFLM), between one 
and four adherent mCherry-positive cells were found per well. Robust m-Cherry and 
GFP-positive syncytia were found in Affinofile-GGR wells with co-cultured HMDM 
and SupT1/CCR5 cells, but surprisingly no syncytia or GFP-expressing foci were 
observed in wells with HuFLM. In HMDM wells, mCherry-expressing macrophages 
were evident immediately adjacent to the majority of multi-nucleate syncytia 
formed, suggesting these cells initiated the infection locally. This observation is 
consistent with my previous results suggesting macrophages initiate but do not 
themselves join HIV-induced syncytia in TZM-gfp reporter cells. By contrast, HuFLM 
cells positive for HIV-mCherry were evident neighboring susceptible Affinofile-GGR 
cells, with no apparent transfer of infection (Fig. 27 B-C), an absence of reporter 
signal, and absence of any cell fusion events. These findings were reproduced in 
wells of TZM-bl and TZM-GGR reporter cells (Fig. 27 E-F), showing dramatic mCherry-
positive syncytia developing with an adjacent m-Cherry positive HMDM cell of 
typical morphology, while no infection events were observed surrounding adhered 
HuFLM in corresponding wells . Twenty-four hours later (day 3 of co-culture), syncytia 
in HMDM and SupT1 co-cultures continued to expand in size and fluorescence, with 
no changes apparent in HuFLM cultures despite the persistence of mCherry-positive 
cells of typical macrophage morphology.  Together the data argue that, despite 
strong HIV transcription, infected fetal liver macrophages do not produce infectious  
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Figure 27. HIV-infected HuFLM do not infect co-cultured reporter cells. A,D,G HuFLM, 
HMDM and SupTI/CCR5 cells were sorted for mCherry positivity after infection 
VSV/G-HIV-mCherry (BaL env). Cells were diluted and plated at ~3-5 cells per well 
in 96-well format with pre-seeded reporter cells (indicated in green). Cultures were 
imaged 48 hours later (above) and followed 5 additional days. B HuFLM do not 
seed outgrowth in maximally-induced Affinofile-GGR (A-GGR max) or (B) TZM-GGR 
cells. This observation is conserved in TZM-bl cells (inset, B). By contrast, mCherry-
positive HMDM (C-D) and SupT1/R5 cells (E-F) seed robust infection in both cell 
formats. As previously observed for HMDM, and for HuFLM in A-B, infected HMDM 
adhere, initiate syncytium formation in reporter cells nearby, but do not themselves 
form heterotypic fusions (white arrows).  
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HIV virions during co-culture with engineered reporter cells. These are highly 
surprising findings, and strongly argue for a host factor that restricts HIV maturation 
or release from HuFLM cells under the tested conditions. This would be the first report, 
to my knowledge, of absolute inhibition of virion production or release from primary 
cells infected with HIV. While tetherin and the TIM family of Ig domain proteins have 
been shown to partially restrict HIV release in CD4 T-cells and HMDMs159-161, the 
restriction in HuFLM appears absolute. Future experiments are planned to attempt 
modulation of this pathway to address these and other relevant questions 
surrounding HuFLM cells and HIV transmission (See Chapter 5).  
 
These are preliminary findings that will require more investigation, without 
which only very conservative conclusions can be drawn. However, they highlight 
the large gaps in our knowledge of HIV infection in primary myeloid cells, and 
importantly provide several novel tools to rigorously and conveniently address the 
key questions. I describe here several important phenotypes observed through the 
use of fluorescent HIV reporter cells that are scalable to single cell resolution and 
flexible with multiple readouts.  
 
DISCUSSION 
 
The rationale for these studies was to illuminate what we might be missing in 
standard outgrowth assays of HIV in vitro. If a culture well is PCR- or HIV gag (p24) 
negative at the time of the assay, does that mean no HIV infection was present? 
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Pioneers in the field based and refined their assays on replication kinetics of CXCR4-
tropic late-stage HIV from the peripheral blood, and thousands of papers published 
on the subject are variations on that theme. Standard cell lines were updated 
relatively recently to permit the reliable replication of CCR5-tropic virus, the strains 
that predominate at every stage of infection before and during ART in humans162,163. 
But what if the HIV in tissue macrophages replicates very slowly in vitro? What if the 
virus is present but remains undetectable by enzymatic assays at canonical 
timepoints? The tools available to address these questions were designed and 
validated using a very narrow range of HIV strains, and lack any capacity to provide 
live metrics of infection if attempting outgrowth of diverse strains from novel 
reservoirs. Such experiments would be more likely to succeed if endpoints or 
workflow could be adjusted based on a live readout, especially where input 
material was limiting and derived by semi-invasive methods such as bronchoscopy 
and lavage.  
 
To address these challenges, I modified several standard cell platforms with 
various fluorescent reporter constructs. I show that properties of the industry 
standard parental cell lines impact their utility under various conditions, bearing 
important ramifications for experimental design especially in the context of rare 
infection events, such as serial dilution outgrowth assays.  My work highlights the 
long list of questions that remain unresolved with regard to discrete subsets of 
reservoir cells in vivo, the HIV they may harbor, and provides several robust tools to 
study them ex vivo.  
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CHAPTER FOUR 
 
Application of viral outgrowth assays to characterize HIV infection of BAL-derived 
human alveolar macrophages  
 
This chapter details efforts to deploy some of the tools developed above in viral 
outgrowth platforms in Blantyre, Malawi. Importantly, while I originally envisioned 
the workflow of reporter-informed outgrowth at the clinic in Blantyre, I played just 
one of many critical roles of this multi-center, multi-investigator study. It has been 
the honor of my nearly 15-year career in science to participate in a study of such 
gravitas with direct connection to human patients – an honor experienced by few 
investigators and even fewer graduate students.  
 
 
 
 
The experiments described in this chapter are part of a collaborative undertaking 
with members of the Russell, Mwandumba, and Jambo laboratories, In Ithaca, NY, 
Liverpool, UK, and Blantyre, Malawi. All primary co-culture experiments were 
performed by others, on the ground in Malawi. I performed all secondary culture 
experiments and fluorescence microscopy studies.  Molecular analyses were 
carried out by Saikat Boliar, with some of my own contributions.   
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INTRODUCTION 
 
Since its emergence in 1980 HIV has become perhaps the most intensely 
studied virus around the world, and for much of the past 30 years has accounted 
for the largest number of deaths from any single global pathogen164. Sustained 
efforts to bring antiretroviral therapy (ART) to a majority of infected people 
worldwide – with a focus on sub-Saharan Africa – have provided steady reductions 
in the number of HIV-related deaths. Paradoxically however, a corresponding 
decrease in the number of new infections has stalled in the same timeframe164. In 
2016, only half of the HIV-infected population around the world were receiving ART, 
showing we still have a long way to go.   
 
Blantyre, Malawi is a city near the geographic epicenter of the HIV epidemic, 
in a country faced with more than 9% HIV prevalence among adults165. Among HIV-
infected individuals in Malawi taking frontline antiretroviral therapy (ART), each year 
approximately 10-15% experience ART failure, underscoring the importance of 
understanding reservoir cells and the virus they harbor.  While many investigators 
globally have pursued latent HIV reservoirs in bloodborne CD4 T-cells, tissue 
reservoirs are much more difficult to study. Tissue access is limited, often surgical, 
and medical justification for such studies is challenging. Notable exceptions are 
routine diagnostic procedures such as BAL and colonoscopy, and are being 
pursued in our lab and elsewhere to access potential reservoir tissues for the 
collection and analyses of HIV-infected cells74. The high coincidence of active 
pulmonary tuberculosis (TB) with HIV infection in sub-Saharan Africa means that in 
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Malawi, BAL is a diagnostic standard of care. In this procedure, AMs and other cells 
are washed out of the airway and collected for diagnosis of tuberculosis and other 
opportunistic pathogens. Blantyre is an ideal setting for such studies, and Dr. Henry 
Mwandumba has been a highly valued collaborator of our laboratory for many 
years in this context. Indeed, Dr. Mwandumba and our laboratory first developed 
the FISH:FLOW platform as a means to detect HIV infection at the cellular level 
during what was originally a TB-centric study of AM function74.  
Quantitative studies of Clade C reservoirs 
 
Industry standard methods to quantify the HIV reservoir are labor-intensive 
and costly; hence, much of the quantitative work on HIV reservoirs has been done 
in a handful of laboratories, in large part on North American patient cohorts (Clade 
B HIV)166. As a consequence, very little is known about the size and character of HIV 
reservoirs in African (Clade C) cohorts, where HIV genotypic differences are known 
to drive key phenotypes particularly related to virus entry and baseline 
macrophage tropism57. The current study is an early step toward addressing this 
shortage, and is designed to provide reliable, industry standard tools to researchers 
in a wide variety of settings (including resource-limited) with the means to at least 
illuminate what we might be missing using common viral outgrowth assays.  
RESULTS 
Primary co-culture for HIV capture in Blantyre, Malawi 
Previous work from our lab used FISH:FLOW and functional assays to show 
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that HIV gag-positive AMs were found preferentially in the ‘small’ AM subset (low 
forward scatter) and were deficient in phagocytic activity74. However, HIV RNA FISH 
signal has not yet been reliably associated with replication competent HIV infection 
in AMs.  We hypothesized it was feasible to capture infectious HIV provirus within 
primary co-cultured cells and supernatants of AMs, TZM-gfp or Molt4R5 cells. In 
parallel we plated adherent co-cultures of TZM-gfp and AM cells on coverslips, for 
analyses by electron microscopy. The result was a coordinated workflow that is 
manageable in the context of a busy patient recruitment and bronchoscopy 
schedule in Malawi, under the direction of Dr. Henry Mwandumba. The primary 
culture window (48 h) was short in compliance with institutional biosafety 
requirements (the risk of TB outgrowth in primary cultures precludes long-term BSL-2 
experiments).  
 
Bulk cells from BAL including AMs, lymphocytes and other cells were plated 
with reporter TZM-gfp cells or non-reporter Molt4R5 cells in culture for 48 hours of 
primary culture. In some cases, patient-matched PBMC were isolated and seeded 
separately in co-culture for viral capture. In theory, this window would allow for a 
single round of HIV infection only, and would result in shedding of the virus into the 
medium of infected wells. The magnitude of virus production would be dependent 
on the number of primary BAL cells productively infected. Cells were harvested 
either using trypsin-EDTA for adherent TZM-gfp or by centrifugation for Molt4R5 cells. 
In both cases, primary culture supernatants were saved for additional outgrowth, 
vRNA and HIV p24 quantification. Cells were viably archived in DMSO-containing 
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medium, and both cells and their associated supernatants were forwarded to 
Ithaca, NY on dry ice for downstream analyses.  
 
Analyses of HIV content within primary co-culture supernatants  
 
Primary co-culture supernatants from ten patients were first analyzed by p24 
ELISA (Fig. 28) to test for the presence of viral gag antigen. This assay is an industry 
standard estimate of HIV virion concentration in culture medium or patient-derived 
material. It is not used as a surrogate for infectious HIV, since defective virions and 
cellular debris contain gag protein. Of twenty samples analyzed (multiple co-
culture formats were plated for some patients), we detected p24 antigen in two 
samples from different patients, 10.52M (BAL) and 10.27Z (PBMC). Both p24-postive 
samples derived from TZM-gfp co-cultures; the TZM-gfp outgrowth platform was not 
the only successful strategy however, as infectious HIV-1 was later found in 
supernatants deriving from Molt4R5 co-cultures (described below). Interestingly, 
patient 1052M is an ART-treated individual (duration >1 year), who at the time of 
BAL harvest had a CD4 count of 471, and an undetectable plasma viral load.  
 
The PBMCs of patient 10.27Z (ART naïve) also yielded p24-positive 
supernatant in TZM-gfp co-culture, but only after 48 hours of culture. The 24-hour 
timepoint could not be distinguished from background p24 levels. These findings 
suggest either that infection of TZM-gfp cells produced new virions that were 
detected only on the second day of culture, or that primary cells shedding virions 
did not accumulate sufficient p24 in the medium by 24-hours to be detected by the 
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assay. Demonstration of budding HIV by electron microscopy, or secondary 
outgrowth culture assays would be required to establish the replication 
competency of the HIV we detected.   
 
The detection of HIV p24 in primary culture supernatants from an ART-treated 
patient was important preliminary evidence obtained using an industry-standard 
assay that HIV is present in the airway of human patients. Importantly, these results 
Figure 28. Measurement of HIV-1 p24 concentration 
in primary co-culture supernatants from Blantyre, 
Malawi. A series of p24 standards (red) demonstrate 
the linear region of the assay. Pooled samples 
(hatched box) are plotted with outliers established 
using the Tukey method of 1.5x IQR. Positive samples 
plotted correspond to patient 1052.M (ART positive, 
green) and 10.27Z-PBMC (ART naïve, blue).   
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were obtained without exogenous cytokines stimulation and in 48 hours of primary 
culture, arguing that active, not latently-infected cells seeded outgrowth or 
produced virions in the assay timeframe. However, more rigorous proof of infectivity 
and the genetic sequence of the virus would be needed to demonstrate that HIV 
in the airway has reservoir potential in the context of ART.  
 
Primary co-cultures harbor HIV virions revealed by electron microscopy 
 
 TZM-gfp co-cultures with primary BAL were performed on coverslips in 
Malawi, that were fixed and transported to Ithaca, NY for processing and electron 
microscopy (EM). Similar to the schematic performed using correlative EM in Figure 
18, regions of interest were embedded in resin and the coverslip removed prior to 
ultrathin sectioning in the z-axis.  
 Alveolar macrophages and many HeLa/TZM-gfp cells were observed by EM 
imaging. While accumulation of HIV within VCCs of cultured AMs was not observed 
in the samples examined, characteristic virions of HIV morphology were found in 
several samples deriving from BAL co-culture (Fig. 29), including from patient 10.27Z, 
10.55G and 10.53K. No patients on ART regimens were examined by EM in this pilot 
study.  However, the relative ease of HIV identification by EM in these samples 
despite no robust downstream outgrowth of virus from secondary cultures of 10.55G 
and 10.53K validates this combined approach to collect evidence of HIV 
production within cells of the airway, and increases confidence that low-level or 
rare signal observed during secondary outgrowth in Affinofile-GGR or Molt4R5 cells 
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corresponds to virus that does not meet the burden of fitness for replication in vitro 
under current conditions. Future experiments should revisit these methods to support 
outgrowth data obtained from ART treated patient samples.  
Figure 29. Primary BAL co-cultures reveal HIV virions budding in TZM-gfp cells. 
Cultures from three patients not on ART were analyzed by electron microscopy. HIV 
was evident throughout the culture, with representative fields shown.  
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Secondary outgrowth cultures: primary cells reseeded for outgrowth  
 
Our working hypothesis held that harvested co-culture cells would be 
suitable hosts to transport the virus and would provide outgrowth in secondary co-
cultures at Cornell University. Encouraged that some primary supernatants were 
p24-positive with evidence of virion production by EM, we thawed cells for a longer-
duration secondary co-culture with either Molt4R5 cells or maximally-induced 
Affinofile-GGR cells (CCR5hi/CD4hi). Cultures were propagated for 10 days, and 
Affinofile-GGR (A-GGR) cells were monitored daily by fluorescence microscopy for 
the emergence of GFP-positive foci that might indicate active HIV infection. These 
efforts were unsuccessful however, and we were unable to generate any evidence 
of HIV replication in these secondary co-cultures. PCR on isolated vRNA from the 
secondary co-culture medium and amplification of A-GGR or Molt4R5 cellular RNA 
produced no HIV-derived amplicons in any sample tested, even those that had 
returned a positive HIV p24 result in earlier tests (Fig. 28).  
 
Secondary outgrowth cultures: supernatant inocula 
  
Parallel cultures using primary co-culture supernatants as inocula were more 
successful. Molt4R5 and maximally induced A-GGR cells were used as secondary 
outgrowth targets for these supernatants, and cultures were carried for 13 days 
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post-inoculation. Daily monitoring of A-GGR cells revealed the emergence of rare, 
early GFP-positive foci by 42 hours (not shown), with syncytium formation 
characteristic of HIV cytopathic effects by 3 days post-infection (Fig. 30). 
Compared to robust infections observed using positive control lab-adapted HIV 
strains (Fig. 30, top row), patient-derived supernatants exhibited much-reduced 
apparent infectivity, with very rare (2-10) GFP-positive foci per 35mm dish (except 
in mock-infected cultures receiving no inoculum). By day 4.5 however, it was clear 
the number and size of most GFP-positive foci were not expanding logarithmically 
(with the exception of those originating from PBMC-derived primary co-cultures).  
 
Affinofile cells were chosen in these experiments due to the rapid and highly 
robust readout following HIV infection with all viral strains previously tested. 
However, these cells require the addition of drugs to culture medium to induce the 
co-receptors for HIV. Thus, one possible explanation for the initial signal that 
appeared to slow after 2-3 days in culture is a decline in HIV co-receptor expression 
(CCR5 and CD4) in the absence of induction by doxycycline and ponasterone-A. 
Hence, on day 5 cultures were dosed with new induction drugs, incubated 2 
additional days to allow a single round of infection with virions already present in 
the medium, then passaged on day 7 onto freshly-seeded and induced A-GGR 
cells. However, robustly expanding infection was confined only to cultures derived 
from patient sample 10.27Z-PBMC.   
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Figure 30. Live confocal imaging of HIV outgrowth cultures in Affinofile-GGR cells. 
Primary viral supernatants were added maximally-induced A-GGR cells and cultures were 
images on day 3 (top panel) and day 4 (bottom panel) post-inoculation. Samples from ART-
treated patients marked with red. PBMC (-P suffix) and BAL (-B suffix) samples from Molt4R5 
(M4) and TZM-gfp capture were tested. Cultures developed hallmarks of HIV infection in A-
GGR cells, but persistent syncytia did not expand beyond day 4, except 10.27Z-PBMC.   
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These findings seemed to suggest the presence of HIV replication in several 
cultures of A-GGR cells early post-inoculation, but that replication was not 
sustainable under the assay conditions tested. Given the sensitivity of the A-GGR 
readout and observed characteristic morphology of HIV infected Affinofile-GGR 
cells, cultures were incubated for 6 additional days in an effort to allow viral 
amplification. However, foci were progressively lost with no additional evidence of 
replicating infection. The apparently self-limiting nature of the infection was 
unexpected in this culture format, but was a scenario that could not be adequately 
modeled a priori using lab-adapted virus. This wait-and-see approach of a more 
prolonged culture was unsuccessful, and PCR on both supernatant vRNA and cell-
derived mRNA harvested at 13 days yielded no HIV-1 amplicons, with the exception 
of 10.27Z-PBMC.  
Lymphoid cell platforms generate evidence of viral outgrowth 
 
Interestingly, in contrast to the secondary outgrowth cultures in Affinofile-
GGR cells, a greater subset of the same supernatants inoculated into Molt4R5 cells 
did produce PCR-detectable HIV infection by day 13, assayed by vRNA PCR. These 
cultures were spinoculated every other day for the first week to maximize HIV 
spread. These samples included BAL-derived medium from 10.27Z and 10.244 
primary co-cultures, and PBMC-derived medium from 10.27Z cultures. Among these 
PCR-positive cultures, however, HIV replication was markedly attenuated 
compared to lab strains of virus. When assayed for HIV by removing a small sample 
of supernatant and testing infectivity on A-GGR cells, only laboratory strains BaL and 
JR-CSF and 10.27Z-PBMC cultures produced infection (not shown). Moreover, 
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attempted expansion in Molt4R5 cells of BAL-derived virus to generate infectious 
stocks was unsuccessful, suggesting these viruses adapted too slowly to Molt4R5 
culture conditions and were eventually lost. This stands in contrast to the outgrowth 
of 10.27Z-PBMC-derived HIV, which replicated to high titer in Molt4R5 cells and 
generated infectious stocks of 5 x 104 TDIC50/mL, a titer comparable to that of HIV-
1 BaL viral supernatant prepared by transient transfection of 293FT cells. Importantly, 
no cultures of ART-treated patient-derived material replicated in this assay format 
sufficient for PCR amplification in either the supernatant or cell lysate. Ultimately, 
Molt4R5 outgrowth yielded multiple PCR-derived sequences from patient 10.27Z 
(BAL and PBMC) and 10.244 (BAL), covering the full length ORFs for env, tat/rev and 
gag (Fig. 33).  
 
As others have previously reported167, our findings may reflect the poor 
infectivity of some primary HIV isolates in vitro, which may not be adaptable to 
transformed cell lines in our assay timeframe. The sensitive readout of the reporter 
cells I describe here indicates that these tools may identify early infection events 
missed by standard measures of bulk viral replication, and afford opportunities to 
study the mutations associated with adaptation to culture over time. Interestingly, 
while we were able to isolate the genetic sequence of the 10.27Z (BAL) virus from 
Molt4R5 cells, replicating virus stock could not be obtained in the Molt4 platform 
even after extended culture, despite the strong outgrowth of patient-matched 
10.27Z (PBMC) stocks in the same cells.  
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The SupT1/R5 platform supports replication of HIV isolates that other cell lines do not 
 
Whereas primary TZM-gfp or Molt4R5 co-culture supernatants from 10.27Z 
(BAL) failed to generate a replicating infection during secondary outgrowth in 
Molt4R5 or A-GGR cells, inoculating these same primary supernatants in the SupGFP 
platform gave rise to robust replication (Fig. 31). These primary supernatants had 
originally tested negative by p24 ELISA, and produced only a self-limiting infection 
in Molt4R5 cells that was sufficient to clone some viral sequences by PCR, but not to 
generate infectious stocks. By contrast, outgrowth in SupGFP cells was continuous 
and logarithmic, with the Molt4R5 primary supernatant apparently replicating more 
efficiently than that from TZM-gfp primary co-cultures (Fig. 31). Viral stocks isolated 
from both samples at 21 days reflected this advantage, with Molt4R5 stocks 
Figure 31. SupGGR cells support replication of HIV from BAL-derived supernatant. 
Compared to mock-infected SupGFP cells (mock, left panel), cultures receiving 
10.27Z-BAL supernatant from the Molt4R5 (middle panel) or TZM-gfp capture 
platform (right panel) reveal robust induction of GFP reporter. These cultures 
generated infectious stocks and yielded PCR env clones after a 21-day outgrowth 
period.  
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exhibiting a nearly fifteen-fold enrichment in HIV titer (TCID50 in TZM-bl, data not 
shown). These data show the variability of HIV primary isolate fitness in various 
transformed cell populations, and help validate the approach of testing multiple 
outgrowth platforms with accessible readouts.  
 
Envelope evolution in different in vivo compartments and during outgrowth in vitro  
Envelope clones were generated from patient 10.27Z to compare the full-
length sequences of virus replicating in the peripheral blood versus the airway, and 
to learn whether the choice of capture platform (TZM-gfp vs. Molt4R5 primary co-
culture in Malawi) or outgrowth platform (Molt4R5 vs. SupGFP secondary outgrowth 
in Ithaca, NY). Figure 32AB shows the schematic of cell isolation. Three separate 
secondary outgrowth cultures were initiated from BAL-derived supernatants and 
one for PBMC-derived supernatant. Env clone sequences were aligned and 
clustered (PhyML, Figure 32C). Interestingly, this revealed that the outgrowth cell line 
(Molt4R5 or SupGFP) impacted viral adaptation more than the capture cell line, a 
finding that may be a consequence of the much longer secondary culture window 
(21 days vs. 2 days for the primary capture window). Viruses adapting to culture 
conditions would converge based on pressures from the host cells over this 
extended timeframe. However, tissue origin also impacted the clustering of these 
envelope genes, as the coding mutations apparent in PBMC vs BAL-derived 
cultures centered heavily in the V3-V5 loop region, with special emphasis in the V4 
loop of env ectodomain. Importantly, a high fraction (~29%) of the sequence 
differences between PBMC and BAL-derived virus disrupted residues known to be  
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N-linked glycosylated in vivo168. By contrast, the V1 loop and signal peptide seemed 
to dominate among mutations that clustered according to outgrowth cell line 
(Molt4R5 vs SupGFP) with comparatively little impact on the glycan shield (9% of 
coding mutations). These data suggest divergent pressures on the virus in vitro 
during outgrowth and in vivo during adaptation to different anatomical 
compartments. Importantly, very few sequence differences were identified within 
the V3 loop among these clones in accordance with previous findings169.  
 
A summary flowchart of the culture formats and outgrowth results is given in 
Figure 33. The workflow validates a combined approach to attempt viral outgrowth, 
and has refined our goals for subsequent cohorts. The primary conclusion from these 
studies was the marked success of primary outgrowth supernatants in subsequent 
downstream analyses versus work on viably archived primary co-culture cells.  Our 
future pursuits will feature longer primary co-culture windows of five days to allow 
viral expansion prior to supernatant harvest, combined with the use of the SupGFP 
cell platform for primary outgrowth in Malawi to easily monitor outgrowth by flow 
cytometry with limited liquid handling and convenient longitudinal sampling.  
 
DISCUSSION 
 
 The viral outgrowth platform in Blantyre, Malawi is still being refined.  With the 
tools I have developed, team members in Malawi and Ithaca have advanced the 
program with critical improvements at each iteration. We have shaped the 
protocol for viral capture and characterization around hard-won data, but have 
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much more work to do. This type of project is of course bigger than any one team 
member’s contribution, but my concepts and cellular reagents have made 
iteration possible through rapid, convenient readouts at critical timepoints of the 
protocol. Using TZM-gfp, SupGGR, and Molt4-based platforms, we have produced 
large viral swarms from both BAL and peripheral blood, which can now be 
characterized at the single-virion level using variations on the assays I present here. 
Future experiments should seek to understand any differences or 
compartmentalization of the viruses in the peripheral blood compared to the 
Figure 33. Flowchart summary of reporter cell-guided viral outgrowth results. Primary 
BAL cells (-B suffix) or PBMCs (-P suffix) were co-cultured in Blantyre with capture 
cell lines TZM-gfp or Molt4R5 (capture format indicated in purple). Secondary 
outgrowth culture was performed in Ithaca, NY. Successful PCR and viral output is 
indicated for each sample including specific genes amplified and sequence 
verified shown in blue.  
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airway, their molecular and cellular tropism using both affinity profiling (Affinofile 
cells) and absolute titer experiments, and characterize the heterogeneity in each 
vial population for clones that are either strongly or poorly adapted to replication 
in vitro.  
 
Furthermore, while our previous data showed that HIV gag mRNA FISH signal 
is found more commonly in AMs than lymphocytes in the airway74, the contribution 
of lymphocyte-derived HIV in these outgrowth assays cannot be excluded. With a 
more reliable and matured primary outgrowth platform being tested, future 
experiments should address the cellular source of any HIV outgrowth from human 
BAL (see Chapter 5). Such pursuits were considered premature for the current 
studies prior to proof-of-concept, but would entail immunomagnetic separation of 
myeloid from lymphoid cells in BAL samples.  Nonetheless, rigorous demonstration 
of HIV replication in the airway of Malawian adults, absent information about the 
specific cell types harboring the virus, was considered to be a significant advance 
that would help define our future directions in Blantyre, and clarify the role of the 
airway as an anatomical reservoir for the virus.  
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CHAPTER FIVE 
 
Future work: broadly expanding horizons  
 
In this chapter, I address the challenges and exciting opportunities ahead using the 
tools and insights generated during these studies. While my work highlights several 
paradigms that need attention, this thesis lays the foundation and provides the 
infrastructure to make rapid progress towards these goals. 
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HIV-infected monocyte-derived macrophages are refractory to heterotypic cell 
fusion 
 
I repeatedly observed that HIV-infected human monocyte-derived 
macrophages (HMDM) could seed rapid outgrowth of HIV in co-culture with a 
variety of reporter cell platforms. This was especially true of adherent reporters such 
as the TZM family of HeLa-based HIV reporter cells, and of HEK293-derived Affinofile-
GGR cells (Figures 14-16, 27). Using several lab-adapted and primary isolates, the 
strength of the reporter cell readout was bolstered by the formation of large, multi-
nucleate syncytia that expanded in size and signal intensity over several days in 
culture. A key feature of such syncytia is an upregulation of HIV output and longer 
half-life of the fused cells170, a windfall for outgrowth studies attempting to capture 
rare HIV-infected cells in a primary cell population. However, the dramatic 
formation of these cell fusion events was contrasted with the appearance of a 
solitary adhered HMDM cell in the immediate vicinity, that was observed to be HIV-
positive in experiments using fluorescent reporter virus such as HIV-mCherry (Fig. 27). 
This is correlative data, but the strong suggestion is that an HIV-infected HMDM 
adhered and transferred the infection locally to adjacent reporter cells, initiating a 
chain reaction of serial infection and homotypic fusion among the reporter cells. 
The macrophage itself, however, does not appear to fuse membranes and join the 
growing syncytium, as previously reported119.  
 
The fusogenic properties of the HIV envelope protein are well known to 
induce cell fusion among neighboring cells171,172. Indeed, all enveloped viruses 
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employ a variation on this theme, using envelope/spike-mediated mechanical 
deformation of the cellular membrane bilayer sufficient to disrupt the hydrophobic 
interactions among phospholipid tails in both membranes and thereby evert the 
membranes to mix lipid phases173. Conjugate pairs of neighbor cells (one HIV-
infected and the other expressing the viral co-receptors) participate in similar 
membrane fusion, only between two cells instead of a cell/virion pair.  However, 
that macrophages immediately adjacent to receptive cells can transfer the viral 
infection without engagement in membrane fusion argues against a simplistic 
model of how HIV is budded or transmitted. It is possible that the fluid properties, 
lipid or protein content of macrophage plasma membrane are inherently different, 
such that they are refractory to such deformation. Consistent with this notion, it has 
been reported that cholesterol-rich lipid raft domains are required for HIV infection 
in macrophages, suggesting that subdomains with distinct physical or chemical 
properties are subject to viral membrane fusion174.  However, dependent on the 
viral envelope protein, macrophages are themselves susceptible to cell-free HIV 
infection, proving the macrophage plasma membrane can be bent to 
accommodate HIV entry. Moreover, macrophages can actively bud large 
quantities of infectious HIV virions, showing the plasma membrane is competent, 
somewhere along it’s perimeter, for robust HIV exit. While the universality of HIV 
budding into VCCs has been debated175,176, multiple groups have suggested that 
membrane subdomains are highly enriched for viral assembly and budding activity 
that co-localizes with intracellular compartments enriched for env, gag, 
tetraspanins, ESCRT machinery, and the restriction factor tetherin, linking virions to 
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the membrane and to each other123. These findings may partially explain the low 
level of macrophage participation in heterotypic syncyita, since in HMDM cells the 
viral envelope proteins and co-receptors may be sequestered away from cognate 
binding partners on adjacent cells, pinched off from the extracellular space into 
VCCs. The lumen of such compartments is connected to the extracellular space by 
very thin channels, which prevent viral escape in the absence of a virological 
synapse124-126. One avenue to test this hypothesis is the addition of exogenous ATP 
to HMDM co-cultures, which causes evacuation of VCCs in HIV-infected 
macrophages132. If sequestration of fusogenic components is driving the absence 
of HMDM heterotypic fusion, then large scale emptying of these VCCs may expose 
this machinery to neighbor cells and thus to fusion.  
 
Despite being refractory to cell fusion with other fusogenic cell types 
however, HMDM do retain the ability to form homotypic syncytia (classically 
referred to as giant cells), for example demonstrated by the addition of GM-CSF 
and IL4 to the culture medium177 (Fig. 35). One possible means to augment the 
transfer of HIV infection to neighboring cells would involve stimulation of heterotypic 
fusion among co-cultured HMDM and reporter cells, especially in low-inoculum 
scenarios such as from ART-treated human samples or rare HIV-infected cell subsets 
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harboring virus of unknown in vitro fitness. As further evidence of specialized 
regulation of macrophage fusion properties, very recent data revealed that 
productively infected T-cells can form contacts with cultured HMDM, resulting in cell 
fusion and binucleation178. Interestingly, this initial fusion event further dysregulates 
HMDM anti-fusogenic properties causing additional cells join the syncytium, 
reminiscent of those seen in the tissues of HIV- and SIV-positive individuals at 
necropsy. The absence of this observation using HMDM co-cultured with adherent 
reporter cell lines (TZM- and Affinofile platforms) might indicate that primary 
lymphoblasts (and not engineered cells) are required to induce fusogenic behavior, 
likely downstream of cytokine secretion178   
 
Figure 34. HMDM possess fusogenic capacity. A HMDM cultured for 
48 hours in the absence of culture additives exhibit characteristic 
morphology with one nucleus per cell (yellow circles). B Addition of 
IL-4 and GM-CSF induces formation of multinucleate homotypic 
syncytia (white dashed boundaries) within 48 hours.  
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Even more interestingly, however, is the notion that the fusogenic tendency 
of infected macrophages might be governed by the viral sequence (likely env) 
they harbor – different viruses may cause cell fusion while others do not. This is an 
important question, as the longevity of a macrophage in vivo as a solitary cell or as 
a syncytium participant would be different, impacting the persistence of the virus. 
Fusion activity is determined, in part, by the cytoplasmic domain of gp41, where 
immature gag polyprotein binds and prevents premature fusion activity before the 
virus is properly encapsidated and enveloped179. And just as there are HIV strains 
with canonical ‘syncytium-inducing’ character in primary lymphocytes (mostly 
CXCR4-tropic strains isolated during late stage AIDS disease), so too might there be 
strains with varying capacity to induce homotypic fusion among infected 
macrophages. For example, in very recent preliminary experiments I observed 
highly divergent phenotypes among T/F viral clones in HMDM, both at the level of 
infectivity, and in their capacity to induce cell fusion among HMDMs in 
monoculture. While in previous studies, clone REJO.c was found to replicate in 
HMDM cultures58, albeit markedly less than in lymphocytes, I found this clone 
induces a strong homotypic fusogenic phenotype in HMDM cultures compared to 
other T/F infections (data not shown). The uncoupling of homotypic fusogenic 
capacity with replicative potential in various cell types is an interesting paradigm, 
but what is missing at this point is more robust data to assign cell-cell fusogenic 
capacity of a given virus in macrophages to a specific env sequence motif. Future 
studies should address the impact these events have on shedding of HIV and 
forward infection in naïve T-cells or reporter cell target populations. These properties 
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may contribute to the way in which certain viral strains transmit between cells, and 
their biology in macrophages and lymphoid cells requires further characterization.  
 
Using the tools developed here, these questions can be systematically 
addressed. Using the single cell QVOA platform described in Fig. 22, macrophages 
(HMDM and HuFLM) and lymphocytes (primary blood lymphocytes and SupGFP 
cells) should be infected with a large panel of T/F viruses to identify trends that may 
align with HIV subtype (Clade), tropism, or infectivity in lymphocytes vs. 
macrophages. To normalize for infectivity of individual stocks, these primary 
macrophages should be FACS-purified, as in Fig. 27. To obtain fluorescent readout 
in primary macrophages using wild type T/F strains, the pNL-GFP-RRE(SA) lentiviral 
reporter should will be used. My recent work has shown this is a feasible approach 
using HMDM and several T/F viruses, and revealed differential fusogenic properties 
among the T/F clones in HMDM, notably clone REJO.c. Importantly, very few cells 
are required for these experiments (50-70 GFP-positive cells per 96-well plate, or ~0.5 
cells per well). As shown in Figure 22, positive wells emerge by gaussia luciferase 
(GLuc) readout very early during the assay, and global differences in the kinetics of 
GLuc signal development are directly interpreted as varying cell-to-cell infection 
efficiencies at early timepoints (note the difference between BaL and 27ZP 
outgrowth at 3 days). Using results from HuFLM in Figure 27 as a guide, similar 
experiments using single sorted HuFLM cells harboring varying T/F HIV infections 
would be hypothesized to yield little or no outgrowth in the absence of stimulus to 
release the virus (discussed further below). This type of experiment is biologically rich, 
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and depends on the single cell resolution of the input.  
 
This pivotal feature of the platforms I describe stands out considerably from 
the bulk culture approaches pursued in the field78,114,135. Specifically, these standard 
approaches rely on bulk PCR or enzymatic readouts, which conceal all the nuances 
that might define the biology of HIV during cellular transmission. Armed with new, 
more tractable tools, future questions should address whether heterotypic 
membrane fusion in macrophages and reporter cells is genetically determined by 
the virus, and how sequence variation drives augmented or handicapped cell-to-
cell transfer kinetics. Similarly, using cell-free supernatants from wells seeded with 
single infected macrophage or lymphoid cells, we need to ask how viral genotype 
versus source cell type determines the rate of shedding and infectivity of produced 
virions. With the tools described here, these questions are now approachable.  
 
Systematic analyses of the intracellular virus-containing compartment in 
macrophages 
 
We and many others have reported the accumulation of mature and maturing 
virions in plasma membrane-connected VCCs in monocyte-derived macrophages. 
These structures have been imaged with timelapse microscopy using fluorescently-
tagged HIV gag, which is shed en masse onto the surface of a synapsing T-cell in 
culture119; these targeted T-cells then become productively infected. Such data are 
difficult to refute. However, despite the allure of the hypothesis, the extent to which 
this process is a viral adaptation remains unknown. One possible approach is to ask 
 127 
whether various viral strains differentially accumulate in VCCs or shed continuously. 
Indeed, much of the current knowledge has been attained studying a very limited 
set of lab-adapted macrophage-tropic strains of HIV. Using the correlative electron 
microscopy approach in Fig. 18, primary HMDM or HuFLM cells can be transduced 
with the pNL-GFP-RRE(SA) reporter construct to generate a primary reporter “cell 
line”, as I have very recently achieved (not shown). One could also re-engineer the 
reporter vector to express a bicistronic gag-imCherry ORF in addition to the IRES-
GFP cassette to visualize the location of gag protein accumulation in these primary 
“reporter cells”.  These macrophage reporters would then be infected in bulk (6-
well dishes) with a panel of competent T/F clones, and HIV-positive cells purified by 
FACS as described above. A single infected cell is plated per well, with target cells 
added in co-culture, and the fate of virions can be imaged over time. In theory, 
one could image all 96 wells for several days. In the same experiment, GLuc reporter 
signal in target cell lines can be measured longitudinally to correlate the timelapse 
of virion transfer with quantitative productive infection. The outcome is a visual 
representation of whether or not VCCs are evacuated after exposure to target cells 
or other modulators (assessed by fluorescently-tagged gag protein), and whether 
this depends on the viral genotype in question. While there are many variables here, 
with 96 (or 384) wells on a plate there’s room for all the controls. If interesting 
phenotypes are observed among certain cell-virus pairings, these can be probed 
more deeply – even by high throughput screens for compounds that modulate 
VCC evacuation. What if a drug could stop myeloid cells from shedding virus? There 
are many questions here worth answering.  
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Alternative hypotheses for lack of HIV transfer from infected HuFLM 
 
 This intriguing observation may be due to virion accumulation in VCC, but 
other explanations are feasible. Virions may be produced but retained at the 
plasma membrane, or they may not be produced at all. For example, it is known 
that BST2/tetherin protein physically tethers virions to the plasma membrane surface 
and prevents their release97,159,160. This restriction factor is counteracted by 
adaptations in the HIV-1 vpu protein to induce effective shedding of HIV virions 
during infection. Similarly, the T-cell immunoglobulin (Ig) and mucin domain (TIM) 
proteins also prevent HIV release, notably TIM3 in HMDM161. Knockdown of this gene 
augments virion production from infected HMDM. Interestingly the TIM proteins have 
also been found to significantly increase HIV entry in macrophages161, and the 
possibility that HuFLM overexpress TIM proteins could simultaneously explain their 
increased susceptibility to HIV infection and their apparent inability to propagate 
the infection.  
  
 I present evidence that HIV-mCherry-positive HuFLM cells do not transmit the 
infection to co-cultured cells. However, the current data cannot exclude the 
possibility that virions are entirely absent within HuFLM. Electron microscopy studies 
currently in process will reveal whether any virions accumulate within VCCs or at 
the plasma membrane of HuFLM in culture. In case no formed virions are observed, 
RNA FISH:FLOW experiments and qPCR using gag probes will establish whether gag 
mRNA is present.  
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 Finally, recent findings show that in HMDM in vitro and AMs in vivo, high 
endogenous levels of dUTP produce uracilated proviral genomes that yield 
hypermutations in offspring viruses96. While it is clear in HuFLM cells that the LTR 
promoter and the mCherry ORF are sufficiently intact to drive transcription, the 
remainder of the genome may harbor mutations that interfere with virion 
production. Follow up studies should address this explanation for failed transmission.   
 
 Whatever the mechanism, this important observation warrants further 
investigation. The potential of novel restriction factors or post-transcriptional 
regulation of HIV production will yield important insight into the behavior of HIV 
within myeloid cells, and may represent pathways specific to tissue-resident 
macrophage reservoirs in vivo.  
Mechanisms of increased HuFLM susceptibility to HIV 
  
The observed increased susceptibility of HuFLM to HIV infection is a novel finding, 
given the controversy surrounding the efficiency of HIV infection in macrophages in 
vitro (modeled by HMDM). However, the mechanism for this feature in HuFLM 
remains unexplored. While I present evidence that cell proliferation is likely not a 
factor in this observation (Fig. 26), the recent history of proliferative potential in these 
cells may be important. For example, the pools of dNTPs used for cell division in 
HuFLM may be governed by expression of SAMHD1 as in HMDM. Despite their exit 
from the cell cycle, dNTP levels may not have been suppressed in these cells. 
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Comparison should be made between HuFLM and HMDM for expression of SAMHD1 
and whether knockdown or overexpression experiments can modulate HuFLM 
susceptibility to infection. Several known HIV restriction factors were discovered in 
this way, comparing RNA expression profiles of restricted vs unrestricted cells.  
 
Modeling alveolar macrophage biology with fetal liver-derived macrophages in 
vitro.  
It is known that tissue macrophages such as AMs, microglia, and Kupffer cells 
(liver) derive from an embryonically-derived precursor wave that initiates in the yolk 
sac, is specified in the fetal liver, and populates the tissues in late gestation or early 
post-natal period66-68. These tissue macrophages are self-renewing, and proliferate 
to replace their ranks in the case of genotoxic insult66,68,180. In the lung, the 
differentiation and self-renewal of AMs is dependent upon GM-CSF signaling, 
without which AM precursors are present but non-functional and short lived68,154,156. 
Interestingly, this property is shared with HuFLM, which rely on GM-CSF during culture 
for both differentiation and proliferation. Furthermore, in humans and mice with 
bone marrow ablation and transplant, AMs are still recipient-derived a year post-
transplant68-70,156, showing the longevity of these cells that derive from the earliest 
days of the embryo. Conversely, in lungs that have been transplanted into a 
recipient human, the AMs are still donor derived months or years after the 
transplant, arguing that these cells can persist for a large majority of the life of the 
organism181. By contrast human monocyte derived macrophages never divide in 
culture, and are short lived in vivo182. These cells are recruited to areas of infection 
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or tissue injury and responsible for inflammatory cascades and wound healing. Yet 
despite these large differences in the role and phenotypes of HMDM and tissue 
macrophages in vivo, we model virtually all aspects of myeloid infection biology in 
monocyte derived macrophages (true in humans and mice).  
 
I have shown that large functional differences also exist between HMDMs and 
HuFLM pertaining to HIV infection (Fig. 26-27). Given these disparities, I hypothesize 
that HMDM may be a misleading model of tissue macrophage biology for HIV 
studies. At the very least, we should seek to resolve whether the observed 
differences in HIV infection between these two cell types can be correlated with 
their underlying biology. To address this, a series of foundation experiments will be 
very useful. The performance in QVOA assays of naïve AMs from uninfected 
volunteers should be compared with that of HMDM and HuFLM. Do AMs “cluster” 
more closely with HMDM or HuFLM? Furthermore, the heterogeneity of AMs should 
be addressed at least on a cursory basis with immunomagnetic separation of AMs 
from interstitial macrophages183 that may also appear in the airway, especially in 
the context of disease. Basic assays of macrophage function, including those our 
lab previously reported74 can be used to align the phagocytic, proteolytic, and 
oxidative function of AMs with HMDM or HuFLM. Moreover, the transcriptional profile 
of HMDM, HuFLM, and AM should be compared in the presence or absence of HIV 
infection to learn the global response of these cells types to infection.  
 
Finally, the observation that HIV release or maturation is delayed or inhibited in 
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infected HuFLM cells should be probed in AMs as well, given that viral outgrowth 
assays from AM cells have been challenging in our hands and in those of several 
other groups. It is attractive to speculate that tissue macrophages (modeled by 
HuFLM) may accumulate virus in the absence of a proper inductive signal to release 
it. Perhaps activated lymphocytes are sufficient for such a signal – the simplest 
version of release regulated by the most advantageous target cell of the virus. 
However, tissue-specific signals may also transact in this process, a paradigm much 
more difficult to study.  
 
Together, the existing data suggest functional divergence in HMDM and HuFLM 
cells67,70,180. Whether HuFLM cells are truly a better model of tissue resident 
macrophages remains unknown, but their lineage and observed proliferative 
potential argue they share important phenotypes that pertain to HIV infection. 
Nevertheless, the notion that studies of HIV biology in macrophages may be poorly 
modeled in HMDM remains a possibility. The accessibility of human AMs, HuFLMs, or 
other primary macrophage populations such as those from colonoscopy tissue 
biopsies, make this an important and feasible question to resolve.   
 
Define the boundaries of novel QVOA platforms 
  
 I reported that differences in gaussia luciferase (GLuc) reporter activity were 
observed between BaL and 27ZP strains at 3 days of co-culture in the single cell 
QVOA platform (Fig. 22), and that for 27ZP, no additional sensitivity was gained after 
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8 days. However, differences in replication fitness of various strains studied and the 
cell formats employed will impact these timelines. What is needed is a more 
comprehensive test of the assay timepoints using a panel of viruses, with reporter 
sampling daily. The value of these types of readouts is their improvement over the 
current p24 ELISA or qPCR readouts to allow HIV determination in minutes, and in 
real time. However, trends for each cell format using several viruses are needed as 
a training set to guide their deployment in human cohorts. We are currently 
collaborating with Dr. Andrew Lever’s group in Cambridge, UK to test the SupGGR 
platform in their clinical pipeline. More studies will be needed to establish the utility 
of the SupGGR and other cellular tools reporter here in diverse applications and 
cohorts.  
 
Absolute titer of transmitted founder HIV in myeloid vs lymphoid cells 
 
 Data showing poor replication of T/F clones in HMDM cells are interpreted to 
mean that macrophages likely play no role in their biology in vivo. However, the 
specific titration experiments I describe here reveal that, while one such clone is 
~16-fold more infectious in lymphoid (SupGFP) vs myeloid cells (HMDM), the viral 
stock was highly infectious in both cell types. In the context of high viral titer during 
acute HIV infection in vivo (107 copies per mL of blood), and the dominance of T/F 
clones during the key stages of infection (transmission, acute, and rebound), a 16-
fold reduction in infection efficiency of macrophages may be of little practical 
significance. On the balance of these observations, I expect that many 
macrophage cell types in diverse tissues of the body are productively infected with 
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very relevant strains of T/F HIV, and that these macrophages play key roles in 
persistence and transmission. Consider for example the airway: AMs comprise 
about 80-95% of all leukocytes recovered in BAL fluid. During acute infection, 
exposure of AMs to high titers of T/F HIV in the blood or migrating lymphoid cells 
would almost certainly lead to their infection; AM longevity and durability during 
HIV infection would make these cells key candidates as reservoirs. Furthermore, the 
airway is not the only myeloid-dominant compartment. The brain is an immune-
privileged site with an overwhelming majority of microglia and other macrophage 
cells compared to lymphoid subsets51,147, and has been well studied in the context 
of HIV infection and compartmentalization53,55,69,98. Moreover, just as the airway has 
direct access to the outside environment, so does the seminal vesicle and the 
testes. Like the airway, the dominant leukocyte fraction in the seminal fluid are 
macrophages, and have been demonstrated to harbor a high burden of cell-
associated HIV even in the relative absence of cell-free virus184,185. Thus, while slight 
handicaps in T/F HIV infection of macrophages are observed in vitro, the likelihood 
remains high that macrophages are key targets for infection in vivo and may 
contribute to persistence and transmission.   Finally, what macrophages might lack 
in terms of susceptibility to T/F virus infection, they make up with longevity and  
increased efficiency of transmission to target cells97.  
 
Optimized primary HIV outgrowth pipeline in Blantyre, Malawi 
 
 Future studies in Malawi will focus in the near term on extending the primary 
culture window to allow additional rounds of replication prior to supernatant 
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harvest. With our work over the last several years, the pipeline for these clinical 
samples has dramatically improved. We have obtained replication-competent 
virus in primary and secondary outgrowth experiments sufficient to clone full length 
env and gag genes, and in one case have patient-matched infectious viral stocks 
from both lavage and peripheral blood. Preliminary functional studies have been 
performed on a limited set of envelope clones, with the goal of establishing their 
HIV co-receptor usage (CD4 vs CCR5 titration). Using an infectious viral swarm 
isolated from the peripheral blood of a patient not on ART I show that Clade C 
circulating virus is equally infectious in macrophages and lymphoblastic cells, 
underscoring the urgency with which macrophage reservoirs for HIV in sub-Saharan 
Africa remain to be characterized. Using additional samples in this pipeline we aim 
to expand on these results and report trends in the tropism or anatomic 
compartmentalization of Clade C virus in Malawian adults in the presence and 
absence of ART. Virus genotype vs titer in FLM; evidence for adaptions?  
 
Cellular source of HIV in the human airway 
  
 Of utmost importance in reservoir studies is not the presence of virus in a 
specific anatomic compartment, but the cells in which this virus persists during 
therapy. A central controversy in the field is whether macrophages can harbor HIV 
in vivo. Anecdotal evidence suggests infectious HIV is found in macrophages of the 
airway101,102,105,106,108, and our lab has shown the presence of HIV RNA in AMs and 
their consequent functional deficits in phagocytosis74.  However, the studies 
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reported here perform outgrowth on bulk BAL cells, which include mostly 
macrophages but also some lymphocytes. Thus, whether macrophages are the 
origin of viral outgrowth in this platform has not been definitively shown.  
 
 Two main approaches will help demonstrate the cell of origin for HIV in the 
airway. With the co-culture pipeline in Malawi now established, physical separation 
of the cell subsets is possible to separately interrogate myeloid and non-myeloid 
subsets for outgrowth of HIV, from patients treated or untreated with ART. This first 
approach would involve immunomagnetic separation of bulk BAL with CD3 and 
CD33 microbeads to enrich lymphoid and myeloid cells, respectively. While long 
established protocols to harvest primary macrophages involve their purification by 
rapid adherence in cell culture186,187, more definitive evidence requires cell surface 
identification of lymphocytes and monocytes. The sequential positive selection of 
CD3-positive lymphocytes, followed by CD33-positive myeloid cells188,189 would 
maximize the return of the relatively minor subset of lymphocytes in the airway. Using 
the QVOA platforms described here, the outgrowth of virus from both enriched 
subsets could be tested. Importantly, independent of the outgrowth fitness of HIV 
within either cell subset, the early readouts afforded by the GGR platform reporters 
I describe make it possible to characterize early isolates from both cellular and 
supernatant RNA pools, and obtain their genomic sequence. 
 
 The second approach for defining the specific cell types harboring HIV in 
vivo derives from a single cell sequencing platform “SeqWell” developed by Alex 
Shalek’s group at MIT190. The system uses custom arrays of nanowells, thousands of 
small machined cavities on the array surface to hold a single cell and a single bead. 
The BAL cell suspension is loaded onto the array, and single, dissociated cells settle 
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into each well with a Poisson distribution. To these wells are added lysis buffer and 
single magnetic beads, each labeled with unique barcoded oligonucleotides that 
capture poly-adenylated RNA from the lysed cell. Capture transcripts, including HIV 
transcripts expressed, are bound and reverse transcribed in the wells while bound 
to the beads190. Once these beads are pooled and the oligos cleaved, the cDNA 
library contains thousands of barcoded species that can be sequenced and 
aligned to the human and HIV genome. The barcode of reads aligning to the HIV 
genome are matched with reads of the host transcriptome that have the same 
bead barcode, and the cell type harboring HIV can be inferred from the transcripts 
expressed.  
 
We have performed a pilot experiment using this invaluable technology on 
the ground in Malawi and have returned the HIV sequences from three separate 
samples, as a proof-of-concept. Underway now is the analyses of the host transcript 
and refinement of the platform for follow-up studies.   
 
 The intrinsic value of SeqWell is the ability to analyze host transcriptional 
changes within HIV-infected cells in vivo190, from a large pool of input cells. Host 
responses to HIV infection will help illuminate potential targets in diverse cell subsets. 
It is clear from the persistence of HIV during long term antiretroviral therapy, that 
targeting specific cellular reservoirs won’t follow a ‘one size fits all’ model.  
 
Concluding Remarks 
 Persistence of HIV is driven at the cellular level by cell type-intrinsic biology 
that shapes the production or latency of HIV during ART39. Our current drug 
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regimens attack viral replication at the level of new infections, such as inhibition of 
HIV entry, protease, integrase, and reverse transcriptase. However, current 
therapies do not affect reservoir cells already infected with HIV. Much work remains 
to elucidate the ways HIV interacts with multiple host cell types, so these processes 
can be specifically targeted with new therapies. The first step in this process is 
retooling, to illuminate the ways in which novel reservoir cells are different, and find 
the opportunities we didn’t know we were missing.  
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METHODS 
 
Cells 
Cells were obtained through primary repositories ATCC (8E5/LAV) or the NIH 
AIDS Reagent Program (TZM-bl, CEM, 8E5/LAV, Molt4R5), or through generous gifts 
from academic investigators (JC53, David Kabat, OHSU; Affinofile-GGR, Benhur Lee, 
Mount Sinai; SupT1/R5, James Hoxie, UPenn). 293FT cells were purchased from 
Invitrogen.  
 
Cell culture 
HMDM were generated from elutriated monocytes obtained from the 
University of Nebraska Medical Center. Monocytes were plated at 1 x 106 / cm2 
culture area in various culture formats, in human macrophage medium: DMEM 
medium containing 2x L-glutamine, 1X sodium pyruvate, HEPES, 1x Pen/Strep, and 
10% pooled human AB-type serum (SeraCare).  Cultures were incubated for 7 days, 
with complete medium being supplemented by 30% v/v/ 2 and 5 days after plating. 
Medium was changed at 7 days, and cultures were fed three times per week 
thereafter until harvest or infection.  
 
For experiments requiring reseeding, HMDM were cultured on untreated 
bacteriological plasticware. HMDM were harvested by washing with DMEM and 5 
minute treatment with Tryple-Select (Invitrogen) followed by gentle scraping with a 
rubber policeman and inactivation in serum-containing medium. Cells were 
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centrifuged in conical tubes at 200 RCF (1000 RPM) for 5 minutes at room 
temperature. Medium was discarded and cells resuspended and counted for 
replating. Under these conditions, cell viability was high and morphology 
unchanged after reseeding.  
 
HuFLM were generated from culture of 5 x 105 CD34+ human fetal liver 
progenitors (Lonza) in human macrophage medium described above with added 
recombinant human GM-CSF (Peprotech) at 100ng/mL. The cytokine was 
replenished twice weekly over a period of 3-4 weeks, during which time non-
adherent blastic cells were observed to vigorously proliferate in suspension. After 
1.5-2 weeks of culture, gradual emergence of adherent single cells and ostensibly 
clonal foci was observed. After 2.5 weeks, suspension cells were split 1:3, leaving 
adherent cells on the plastic surface in fresh medium. Continued proliferation was 
observed among non-adherent wells and to a lesser extent among adherent cells; 
by 3-4 weeks of culture, adherent wells depleted of suspension cells appeared 
static and were trypsin harvested for cryopreservation. Progressive differentiation 
was observed in wells with non-adherent cells, which gradually adhered to the 
plastic over an additional 2-3 passages. By six weeks, all cells were trypsin harvested 
and cryopreserved.  
 
Lymphoid cells including Molt4-, SupT1-, CEM-, and 8E5-derived cell lines 
were propagated in RPMI containing 2X L-glutamine, 1X sodium pyruvate, 1X HEPES, 
1X Pen/Strep, and 10% fetal bovine serum. Cultures were maintained between 105 
 141 
and 2x206 cells/mL, and split 1:10 or 1:15 twice weekly. For aggressive subcultures 
described using 8E5 cells, confluent cultures were split 1:50 and allowed to recover 
over 1.5-2 weeks, when the process was repeated. For co-culture experiments using 
lymphoid cell lines and adherent cells, RPMI was used in place of DMEM medium to 
accommodate lymphocyte culture preferences.  Molt4R5-derived cells were 
maintained under 1mg/mL Geneticin selection. SupT1/R5-derived cells were 
maintained under 3µg/mL blasticidin selection.   
 
Transformed adherent cell lines were maintained in DMEM complete 
medium 2X L-glutamine, 1X sodium pyruvate, 1X HEPES, 1X Pen/Strep, and 10% fetal 
bovine serum. Affinofile-GGR cells were maintained under 50µg/mL blasticidin 
selection, while 293FT cells were periodically selected using 500µg/mL Geneticin.  
 
Viruses 
HIV clones JR-CSF, JR-FL, and pWT-BaL, and a panel of Clade B 
transmitted/founder viruses were acquired through the NIH AIDS Reagent Program. 
Clade C T/F clones were graciously offered by Dr. John Kappes (UAB). HIV clone 
ADA and stock of BaL were graciously provided by Mario Stevenson, Miami CFAR. 
Tagged HIV-nef-IRES-GFP (BaL env) was a gift of Thorsten Mempel, MGH, and 
Thomas Murooka, U.Manitoba. Tagged HIV-gag-imCherry (BaL) was generously 
offered by Phillipe Benaroch, institutCurie, and Mike Schindler, Helmholtz Center 
Munich. HIV-nef-IRES-mCherry was generated by cloning the mCherry cDNA into 
HIV-nef-IRES-GFP, using PCR amplification from pCAAGS-mCherry (a kind gift of 
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Natasza Kurpios) and cloning a 1.7kb MluI-IRES-mCherry-LTR-XbaI cassette into 
digested pNL4-3-nef-IRES-GFP(BaL).  
 
Production of virus stocks 
 
Infectious molecular clones of HIV were transfected into 293FT cells without 
helper plasmids (for wild type HIV) or with pLP-VSV/G (Invitrogen) to produce 
pseudotyped virions. Transfections of 80-90% confluence 293FT were carried out on 
day one in T-150 culture flasks using Lipofectamine 2000 according to the 
manufacturer instructions, using 40µg of HIV DNA ± 5 µg of VSV/G DNA. After 
overnight incubation, medium was replaced on day two with fresh DMEM complete 
medium containing Pen/Strep and cultured for 24 additional hours. Harvest of 
supernatant was made on days three and four, with day three supernatant stored 
at 4°C overnight. On day four, supernatants were pooled, cleared by centrifugation 
at 1000 RCF for 10 minutes at 4°C, filtered through a 0.45uµM PVDF ultra low protein-
binding filter (Millipore) and aliquoted for storage at -80°C. Viral titer was established 
on single freeze-thaw cycle stocks.  
 
Lentiviral vector construct pNL-GFP-RRE(SA) was packaged in a similar 
fashion, with the addition of plasmid DNA pCMV-dR8.2-dvpr to express Rev, 
Gag/pol, and Tat. To package pNL-GGR-RRE(SA), Affinofile-GGR cells were used as 
packaging cells given that the GGR plasmid clone was unavailable. Affinofile-GGR 
cells were transfected with pCMV-dR8.2-dvpr and pLP-VSV/G to package the GGR 
provirus integrated in these cells. To overcome the low lentiviral output (single copy 
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proviral transcription vs. plasmid DNA overexpression), target cells were mixed with 
Affinofile-GGR cells budding GGR lentivirus and spinoculated at 1000xg for 2 hours 
at room temperature. Target cells were then separated from packaging Affinofile-
GGR cells by limiting dilution and cloning. Low-titer GGR lentiviral stock was also 
archived from the Affinofile-GGR supernatants. 
 
Infections 
 
Inoculations were performed as described above, with modifications. HMDM 
were infected in adherent culture or in Teflon screwtop jars (Savillex), without added 
DEAE-dextran or polybrene. Inoculum medium was changed after 24-48 hours, and 
cells incubated for 4-14 days for viral replication. HMDM cultures were never 
infected before day 7 of differentiation.  
 
Adherent reporter cells were infected with varying doses wild type or VSV-
pseudotyped viral stocks without DEAE dextran. Medium was changed after 24-48 
hours and cells followed for reporter gene expression.  
 
Non-adherent lymphoid cell lines were infected with HIV or lentiviral stocks 
using spinoculation in 20 µg/mL DEAE-Dextran, except where indicated above. For 
experiments directly comparing infection in adherent or HMDM cultures, lymphoid 
reporter cells were infected in standing culture without spinoculation or 
polycationic culture additives.  
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Absolute titer assay 
 
Stocks of wild type infectious molecular clones were tittered on a panel of 
cell lines. To 2,500 target cells in 96-well format was added 50µL of tenfold serially-
diluted viral stocks. Target cells were 10 day-old HMDM or SupT1/CCR5 cells, 
cultured without DEAE-dextran.  Target wells with medium only (no target cells) were 
plated simultaneously to test viral decay in the period prior to reporter cell addition. 
Target cells were cultured for 5 days without medium changes to allow viral 
infection. On day 5, 10,000 SupGGR cells were added to each well to quantify the 
presence of HIV in target wells compared to medium only wells. For each viral 
dilution, the percentage of positive wells was established by reporter assay, and the 
fraction of positive wells used to discern the TCID50 for each viral stock. Background 
correction was performed for each viral dilution by subtracting the TCID50 dose in 
medium-only wells from that in target wells.  
 
Single cell VOA  
 
Bulk cultures of donor cells were infected with relevant strains of infectious 
HIV. During proof of concept experiments, 5 x 104 TZM-gfp cells were infected with 
lab adapted strain BaL or primary Clade C swarm 27ZP for 5 days. Cells were trypsin 
harvested on day 5, strained through a 40 µm nylon cell strainer (Fisher) to remove 
large syncytia and aggregates, and an aliquot quantified for GFP penetrance on 
a BioRad S3e cell sorting instrument. The original (unsorted) bulk cells were diluted 
to 0.75 cells per 50µL of fresh DMEM complete medium, and 50µL of cell suspension 
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were dispensed into each well containing 10,000 pre-seeded MoltGGR cells using 
a multichannel pipette. Cultures were incubated for 8 days, with longitudinal 
sampling performed on days 3 and 8 by removing 20µL of medium from the top of 
each well with a multichannel pipette. GLuc assay was performed according to 
the manufacturer’s instructions (Thermo), using an integration time of 0.1s in an Ultra 
sensitivity luminescence protocol on an Envision multilabel plate reader (Perkin 
Elmer). Data were plotted in Prism 6.0 on log box and whisker plots, using Tukey 1.5x 
IQR criteria to score positive outliers.  
 
For single cell viral outgrowth assays using HMDM, HuFLM, and SupT1/R5, 
these target cells were infected with VSV-HIV-IRES-mCherry stocks for 3-5 days in 
bulk culture on untreated 6-well dishes (Corning). The afternoon prior to harvest, 
optical bottom 96-well plates of outgrowth reporter cells were seeded with 5,000 
Affinofile-GGR, TZM-GGR, or TZM-bl cells; the Affinofile GGR cells were seeded in 
maximum induction medium containing 4.0 ng/mL of Doxycycline and 2 µM of 
Ponasterone A. On the day of sorting and co-culture, outgrowth cells were 
replenished with fresh medium. Adherent target cells (HMDM, HuFLM) were trypsin 
harvested as described above, while SupT1/R5 cells were collected by simple 
pipetting. Harvested cells were filtered using 40-70µm nylon cell strainers (Fisher) 
prior to purification of the mCherry-positive fraction on a BioRad S3e FACS 
instrument. Purified cells were pelleted and resuspended in fresh complete medium 
at a theoretical concentration of 5 cells per 50uL. To each well of the reporter plates 
was added 50µL of target cell suspension. Cultures were incubated for 5 days, and 
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followed for reporter gene expression by confocal microscopy starting 48 hours 
after co-culture.  
 
Drop culture 
 
TZM-gfp cells were trypsin harvested and resuspended at ~107/mL in a sterile 
microfuge tube. A series of 20 twofold dilutions was prepared, with dilutions down 
to 20 cells/mL (0.04 cells per 2µL). From each dilution tube and starting from the 
most dilute, 2µL were spotted onto the surface of a 35mm glass-bottom plate (ibidi) 
in a 5 x 5 spot array.  The plate was sealed and incubated overnight in a cell culture 
incubator to allow adherence of foci in each drop. The following morning, the plate 
was washed with fresh medium and inoculated with wild type HIV-1 ADA 
supernatant, such that all foci shared the same viral supernatant. Cultures were 
incubated for 72 hours, and each cell focus analyzed for HIV infection by confocal 
microscopy.  
 
Primary HIV capture – performed by collaborators in Blantyre, Malawi 
 
Twenty-four hours prior to BAL harvest, 200,000 TZM-gfp or Molt4R5 cells were 
plated in 6-well format by team members in Blantyre. On the day of BAL harvest, 
250,000 bulk lavage cells were added to TZM-gfp or Molt4R5 cultures, including TZM 
cultures on glass coverslips for electron microscopy. At 24 or 48 hours post-
inoculation, culture supernatant was harvested and cleared by centrifugation, 
while adherent cells were trypsinized and viably archived in freeze medium 
containing 10% DMSO and 90% FBS. Non-adherent Molt4R5 cells were pelleted and 
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similarly archived. Supernatants and cells were stored at -80°C and shipped to 
Ithaca, NY on dry ice. Coverslips were submerged in fixative containing 2.5% 
glutaraldehyde in 0.1M sodium cacodylate buffer, pH 7.2. in a Wash-N-Dry coverslip 
rack (Diversified Biotech), and sealed in a teflon jar (Savillex) for shipping to Ithaca, 
NY at room temperature.  
 
Secondary outgrowth – performed in the Russell Lab, Ithaca, NY 
Secondary cell co-cultures were initiated by thawing viably archived primary 
co-culture cells, diluting 1:10 in fresh medium and pelleting cells at 200x g for 5 
minutes. Pellets were resuspended in fresh DMEM complete medium, and were (1) 
placed into co-culture with maximally-induced Affinofile-GGR cells seeded the 
afternoon prior, (2) spinoculated with MoltGGR cells in the presence of 20µg/mL 
DEAE dextran, or placed into viable monoculture. A-GGR and MoltGGR cells were 
followed by fluorescence microscopy over 10 days. No reporter signal of any kind 
emerged in the three culture formats, including the primary TZM-gfp monoculture 
cells. Cells and supernatants were harvested for RNA PCR analyses as described 
below.  
 
Secondary supernatant outgrowth cultures were initiated by thawing 
aliquots of primary viral supernatants, and inoculating maximally-induced Affinofile-
GGR cells or spinoculating Molt4R5, or MoltGGR cells in the presence of 20µg/mL 
DEAE-dextran. Outgrowth cultures were followed by fluorescence microscopy over 
a 13-day period where lymphoid outgrowth cultures were harvested and 
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centrifuged (200xg) every other day for the first week. On day 5, A-GGR co-cultures 
were re-induced with Doxycycline and Ponasterone A as described above, 
incubated 2 additional days to allow a single round of viral replication, then 
supernatants and floating cells were passaged onto freshly-seeded and max–
induced A-GGR cells for an additional 7 days of co-culture. On day 13, supernatants 
were harvested and cells lysed in TRIZOL for PCR amplification of viral RNA. On day 
13, overt and logarithmic infection was observed in 10.27Z-PBMC outgrowth 
cultures. Fresh Molt4R5 cells were spinoculated with the Molt4R5 culture for this 
10.27Z-PBMC sample, and the culture was extended for a third week. Infectious viral 
supernatant was harvested on day 21, 0.45µm PVDF-filtered, and aliquoted for 
storage at -80°C as “27ZP stock”.  
 
Electron Microscopy – performed in the Russell Lab by Shannon Caldwell 
Upon their return to Ithaca, coverslips were rinsed 3x10 minutes in sodium 
cacodylate buffer, then fixed for 1hour in buffered 2% osmium tetroxide. Three x 5 
minute rinses in sodium cacodylate buffer were followed by a single 5-minute rinse 
in distilled water and 20-minute soak in 1% aqueous uranyl acetate. Coverslips were 
rinsed again in distilled water, then dehydrated in a 10-minute graded aqueous 
ethanol series of 10, 30, 50, 70, 90, 100, and 100% ethanol. A graded ethanol: Ultra 
bed resin infiltration series was performed: 4:1, 20 minutes; 2:1, 60 minutes; 1:1, 
overnight; 1:2, 3 hours; 1:4, 4 hours; 0:1, overnight (air exposed); and finally 0:1, 4 
hours. Infiltrated coverslips were then inverted over the end of a Beam capsule filled 
with resin and polymerized overnight at 65-70°C. Embedded specimens were 
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processed through hydrofluoric acid to dissolve glass coverslips. Blocks were 
cleaned and trimmed, ultrathin sections were cut and placed on formvar coated 
grids. Grids were stained for 20 minutes in uranyl acetate, 7 minutes in lead citrate, 
then dried and imaged on an FEI Tecnai 12 Bio-twin transmission electron 
microscope. 
FISH:FLOW 
 
Live cells were harvested by BAL, venipuncture, or from cell culture. Single 
cell suspensions were generated, rinsed in PBS, and fixed in 1% PFA for 30 minutes.  
Cells were pelleted at 2500 RPM in a swinging bucket Hermle Z200 microfuge, and 
resuspended in 70% ethanol in RNAse-free water overnight for permeabilization or 
long-term storage. For FISH staining, cells were pelleted, the ethanol was discarded, 
and 1mL of FISH wash buffer was added: 2X SSC (Ambion), 1X Denhardt’s solution 
(Affymetrix), 10% deionized formamide (EMD Millipore)  in nuclease-free water. After 
standing for 5 minutes in wash buffer, cells were pelleted and resuspended in 100µL 
hybridization buffer with 1mg/mL E.coli tRNA or a modified buffer lacking tRNA but 
containing 1mg/mL unlabeled, scrambled ssDNA oligonucleotide, “X-buffer”.  H- 
and X-buffer were otherwise identical, containing 200 mg/mL of dextran sulfate 
(Amresco), 2mM vanadyl ribonucleoside complex (NEB), 200µg/mL RNAse-free BSA, 
2X SSC, 10% deionized formamide in nuclease-free water. To 100µL hybridization 
reactions was added 1µL of FISH probe (LGC Biosearch technologies, final 
concentration 2.5-250 nM). Tubes were sealed and incubated at 37°C in a tissue 
culture incubator in the dark overnight. The following day, 1mL of FISH wash buffer 
was added, left to stand for 5 minutes in the dark, then centrifuged at 2000 RPM. 
 150 
Wash solution was discarded, and replaced with another 1mL wash buffer. Tubes 
were sealed and incubated at 37°C for 30 minutes, then pelleted and resuspended 
in PBS containing 1% BSA for flow cytometry. Biosearch probes targeting HIV-1 gag, 
nef, 3’LTR, and 5’LTR or SIVmac239 nef and 5’LTR were ordered with various 
flurophores including Quasar570, Quasar670, and CalFluor Red 590.  
Confocal imaging 
 
Image analyses of BSL-3 HIV infections were performed on a Leica SP-5 laser 
scanning confocal microscope using either a universal plate holder for glass-
bottom or chamber glass culture formats, or the H201–MEC–LG–MW holder 
(OkoLabs) for optical bottom 96-well plate culture assays. Z-stacks were projected, 
and channels merged contrasted in Leica Application Suite or Adobe Photoshop.  
 
P24 ELISA 
Supernatant samples were applied to the HIV Type 1 p24 Antigen ELISA 
(Zeptometrix) according to manufacturer instructions. Infectious HIV was 
neutralized using the included lysis buffer, and the ELISA was performed using a 
dilution series of known standards of purified p24 protein.  
 
HIV env and gag PCR – Performed in the Russell Laboratory by Saikat Boliar with 
contributions from David Gludish 
HIV sequences were amplified using nested PCR approaches. Cellular mRNA 
or viral RNA in supernatant was isolated using TRIZOL or the Qiamp viral RNA mini kit, 
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respectively per manufacturer’s instructions. Reverse transcription was performed 
using the SuperScriptIII kit (Invitrogen) and the ofm19 RT primer 5’- GCA CTC AAG 
GCA AGC TTT ATT GAG GCT TA. Envelope PCR was performed using Phusion Hi-
Fidelity polymerase in two steps: (1) ofm19 rev with Vif1 fwd, for 40 cycles at 55°C 
annealing, and (2) EnvA with EnvN, for 40 cycles at 55°C annealing. A portion of the 
first step product was used as template in the second step reaction. From the same 
ofm19 cDNA libraries, gag PCR was performed in two steps: (1) OuterFor with 
OuterRev for 40 cycles at 55°C annealing, and (2) InnerFor with InnerRev for 40 
cycles at 55°C annealing, again using a portion of the first step product as template 
in the second step.  
PCR products were gel-purified, cloned using the Zero blunt TOPO PCR 
cloning kit (Invitrogen), and sequenced.   
 
PCR primers:  
ofm19 rev 5’- GCA CTC AAG GCA AGC TTT ATT GAG GCT T 
Vif1 fwd 5’- GGG TTT ATT ACA GGG ACA GCA GAG 
EnvA 5’- CAC CGC CTT AGG CAT CTC CTA TGG CAG GAA GAA 
EnvN 5’- CTG TCA ATC AGG GAA GTA GCC TTG TGT 
OuterFor 5’- AAGTAAGACCAGAGGAGATCTCTCGAC 
OuterRev 5’- GACAGGTGTAGGTCCTACTAATACTGTACC 
InnerFor 5’- TTTGACTAGCGGAGGCTAGAAGGA 
InnerRev 5’ - GTATCATCTGCTCCTGTGTCTAAGAGAGC 
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RNAseq analyses 
 
FISH-sorted cells were pelleted and resuspended in PKD buffer from the 
Qiagen RNeasy FFPE kit. The remaining steps from the Microdissected FFPE tissue 
sections protocol were followed. Approximately 100 ng RNA was used to prepare a 
cDNA library using the Ovation Human FFPE RNA-Seq Library System, according to 
the manufacturer’s protocol. To account to degradation suffered by PFA fixation, 
RNA is reverse transcribed using a mixture of random and poly(T) primers. The 
completed preparation yielded an rRNA depleted, strand-specific, adaptor ligated 
cDNA library suitable for Illumina NGS. Sequencing was performed in single-end 50 
bp lanes on a Illumina HiSeq 2000/2500 (high-output mode). RNA sequencing reads 
were aligned to the HIV reference genome using the TopHat algorithm within 
Geneious software and analyzed for coverage.  
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